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Abstract
The research described in this thesis represents a significant advancement in the current
mechanistic understanding of low-frequency ultrasound-mediated transdermal drug delivery.
Specifically, while prior research has focused on a more general understanding of the
mechanisms associated with low-frequency sonophoresis (LFS), this thesis directly investigates
the mechanisms associated with phenomena that occur due to LFS skin treatment. These include
a deeper understanding of: i) the reasons for heterogeneous perturbation of skin treated with
LFS, ii) the physical mechanism that causes synergism between LFS and chemical penetration
enhancers (CPEs), iii) the interactions between traditional and non-traditional surfactants in LFS
skin treatments, and iv) the effects of LFS and LFS/CPEs on skin structural perturbation.
In the first study of this thesis, the intrinsic properties and formation mechanisms of
localized-transport regions (LTRs), and the surrounding less-perturbed non-LTRs, of low-
frequency sonophoresis-treated skin are investigated. By independently analyzing LTR, non-
LTR, and total skin samples treated at multiple LFS frequencies, it was found that the pore radii
(rpore) within non-LTRs are frequency-independent, ranging from 18.2 - 18.5 A, but significantly
larger than rpore of native skin samples (13.6 A). Conversely, rpore within LTRs increases
significantly with decreasing frequency from 161 A, to 276 A, and to ao (>300 A) for LFS/SLS-
treated skin at 60 kHz, 40 kHz, and 20 kHz, respectively. These findings suggest that different
mechanisms contribute to skin permeability enhancement within each skin region. Therefore, it
was proposed that the enhancement mechanism within LTRs is the frequency-dependent process
of cavitation-induced microjet collapse at the skin surface, while the increased rpore values in
non-LTRs are likely due to SLS perturbation, with enhanced penetration of SLS into the skin
resulting from the frequency-independent process of acoustic streaming.
Next, the effects of a non-traditional surfactant on LFS treatment were analyzed through
a case study with the commonly used fluorescent dye sulforhodamine B (SRB). SRB is often
considered to be a purely hydrophilic molecule, having no impact on bulk or interfacial
properties of aqueous solutions. However, it was demonstrated that SRB is in fact an
amphiphile, with the ability to adsorb at an air/water interface and to incorporate into sodium
lauryl sulfate (SLS) micelles. In fact, SRB reduced the surface tension of water by up to 23
mN/m, and the addition of SRB to an aqueous SLS solution was found to induce a significant
decrease in the critical micelle concentration (cmc) of SLS. Molecular dynamics revealed that
SRB has defined polar "head" and non-polar "tail" regions when adsorbed at the air/water
interface as a monomer. These findings have significant implications into LFS-mediated
transdermal drug delivery, as the inclusion of SRB into an LFS coupling solution can cause a
synergistic increase in skin permeability enhancement. However, in the presence of SLS, SRB
actually causes an antagonistic effect due to the resulting change in bulk and interfacial
properties.
The next investigation of this thesis focused on understanding the synergism between
LFS and CPEs (e.g., surfactants). In spite of identifying that the origin of this synergism is the
increased penetration and subsequent dispersion of CPEs in the skin in response to LFS
treatment, no prior study had proposed a mechanism to explain how LFS induces the observed
increased transport of CPEs. In this study, a physical mechanism by which the transport of all
CPEs is expected to have significantly increased flux into the localized-transport regions (LTRs)
of LFS-treated skin was proposed. Specifically, the collapse of acoustic cavitation microjets
within LTRs was shown to induce a convective flux. In addition, because amphiphilic molecules
are able to adsorb onto the gas/water interface of cavitation bubbles, amphiphiles were shown to
have an additional adsorptive flux. In this sense, the cavitation bubbles were shown to
effectively act as carriers for amphiphilic molecules, delivering surfactants directly into the skin
when they collapse at the skin surface as cavitation microjets. The flux equations derived for the
LTRs and non-LTRs of LFS-treated skin, compared to that for untreated skin, explained how the
transport of all CPEs, and to an even greater extent amphiphilic CPEs, increases during LFS
treatment. The flux model was supported with experiments involving a non-amphiphilic CPE
(propylene glycol) and both nonionic and ionic amphiphilic CPEs (octyl glucoside and SLS), by
measuring the flux of each CPE into untreated skin and the LTRs and non-LTRs of LFS-treated
skin. Data showed excellent agreement with the expected trends from the flux model.
The final study of this thesis investigated the effect of SLS on skin structural perturbation
when utilized simultaneously with LFS. Pig full-thickness skin (FTS) and pig split-thickness skin
(STS) treated with LFS/SLS and LFS were analyzed in the context of the aqueous porous
pathway model to quantify skin perturbation through changes in skin pore radius and porosity-to-
tortuosity ratio (e/t). In addition, skin treatment times required to attain specific levels of skin
electrical resistivity were analyzed to draw conclusions about the effect of SLS on
reproducibility and predictability of skin perturbation. It was found that LFS/SLS-treated FTS,
LFS/SLS-treated STS, and LFS-treated FTS exhibited similar skin perturbation. However, LFS-
treated STS exhibited significantly higher skin perturbation, suggesting greater structural
changes to the less robust STS induced by the purely physical enhancement mechanism of LFS.
Evaluation of c/c values revealed that LFS/SLS-treated FTS and STS have similar transport
pathways, while LFS-treated FTS and STS have lower cF/ values. In addition, LFS/SLS
treatment times were much shorter than LFS treatment times for both FTS and STS. Moreover,
the simultaneous use of SLS and LFS not only results in synergistic enhancement, as reflected in
the shorter skin treatment times, but also in more predictable and reproducible skin perturbation.
In conclusion, the research conducted in this thesis has contributed to the advancement
of the molecular and cellular-level understanding of phenomena associated with LFS-mediated
transdermal skin permeability enhancement. Additionally, the insights provided by this thesis
could lead to the development of optimized LFS treatment protocols and improved LFS coupling
solution formulations. This would permit attaining the desired skin permeability using milder
LFS treatment conditions and smaller skin treatment areas. This could also lead to lower power
requirements of LFS devices, thereby leading to miniaturization of devices and the creation of
more commercially-viable LFS equipment.
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Title: Professor of Chemical Engineering
Thesis Advisor: Robert Langer
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Chapter 1
Introduction
1.1 Transdermal Delivery
The transdermal route provides an attractive alternative method of drug administration compared
to oral delivery and hypodermic injections. With respect to oral delivery, advantages include: (i)
minimization of first-pass metabolic effects, (ii) bypassing of the harsh gastro-intestinal tract that
can cause degradation or denaturing of macromolecules, and (iii) decreased side effects from
dyspeptic drugs.[1, 2] Furthermore, advantages of transdermal delivery over hypodermic
injections include: (i) non-invasive delivery, (ii) decreased pain and increased patient
compliance, (iii) decreased generation of dangerous medical sharps, and (iv) less risk of needle
contamination, disease transmission, and needle misuse.[1, 2] Transdermal delivery also allows
for sustained release profiles for both systemic and localized drug delivery, which is not always
possible with oral or injectable formulations. However, the innate structure of the skin provides
a very robust barrier to drug delivery. In fact, only very small and hydrophobic molecules, such
as clonidine, estradiol, fentanyl, nicotine, nitroglycerine, scopolamine, and testosterone, have
been successfully administered at therapeutic levels through intact skin.[1, 2] This has led to the
so-called "500 Dalton Rule", which states that for a drug to be deliverable through native skin, it
must have a molecular weight of less than 500 Daltons and, in general, be hydrophobic. [3] The
reason for these limitations is that the primary barrier for transdermal transport is the outermost
layer of the epidermis, the stratum comeum, which is typically only 10-20 ptm in thickness (see
Figure 1-1). The stratum corneum is a non-viable cell layer that is comprised of highly-
crosslinked keratinocytes (or corneocytes), embedded in a continuous matrix of skin lipids (see
Figure 1-2).
To increase the permeability of skin, one can generally use one of two approaches. First, if the
drug being administered is sufficiently small, chemical modification can be utilized to increase
its lipophilicity, without directly affecting the structure of the skin. [4] Furthermore, one can also
increase the driving force for permeation using various strategies, including supersaturation of
the delivery vehicle, increasing the vehicle-to-skin partition coefficient, or by electroosmotic
flow induced by iontophoresis, without directly affecting the skin structure.[5] Conversely, one
can use a chemical or physical enhancer to decrease the barrier properties of the skin without
modifying the drug itself. Chemical enhancers include molecules such as surfactants or oils, and
operate by denaturing keratinocytes, disordering/fluidizing lipid bilayers, or creating segregated
phases in the stratum corneum.[1, 2] There are many types of physical enhancers for
transdermal delivery, such as iontophoresis (application of a continuous, low-voltage electric
field),[6] electroporation (application of pulsed, high-voltage electricity),[6] thermal or laser
ablation,[7] liquid or powder jet injectors,[8] or the use of high- or low-frequency ultrasound
(sonophoresis). Low-frequency sonophoresis (LFS), in particular, offers advantages over other
transdermal delivery methods. Specifically, with LFS, the extent of skin perturbation, and the
resulting skin permeability enhancement, can be controlled by varying the application time and
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Figure 1-1. Cross-sectional schematic of the stratified layers of the epidermis. The stratum
corneum provides the skin with the majority of its barrier properties, being comprised of
anucleate corneocytes embedded in a lipid matrix. Legend: corneocytes (CI), keratinocytes with
a nucleus (E), keratinocytes containing granules (a), and lipids ( ).
Figure 1-2. Two-photon microscopy image of the honeycomb structure of the stratum corneum.
The lipid bilayers are stained with the fluorescent dye rhodamine B - hexyl ester. The dark,
approximately hexagonal, regions are the highly cross-linked corneocytes, where the dye cannot
penetrate deeply.
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other ultrasound parameters.[9-13] Therefore, systemic, regional, and local delivery is possible
with LFS. The size of aqueous skin pores created by LFS can also be controlled by varying the
frequency and the intensity of the ultrasound utilized. [11, 14, 15] Moreover, LFS allows for
pretreatment of the skin, prior to application of a drug-containing patch, so that the actual LFS
treatment is only on the order of seconds and the device does not need to be worn constantly.[16-
19] Finally, LFS has shown promise in delivering both macromolecules and hydrophilic
permeants transdermally,[20, 21] as well as in non-invasively monitoring blood analytes, such as
blood glucose.[22, 23]
1.1.1 Historical Perspective on Ultrasound-Mediated Transdermal
Delivery
The use of ultrasound to deliver therapeutic compounds through the skin is generally referred to
as sonophoresis (also known as phonophoresis)[24], and dates back to the 1950s.[25, 26] In these
early studies, the most common applications involved the use of therapeutic or high-frequency
sonophoresis (HFS, frequencies > 0.7 MHz) for the local delivery of corticosteroids. HFS
continued to be used for nearly four decades, with researchers investigating frequencies as high
as 16 MHz.[27, 28] Typical skin penetration enhancements observed with HFS are between 1-
10 fold.[20, 27, 29, 30] However, a crucial shift in the mechanistic understanding of
sonophoresis occurred when the importance of acoustic cavitation was recognized.[28, 31-34]
By exploiting the fact that cavitational effects exhibit an inverse relationship with ultrasound
frequency,[35] Mitragotri et al. hypothesized that low-frequency sonophoresis (LFS), in the
range 20 - 100 kHz, should be more effective than HFS in enhancing skin permeability.[20, 30]
In these studies, it was shown that LFS at 20 kHz is up to three orders of magnitude more
effective than HFS at 1 MHz. In the past decade, research has focused primarily on the use of
LFS for transdermal drug delivery, due to the much greater enhancement ratios attained at these
lower frequencies, while research with HFS has focused on topical or regional delivery. More
background into transdermal delivery can be found in the following reviews: [36-3 8].
1.2 Background
1.2.1 Ultrasound Basics and their Implications in Sonophoresis
An ultrasound wave is a longitudinal compression wave with frequency above that of the audible
range of human hearing (above 20 kHz). Sound waves propagate by causing local oscillatory
motion of particles in the medium through which they are traveling. As the wave displaces
particles at a given location, the local density and pressure of the medium increases or decreases
depending on whether that location is in a rarefaction (low pressure) or compression (high
pressure) cycle of the wave.[39] Many interesting phenomena occur in aqueous solution due to
the resulting oscillation between low and high pressure, which will be discussed in Section 1.
2.1.1.
Ultrasound waves are created by first generating an electric signal which is subsequently
amplified before being sent to the ultrasound horn. Once the electric signal reaches the
ultrasound horn, it is converted into a mechanical wave by piezoelectric crystals (which change
their static dimensions in response to an electric field[40]) through the tip of the transducer,
which is then transmitted to the desired medium. Two characteristics of ultrasound waves are
most significant in sonophoresis: the amplitude and the frequency. The amplitude of the
ultrasound wave is proportional to the displacement of the ultrasound horn during each half
cycle. The frequency of the ultrasound wave corresponds to the number of times that the
transducer tip is displaced per second of application time. Commonly used frequencies for
sonophoresis are generally separated into two groups: (i) low-frequency sonophoresis (LFS),
which includes frequencies in the range 20 - 100 kHz, and (ii) high-frequency sonophoresis
(HFS), which includes frequencies in the range 0.7 - 16 MHz (the range of both therapeutic and
high-frequency ultrasound), but most commonly 1 - 3 MHz. This distinction is made because of
the different mechanisms of enhancement associated with LFS and HFS, as discussed in Section
1.3. The range of frequencies between ~100 kHz and 700 kHz, which is referred to as
intermediate ultrasound, is not included in either (i) or (ii) above because this range of
frequencies has not been thoroughly investigated in the context of transdermal drug delivery, and
therefore, the primary enhancement mechanisms are not as well understood. The most likely
reason that LFS and HFS have been utilized historically for transdermal delivery applications,
while intermediate ultrasound has not, is because of the lack of commercially available
ultrasound equipment in the range 100 - 700 kHz.
Additional experimental variables that are important in sonophoresis include: i) the ultrasound
duty cycle (ratio of the time that ultrasound is on), ii) the distance between the ultrasound horn
and the skin (horn-to-skin distance), iii) treatment time, and iv) composition of the ultrasound
coupling medium (the medium between the ultrasound horn and the skin, which can be an
aqueous solution or a gel-like formulation). Commonly used ultrasound duty cycles are 10%
(e.g., 0.1s ON and 0.9 s OFF),[10, 13, 20, 21, 30, 41-43] 50% (e.g., 5 s ON and 5 s OFF),[1 1, 14,
15, 23, 44-57] or continuous application.[ 12, 41, 58-62] Ultrasound pulsing is common because
it decreases thermal effects associated with ultrasound by allowing time for heat to dissipate
from the coupling medium during the treatment. Many different horn-to-skin distances have
been utilized in sonophoretic research, ranging from placing the ultrasound horn in contact with
the skin (zero tip displacement) to as far as 4.0 cm from the skin surface.[11, 58] The most
common tip displacements reported for use with LFS range from 0.3 cm to 1.0 cm.[9, 10, 12-15,
20, 21, 23, 30, 41, 42, 44-46, 48-56, 60, 62-69] With HFS, it is much more common to have
smaller tip displacements, almost in contact with the skin, for reasons that will become clear
when the enhancement mechanisms associated with HFS and LFS are discussed in Section 1.3.
Treatment times can also vary greatly, from a few seconds,[17-19, 70] to a few minutes,[14, 15,
51, 56] or even to cases where steady-state is attained, which can take many hours to days.[13,
21, 71] Finally, formulation of the coupling medium is also a very important variable in
sonophoresis. The viscosity, surface tension, density, acoustic impedance, and other bulk and
interfacial properties of the coupling medium can all play significant roles in determining the
extent of skin permeability enhancement observed as a result of the ultrasound treatment.
Furthermore, the coupling medium can contain an active ingredient (e.g., a drug) or can include a
chemical enhancer (co-enhancer), such as a surfactant. Because of the mechanisms associated
with LFS and HFS (see Section 1.3), LFS coupling media are typically aqueous formulations,
while HFS coupling media are typically gels. In both cases, the coupling solution has an
acoustic impedance which is similar to that of the skin, such that there is no significant reflection
of the ultrasound wave at the interface between the skin and the coupling medium. The
mechanistic effects associated with the formulation used will be discussed further in Sections 1.3
and 1.4.
1.2.1.1 Acoustic Cavitation
Although all the mechanisms responsible for skin permeability enhancement by sonophoresis are
not fully understood, it is generally accepted that the main contributor is acoustic cavitation,
particularly in the case of LFS.[42, 59, 60, 72] The term cavitation can take multiple definitions
depending on the source of the stress acting upon the system. Strictly speaking, cavitation is the
process by which a liquid is pulled apart when it is acted upon by a force in excess of its tensile
strength, causing the formation of voids in the system. [73] However, due to inhomogeneities in
all real liquids, such as those induced by the presence of dissolved gases, microscopic gas
bubbles, or other particulates, the theoretical tensile strength of a liquid is never observed in
practice. [73] For this reason, cavitation in all systems is observed far below the theoretical limit,
even in extremely purified liquids. This definition of cavitation is not well suited for systems
involving acoustic pressure variations, as is the case with sonophoresis. Instead, acoustic
cavitation can be loosely defined as the process by which any of the following occurs: i) small
gas bubbles already present in a liquid pulsate or grow, ii) gas bubbles form in the bulk or on
nuclei due to acoustic pressure variations, or iii) the occurrence of any other type of growth,
splitting, or interaction of gas bubbles due to acoustic pressure oscillations in solution.[74]
Cavitation can be further divided into two types: stable and transient. Stable cavitation is defined
as the pulsation of cavitation bubbles over many acoustic pressure cycles without collapse.
Transient cavitation is defined as the rapid and uncontrolled growth of cavitation bubbles over
several pressure cycles, eventually leading to their collapse into smaller bubbles or, if near a
surface such as the skin, to the formation of a microjet.[75] A microjet results from the
asymmetry in bubble collapse pressure near an interface. Depending on the properties of the
interface, the bubble can either generate a jet towards the interface, away from the interface, or
collapse in an alternate shape.[76] The collapse of a cavitation bubble as a microjet directed
towards the interface tends to occur near more rigid surfaces[76] and has been implicated in
causing skin perturbation during LFS treatment.[14, 15, 54, 59] The growth of gaseous bubbles
in response to ultrasound occurs by a process called rectified diffusion, which is discussed in
Section 1.2.1.2.
It is important to stress that the resonant radius of cavitation bubbles exhibit an inverse
relationship with the applied ultrasound frequency.[35] Specifically, the linear resonant bubble
radius is defined by the equation r,,, = C / f , where r,, and f are the resonant bubble radius and
the applied ultrasound frequency, respectively, and C is a constant that depends on the
properties of the solution in which cavitation is occurring.[35] Therefore, high-frequency
ultrasound will generate bubble populations having smaller radii than low-frequency ultrasound.
For example, the linear resonant bubble radius of an air bubble in water, which is assumed to be
incompressible and inviscid, for ultrasound at 20 kHz is 150 Im, while at 3 MHz it is only 1 pm
(see the equation above).[77, 78] The average size of cavitation bubbles in a given system will
dictate where cavitation can occur in that system. For example, if the resonant bubble radius is
larger than the dimensions of the skin voids available for cavitation to occur, it is unlikely that
cavitation within the skin itself can play a significant role in skin permeability enhancement. [79]
Therefore, cavitation within the skin is much more likely to occur with HFS, when the resonant
bubble radius is on the order of microns or smaller, rather than with LFS. This will be discussed
further in Section 1.3. Moreover, Ueda et al. have shown, through acoustic spectroscopy
measurements, that the amount of transient cavitation generated in the coupling medium between
the ultrasound horn and the skin membrane increases with decreasing ultrasound frequency, in
the range 41 kHz - 445 kHz.[62] This suggests that not only cavitation bubble size, but also
transient cavitation itself increases with decreasing ultrasound frequency, which has implications
on the level of enhancement that can be achieved at lower ultrasound frequencies, relative to
higher ultrasound frequencies (see discussion on mechanisms in Section 1.3).
1.2.1.2 Rectified Diffusion
Cavitation cannot be thought of as an isolated phenomenon, because it is strongly linked to many
other processes that cause unique behavior in acoustically cavitating systems. For example, the
process of rectified diffusion causes oscillating cavitation bubbles to grow under an acoustic
pressure field.[80, 81] It is this growth and the eventual collapse of cavitation bubbles that is
believed to cause skin permeability enhancement during LFS.[59] During rectified diffusion, a
bubble encountering a negative-pressure half-cycle of an acoustic field will grow due to the
expansion of the gas inside the bubble. In addition, some of the liquid surrounding the bubble
will diffuse through the boundary layer and vaporize, causing the amount of gas in the bubble to
increase. In the subsequent positive-pressure half-cycle, the bubble will collapse to a size which
is much smaller than that in its previous state. Depending on the temperature and the
composition of the gas and liquid phases, some of the vapor will condense and join the liquid
phase surrounding the bubble. This process favors bubble growth for two main reasons: (i) the
"area"' effect, and (ii) the "shell" effect.[82] The "area" effect simply occurs because the surface
area of a bubble in the expanded state is much greater than in the collapsed state. Therefore,
there is much greater area for diffusion into the bubble to occur in the expanded state than for
diffusion out of the bubble to occur in the collapsed state. The "shell" effect occurs due to the
existence of a diffusion boundary layer (see Figure 1-3), or shell, through which gas or vapor
transfers between the gas phase of the bubble and the surrounding liquid phase. When the
bubble is in an expanded state and the concentration of gas in the bubble is at its lowest point
(Figure 1-3, right-hand side), the shell is thin and, therefore, there is a larger concentration
gradient for diffusion into the bubble. Conversely, in the collapsed state, the boundary layer is
thicker, because of the rapid collapse of the bubble, and therefore, the driving force for diffusion
out of the bubble decreases. Opposing the forces of bubble growth is the Laplace pressure,
caused by the surface tension of the bubble. The Laplace pressure, APL, is given by:
AP = 27/r , where y and r are the surface tension and radius of the gas bubble, respectively. If
the radius of the gas bubble is exceedingly small, the Laplace pressure will be extremely large,
causing the gas bubble to dissolve back into the bulk phase once the ultrasound is turned off.[83]
In this respect, the duty cycle of the applied ultrasound can also play an important role. If the
pulse rate is rapid, cavitation bubbles may not have sufficient time to grow, and therefore, when
the ultrasound is in the OFF period of the duty cycle, bubbles may dissolve back into the
solution,[84] and will be unable to contribute to skin permeability enhancement in subsequent
cycles.
Rectified diffusion is most important to cavitation when the amount of liquid vaporized in the
negative-pressure half-cycle is greater than the amount of vapor condensing in the positive-
pressure half-cycle. In this case, there is net growth of the bubble through each consecutive
pressure cycle of the acoustic wave. If this process proceeds quickly, with rapid bubble growth
over a few cycles, the event is considered a transient cavitation bubble and the bubble will either
collapse in the bulk or can generate a microjet near an interface.[75] The occurrence of transient
Figure 1-3. Relative thickness of the diffusion boundary layer (in black) of a spherical cavitation
bubble in the collapsed state (in the compression cycle, left) and in the expanded state (in the
rarefaction cycle, right).
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cavitation depends on the ultrasound frequency, its amplitude, and the size of the cavitation
bubble.[78] On the other hand, if this process proceeds slowly and an equilibrium is reached, a
stable cavitation bubble will result and the bubble will continue to oscillate during many pressure
cycles.[82, 85] The importance of transient and stable cavitation to ultrasound-induced skin
permeability enhancement will be discussed further in Section 1.3.
1.2.1.3 Forces Acting on Acoustic Cavitation Bubbles
In addition to pulsating and growing in response to ultrasound, cavitation bubbles are also
subject to radiation pressure and convective forces in an ultrasound field that can cause
translational motion or interactions between bubbles. The first of these forces, the primary
Bjerknes force, may play a role in LFS by causing translational bubble motion when buoyancy is
not a factor (i.e. when the radius of the bubble is sufficiently small so that the upward buoyant
force does not exceed the drag force and the gravitational force). [77] The primary Bjerknes force
occurs as a result of the coupling of bubble oscillation with the applied acoustic pressure
gradient. It causes bubbles that are smaller than the resonant bubble radius, at the applied
frequency, to move up pressure gradients, or towards pressure antinodes, and bubbles that are
larger than the resonant bubble radius to move down pressure gradients, or towards pressure
nodes.[77] The effect of the primary Bjerknes force can be beneficial to LFS because, under
typical operating conditions, the distance between the ultrasound transducer and the skin is less
than one-fourth of the ultrasound wavelength, k (in water at 20 kHz, k = 7.5 cm), corresponding
to the first pressure antinode (A/4 ~1.9 cm). Therefore, any small bubble produced in the
coupling medium between the ultrasound transducer and the skin will tend to move towards the
surface of the skin as a result of this force. Even more significant than the primary Bjerknes
force, however, is acoustic streaming, which is the convection-induced motion of cavitation
bubbles due to the movement of the ultrasound horn itself.[73] Acoustic streaming causes the
bulk fluid to move in the direction of the applied ultrasound field, which in the case of LFS is
towards the skin surface. This causes smaller bubbles, which do no experience significant
buoyancy, to also move towards the surface of the skin. Furthermore, this bulk fluid movement
causes rigorous mixing of the coupling medium, which can have implications on enhancing
mechanisms in areas of the skin where cavitation microjets do not occur (see Section 1.4.1).[24]
This also implies that, at higher ultrasound intensities, when bubbles grow rapidly and larger
bubbles are formed, bubbles will collect at the surface of the ultrasound transducer due to
buoyancy, causing decreased process efficiency (which has been observed in practice[11]).
A second force of interest in LFS is what is referred to as the secondary Bjerknes force. This
force can cause the mutual attraction or repulsion of oscillating cavitation bubbles, and occurs as
a result of the coupling of the sound field emitted by each oscillating bubble.[86, 87] However,
the secondary Bjerknes force can also cause other, higher-order, phenomena such as acoustic
streamers (the formation of stable pairs of bubbles that oscillate about an equilibrium distance
from each other and move through an ultrasound field) and cavitation bubble clouds (localized
collections of cavitation bubbles in an ultrasound field).[88-90] These phenomena may be
significant in sonophoresis, particularly with respect to the recently recognized heterogeneous
transport observed with LFS, as localized collections of cavitation bubbles may induce skin
perturbation solely in discrete regions (see Section 1.4.1).[51, 54]
1.2.2 Modes of Skin Treatment with Sonophoresis
Ultrasound is applied to skin primarily in one of two ways: i) as a pretreatment of the skin prior
to contact with a drug or permeant (which will hereafter be referred to as "pretreatment"), or ii)
as a simultaneous application of ultrasound through a coupling medium containing the drug or
permeant (which will hereafter be referred to as "simultaneous treatment"). Simultaneous
treatment causes enhancement of drug transport in two ways: i) by structural changes to the skin
that increase skin permeability, and ii) through convection-related mechanisms that occur only
when ultrasound is applied.[91] Conversely, the pretreatment method only enhances skin
permeability by mechanism (i), because the drug is applied only after ultrasound treatment is
completed. The simultaneous protocol is still common in studies that utilize HFS.[92-96] With
LFS, both types of skin treatments have been investigated in the past, although the most common
type of current treatment is the pretreatment method, including in clinical use of the
technology.[17-19, 70] This is mainly because of three reasons. First, the action of ultrasound
on drugs, or other active ingredients, can cause degradation of the molecules or other chemical
reactions to occur. This can result in loss of activity or effectiveness of the therapeutic
compound and may also cause undesired reactions that generate unknown species which could
have deleterious biological effects. [97] Second, for clinical applications, simultaneous treatment
requires that patients wear the ultrasound device for the duration of the treatment, while
pretreatment has the advantage of requiring only that a patch be applied following a brief, -10
second, ultrasound treatment.[91] Finally, the use of LFS for transdermal drug delivery has
resulted in the ability to increase skin permeability to a greater extent than previously possibly
with HFS,[20, 30] making it feasible for pretreatment of the skin to deliver therapeutic levels of
drugs, without the need for the additional convection mechanism associated with the
simultaneous treatment.
1.3 Mechanisms of Skin Permeability Enhancement in Sonophoresis
1.3.1 Non-Cavitational Mechanisms of Enhancement in Sonophoresis
In addition to cavitation, which will be discussed in Sections 1.3.2 - 1.3.4, there are several other
mechanisms whose roles on skin permeability enhancement in sonophoresis have been
investigated. These include: i) convection (acoustic streaming and resulting boundary-layer
reduction),[30, 79] ii) thermal effects,[30, 41, 79, 98] iii) mechanical or radiation pressure
effects,[29, 79] iv) lipid extraction,[43], and v) increase in the solution-membrane interfacial
transfer rate,[99] among others.
1.3.1.1 Convection-Related Mechanisms
It is important to recognize that the mechanisms of enhancement depend on the skin treatment
protocol used. For example, utilizing the simultaneous treatment protocol, enhancement of drug
permeation by convection is quite feasible. However, using a pretreatment protocol, convection
cannot play any role in the enhancement of transport because the drug is not present in the
coupling medium during the ultrasound treatment. Nevertheless, even with simultaneous
treatment protocols, there have been conflicting claims about the role of convection in enhancing
drug delivery. One likely explanation for this seeming incongruity is the skin model and skin
thickness utilized. For example, using 20 kHz LFS (intensity of 1.6 W/cm 2) applied
simultaneously with mannitol or sucrose, Tang et al. showed that convection only plays a
significant role in transport across heat-stripped human skin (which contains solely the
epidermis), while it was not significant in the case of the thicker split-thickness (0.7 mm) or full-
thickness (>1.4 mm) pig skin models.[21] Similarly, Mitragotri et al. showed that convection
did not affect mannitol permeability in full-thickness pig skin (20 kHz, 7 W/cm 2).[10] In other
words, the skin permeability to mannitol was the same regardless of whether mannitol was
present in the LFS coupling medium or was applied post-treatment.
Other studies, however, have suggested that convection can be important using LFS. For
example, Tachibana et al. showed that the analgesic effect of 2% lidocaine, simultaneously
applied with 48 kHz ultrasound (0.17 W/cm 2), was greater than when applied with an aqueous
formulation instead of with a gel.[100] These authors concluded that the most likely reason for
this observation was that ultrasound-induced convective streaming processes (such as acoustic
streaming, see Section 1.2.1.3) were enhancing the bioavailability of lidocaine at the skin surface
in the less-viscous aqueous formulation. In addition to the studies using LFS, a number of HFS
studies have investigated the effect of convective processes as potential mechanisms of
therapeutic delivery. Using cellophane membranes as a model, Lenart et al. deduced that with 1
MHz HFS treatment (1.2-6.0 W/cm 2), the main mechanism of increased diffusion of electrolytes
was due to the formation of acoustic microcurrents.[101] In addition, utilizing 1 MHz HFS (1.5-
3.0 W/cm2), Levy et al. concluded that a combination of convective mixing and cavitation were
the main mechanisms of enhanced delivery of mannitol, inulin, and physostigmine.[33] Simonin
also demonstrated, using a theoretical analysis, that convective reduction of the boundary layer
above the skin by stirring of the donor compartment could decrease the overall resistance of the
membrane by about 10%.[79] Convection has also been cited as a possible mechanism in other
HFS studies,[102] while it has not been implicated in several others.[29, 34, 103, 104]
1.3.1.2 Thermal Effects
Thermal effects have been studied in great detail with respect to sonophoresis, because
attenuation of an ultrasound wave leads to heating of the medium that the wave traverses. An
increase in temperature can increase skin permeability by: i) increasing the kinetic energy and
diffusivity of drug compounds, ii) dilating points of entry of the skin (e.g., hair follicles and
sweat glands), iii) facilitating drug absorption, and iv) enhancing circulation of blood in the
treated area (in in vivo experiments). [29, 79] Because thermal effects are directly proportional to
the ultrasound intensity and duty cycle, reports have differed on the importance of heating as a
mechanism of sonophoresis. Many studies have concluded that thermal effects do not play a role
in HFS (1-16 MHz, 0.2-3.0 W/cm 2) enhanced transdermal transport, although the temperature in
the donor solution was not observed to increase more than 1-2 'C in these studies.[28, 33, 103]
Conversely, and not surprisingly, in studies that observed much larger temperature increases (in
excess of 10 'C), thermal effects were found to play a role in increasing permeant transport,
although a temperature increase alone could not explain the full enhancement observed with the
HFS treatment (1 MHz, 1 W/cm 2).[l 02] Meidan et al. even concluded that heating is the main
mechanism of action with HFS.[98] A study of sonophoresis, at an intermediate frequency of
150 kHz (2 W/cm 2), also concluded that thermal effects may be a significant mechanism of
increased flux of hydrophilic permeants.[105] However, recent studies, especially those
conducted with LFS at higher amplitudes, have paid more attention to controlling and
minimizing thermal effects. This is because significant increases in temperature, and sustained
exposure to high temperatures, can lead to many harmful side effects, such as epidermal
detachment, bums, and necrosis of the viable epidermis or underlying tissues.[41] Therefore,
most current sonophoresis treatment protocols require periodic replacement of the coupling
medium to minimize heating. Thermal effects have therefore been shown not to play a
significant role in LFS studies.[42, 43, 60] For example, in Chapter 2 I will show that heating a
solution to 37 'C does not increase the skin uptake of sodium lauryl sulfate (SLS) to a
statistically significant extent, compared to controls at 25 'C, in 20 minutes of exposure (a
typical duration for an in vitro LFS treatment, with replacement of the coupling medium every 2
minutes).[14, 15] However, similar to observations with HFS, if the temperature is allowed to
increase in the LFS experiments, and the increased temperature is maintained for an extended
time, thermal effects will play a role. For example, Merino et al. demonstrated that during a 2-
hour treatment using 20 kHz LFS (4.5-15.0 W/cm2 , 10% duty cycle), thermal effects could
explain up to 25% of the observed mannitol transport, with the temperature increasing as much
as 20 'C during the treatments.[57] These authors also stated that the remaining enhancement
was likely due to cavitation (see Sections 1.3.2 - 1.3.4).
1.3.1.3 Other Proposed Mechanisms
Other mechanisms of enhancement have also been reported in the literature, albeit less often.
One potential mechanism that has been considered is the direct force of the acoustic wave on the
skin membrane or on the interface between the skin and the coupling medium.[101, 106]
However, an investigation by Simonin has shown that this effect is exceedingly small and is
therefore negligible relative to the overall skin permeability enhancement. [79] A unique study by
Alvarez-Roman et al. showed that up to 30% of the stratum comeum lipids can be extracted into
the coupling medium during LFS exposure (20 kHz, 15 W/cm 2 ).[43] These authors proposed
that the decrease in skin lipids could explain previously observed phenomena such as: i)
decreased skin electrical resistance, ii) increased water permeability, and iii) sustained
permeability enhancement post-treatment. However, Alvarez-Roman et al. suggested that
cavitation in the coupling medium is the most likely mechanism for the observed non-uniform
enhancement across the skin surface, as well as a possible reason for the lipid extraction
itself.[43] Therefore, lipid extraction due to LFS is likely a result of other enhancement
mechanisms (e.g., cavitation), and not a direct mechanism of the LFS treatment. Finally, Julian
and Zentner proposed that 20 kHz LFS (-13-46 W/cm 2) increased the diffusion of benzoic acid
and hydrocortisone across model membranes (polydimethylsiloxane or cellulose) by decreasing
the activation energy for diffusion, and thereby increasing the diffusion coefficients and partition
coefficients between the solution and the membrane for these compounds.[99] However, no
physical explanation was given as to how the ultrasound caused these changes, other than
possible thermal effects. A subsequent theoretical analysis by Simonin to identify a microscopic
physical interpretation as to why ultrasound decreases the interfacial energy barrier was
unsuccessful. [79] Therefore, it is again possible that the proposed energy barrier reduction
mechanism results simply from thermal effects (note the high amplitudes utilized in this
study[99], which are reported above), instead of being a direct mechanism itself.
1.3.2 The Role of Cavitation in HFS
In some of the first mechanistic investigations using HFS, Kost et al. and Levy et. al.
hypothesized that cavitation could play a role in transdermal delivery with sonophoresis.[32, 33]
It was then shown by microscopy-based histological examination that cavitation within the skin
is a significant mechanism at 10 MHz and 16 MHz.[28] A following theoretical analysis
suggested that, at frequencies above 1 MHz, cavitation within skin appendages (such as hair
follicles) could explain observed skin permeability enhancements using HFS, although it was
unlikely that cavitation within the stratum corneum lipid bilayers could occur. [79] However, the
most significant experimental study into the mechanisms of HFS, at frequencies between 1-3
MHz, was conducted by Mitragotri et al., and showed that cavitation within the skin is the
primary mechanism of skin permeability enhancement.[34] Moreover, the microscopy-based
findings showed that cavitation occurs within cavities near the corneocytes of the stratum
corneum, leading to the hypothesis that the direct interaction of the oscillating cavitation bubbles
induces disordering of the stratum corneum lipid bilayers, causing the observed increase in skin
permeability (see Figure 1-4).[34]
1.3.3 The Role of Cavitation in LFS
The role of cavitation as the primary mechanism of skin permeability enhancement during LFS
was demonstrated by Tang et al. in a series of experiments involving the selective suppression of
cavitation inside and outside the skin. [42] First, to show that cavitation outside the skin plays a
more significant role than cavitation inside the skin, a highly viscous liquid, castor oil, was used
in place of water in the coupling medium. This, in effect, completely suppressed cavitation in
the coupling medium outside the skin, while not changing the conditions inside the skin
significantly. It is important to note that the acoustic impedance of both water and castor oil are
similar to that of skin, and therefore, the efficiency of energy transfer between the coupling
medium and the skin is similar using either type of formulation. In the next series of
experiments, a high-pressure diffusion cell was built, allowing for the suppression of cavitation
Figure 1-4. Illustration of cavitation bubbles inducing disordering within the stratum comeum
under HFS. Legend: Keratinocytes (E^7), cavitation bubbles (0), lipid bilayers ( ), and
coupling medium ( ).
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in the entire system, both outside and inside the skin, by generating high static pressure. In both
the castor oil and high-pressure studies, no significant change in skin permeability was observed
compared to passive controls, and therefore, it was concluded that cavitation outside the skin was
indeed the most important mechanism of skin permeability enhancement. [42] To elucidate
whether transient or stable cavitation plays a more significant role in skin permeability
enhancement by LFS, Tang et al. and Tezel et al. independently measured the pressure
amplitudes of subharmonic emissions and broadband noise.[42, 60] Subharmonic emissions (i.e.,
f/2) are in part caused by the repeated oscillation of bubbles in an acoustic field and are
associated with stable cavitation.[107] Broadband noise is associated with the rapid growth and
collapse of bubbles and is therefore linked to transient cavitation. The findings of Tang et al. and
Tezel et al. showed that there is no relationship between the sub-harmonic emission recordings
and skin permeability enhancement. However, a strong correlation between skin permeability
enhancement and broadband noise was observed.[42, 60] Therefore, it was concluded that
transient cavitation is the most significant mechanism of skin permeability enhancement during
LFS. It has also been shown that by enhancing cavitation activity outside the skin, by the use of
porous resins as cavitation nuclei in the coupling medium, increased skin permeability can be
attained. This further demonstrates the significance of cavitation outside the skin in causing skin
permeability enhancement using LFS.[49]
The findings above, however, did not elucidate: (i) which types of transient cavitation events
(microjets or shockwaves) lead to the observed enhancement of skin permeability, and (ii) the
location of these transient cavitation events in the coupling medium: at the surface of the skin,
Figure 1-5. Illustration of a cavitation bubble asymmetrically collapsing into the stratum
corneum as a microjet under LFS. Legend: Keratinocytes (1^7), lipid bilayers ( ), and coupling
medium ( ).
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close to the surface of the skin, or in the bulk. Tezel et al. were able to show that the critical
distance of a bubble from the skin surface required to cause disruption to the surface is
approximately one maximum bubble radius.[59] The maximum bubble radius is the largest
radius to which the bubble expands to in the negative pressure half-cycle of the ultrasound field
(which is a function of the operating ultrasound parameters). This corresponds to no more than
about 150 ptm at the operating frequency of 20 kHz.[59] However, a bubble which is only one
diameter away from a solid surface is not likely to maintain symmetry during its oscillation.[108]
Therefore, it is not likely that symmetric bubble oscillation resulting in shock waves plays a
central role in the perturbation of the skin. This indicates that the most likely reason for skin
permeability enhancement during LFS is microjet penetration into the skin surface, or microjet
collapse near the skin surface, resulting in skin perturbation (see Figure 1-5).[14, 15, 54, 59]
Additional research by Ueda et al. has revealed that transient cavitation in the vicinity of a
membrane is only significant at frequencies in the LFS range. [62] Specifically, these authors
demonstrated that 41 kHz LFS treatment caused the disruption of a rhodamine B layer adsorbed
to a gelatin membrane in discrete regions, while cavitation in the vicinity of the membrane was
not significant at 158 kHz and 445 kHz, because no disruption of the rhodamine B layer was
observed.[62] Ueda et al. also demonstrated that transient cavitation generation increases with
decreasing ultrasound frequency, which scales directly with the membrane permeability. [62]
Furthermore, by conducting experiments at multiple frequencies in the range 20 kHz - 60 kHz,
in Chapter 2 I will show that there is a strong correlation between skin pore radius and
ultrasound frequency. This correlation scales similarly to the relationship between the resonant
bubble radius and ultrasound frequency (see Section 1.2.1.1), suggesting that the direct action of
cavitation bubbles collapsing onto the skin, likely as microjets (see Figure 1-5), accounts for the
observed variation in skin pore radius with ultrasound frequency.[14, 15] Other recent studies
have also suggested that cavitation bubble collapses on the skin surface as microjets play a
dominant role in skin permeability enhancement compared to other cavitation-related
mechanisms, such as shock wave emission.[44] For example, Watanabe et al. have found that
small pits can be observed on skin imaged with environmental scanning electron microscopy,
which likely results from cavitation at the skin surface.[109]
1.3.4 Difference in the Mechanisms of LFS and HFS
It is essential to recognize that different mechanisms are responsible for skin permeability
enhancement in LFS and HFS. A common erroneous practice in the sonophoresis literature is to
rationalize observations made using LFS by invoking enhancement mechanisms which are only
applicable using HFS. In particular, a serious mistake involves identifying the actual location of
cavitation during the ultrasound treatment (compare Figures 1-4 and 1-5). In HFS, as stated
earlier in Section 1.2.1.1, the linear resonant bubble radius is on the order of less than 1 pm,
which is comparable to the thickness of the lipid bilayers of the stratum corneum. This suggests
that it is possible for cavitation to occur within skin appendages (hair follicle shafts, sweat
glands, etc.)[79] or in lacunar cavities within the skin itself.[34] Indeed, there have been
numerous studies reporting that cavitation within the skin is an important factor in skin
permeability enhancement using HFS, at frequencies ranging from 1-16 MHz. [28, 32-34] In
fact, it was believed that cavitation outside the skin would decrease the efficiency of the HFS
treatment by decreasing energy transfer between the ultrasound horn and the skin treatment
site.[27] Therefore, for these applications, it was suggested that suppressing cavitation in the
coupling medium would be advantageous for overall skin permeability enhancement, which
could be achieved by utilizing non-aqueous media, such as mineral oil, in the coupling solution.
Unfortunately, when the switch from HFS to LFS was made,[20] it was still believed that
cavitation within the skin would continue to play a dominant role. This has led to many
erroneous citations and claims in the literature that transient cavitation within the skin is
significant in LFS enhancement of skin permeability (e.g., [58, 64, 110, 111]). However, since
that time, it has been shown conclusively through cavitation suppression experiments, chemical
and acoustic dosimetry methods, and theoretical analysis, that cavitation in the coupling medium
near the skin surface is, in fact, the primary mechanism of skin permeability enhancement in
LFS.[14, 15, 42, 44, 59, 60] Therefore, careful attention should be paid when designing
experiments and explaining observed trends, depending on the frequency of ultrasound utilized.
For example, when utilizing LFS, cavitation above the skin has been shown to be the primary
mechanism of enhancement, and therefore, the utilization of experimental protocols that suppress
this mechanism, such as degassing of the coupling medium, placing the ultrasound horn in
contact with the skin, or using a coupling medium with a high viscosity, is not recommended,
unless suppression of cavitation above the skin is actually desired.
1.4 Phenomena Observed in Sonophoretic Transdermal Drug Delivery
1.4.1 Localized Transport Regions
An important discovery in the area of skin permeability enhancement by LFS was the
identification of heterogeneity in the enhancement of skin perturbation. Tang et al.[48] and
Tezel et al.[68] observed independently that LFS operating at 20 kHz, with a colored permeant
present in the coupling medium, produced highly-stained regions of LFS-treated skin. These
regions of hypothesized high permeability were given the name localized transport regions
(LTRs). Kushner et al. verified that these regions are indeed regions of increased permeability
by using a unique masking method on LFS-treated skin. [51] Experiments using solely LFS (20
kHz, 15 W/cm 2) showed that only a single LTR formed during sonication of skin samples,
directly below the ultrasound transducer.[43] However, further investigation into the
phenomenon of LTR formation showed that when 1% w/v SLS was added to the LFS coupling
medium (frequencies of 19.6 - 58.9 kHz), LTRs formed in stochastic patterns across the surface
of the skin, ranging in coverage from 5 - 25% of the skin surface area (see Figure 1-6).[50, 51,
60, 68] In addition, Kushner et al. showed that the LTRs are not only highly perturbed (5000-
fold decrease in skin resistivity), but that the non-LTRs are also permeabilized relative to
untreated skin (170-fold decrease in skin resistivity) when SLS is present during the skin
treatment.[51] This is a significant finding because it shows that two levels of skin electrical
resistivity enhancement are present. In comparison, in the case of LFS alone, only the LTRs were
shown to be perturbed to a significant extent, with minimal change to the skin in the non-
LTRs.[43] The frequency dependence of the skin permeability enhancement in the presence of
SLS was studied by Tezel et al. at 20-100 kHz and 1.08 W/cm2, and the following trends were
observed: (i) as the ultrasound frequency increases, the threshold ultrasound intensity for the
observation of skin conductivity enhancement increases, (ii) at lower ultrasound frequencies,
localized transport plays a more significant role, with LTRs observed on the surface of the skin,
and (iii) at higher ultrasound frequencies, transport occurs more homogenously across the
surface of the skin.[68] In another study utilizing multiple ultrasound frequencies (41 kHz, 158
kHz, and 445 kHz), Ueda et al. were able to show that disruption of the surface of gelatin
membranes occurred only at 41 kHz, in discrete spots.[62] This suggests that localized transport
Figure 1-6. LTRs formed on the surface of pig skin treated with 20 kHz LFS and a surfactant.
LTRs are stained with allura red.
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is only significant when treating skin in the LFS range. Furthermore, in Chapter 2 I will show
that the pore size within LTRs in skin treated with LFS/SLS is frequency dependent, while in
non-LTRs no frequency dependence is observed.[14, 15] Because the size of cavitation bubbles
is also frequency dependent[35], I will show that cavitation-induced microjet collapse at the skin
surface is the most likely mechanism of LTR formation and of skin permeability enhancement
within LTRs. Conversely, within non-LTRs, due to the frequency independence in the observed
pore size, the action of SLS on the skin will be shown to be the main mechanism of non-LTR
enhancement, with increased uptake of SLS into the non-LTRs taking place via a convection-
related mechanism, such as boundary-layer reduction by acoustic streaming (see Section
1.2.1.3).[14, 15] It is noteworthy that there have been no reports of LTR formation with HFS,
which is expected because it is known that localized transport is more significant only at lower
ultrasound frequencies (interested readers are referred to Refs. [54, 68] for a more detailed
discussion of LTRs).
1.4.2 Synergism of Sonophoresis and Chemical Enhancers
One of the most significant phenomena observed with sonophoresis is that its combination with
chemical enhancers, such as surfactants, results in synergism in the enhancement of transdermal
transport. Chemical enhancers alone are known to permeabilize skin by solubilizing or
extracting skin lipids and by denaturing corneocytes.[2] However, their effect on skin
permeability can be even more dramatic when combined with ultrasound. One of the first
rigorous studies on the synergism between chemical enhancers and ultrasound was conducted by
Johnson et al., who showed that different combinations of chemical enhancers in the presence of
HFS causes an increase in the permeability and flux of lipophilic permeants across in vitro
human cadaver skin.[ 112] Their major finding was that for the model permeant corticosterone, a
combination of ethanol and linoleic acid, in equal proportions, enhanced the skin permeability by
a factor of 8.7 and the flux by a factor of 903. However the same formulation, when combined
with HFS (1 MHz, 1.4 W/cm 2), enhanced the skin permeability by a factor of 14.4 and the flux
by a factor of greater than 13,000.[112] The authors explained that the observed enhancement
induced by HFS/linoleic acid was caused by either an increase in the fluidity of the lipoidal
domain in the stratum corneum or by the formation of a separate bulk oil phase in the skin.
Another study by Meidan et al. demonstrated the synergism between 1.1-3.3 MHz HFS and the
chemical penetration enhancer laurocapram (Azone) in delivering hydrocortisone across in vitro
rat skin.[113] Their mechanistic findings suggested that the synergism between the two
enhancers was due to accelerated laurocapram diffusion into the skin due to ultrasonic thermal
effects. Furthermore, Liu et al. showed that the combined treatment of rat skin using LFS (20
kHz) with laurocapram or SLS exhibited synergistic topical delivery of cyclosporin A.[114]
Specifically, the combination of LFS and chemical enhancers caused an increase in cyclosporin
A skin concentration of over an order of magnitude compared to controls. Additional studies
demonstrating synergism between chemical enhancers and ultrasound include: i) HFS (1 MHz)
and d-limonene in ethanol on the percutaneous absorption of ketorolac tromethamine through in
vitro rat skin,[115] ii) HFS (1 - 1.1 MHz) and thiazone or glycerol (among several others) to
increase skin optical clearing,[l 16-120] iii) HFS (0.8 MHz) and laurocapram, oleic acid, or 2-
propanediol on the delivery of sinomenine hydrochloride through rat skin,[121] iv) HFS (0.8
MHz) and ethanol-containing aqueous gel formulations (hydroxypropyl methylcelullose) on the
delivery of ibuprofen through in vitro and in vivo rabbit skin,[95] v) ultrasound (150 kHz) and 7
different enhancers (menthol being the most thoroughly investigated) on the delivery of
aminopyrene, vi) LFS (20 kHz) and capsaicin or nonivamide on the transdermal flux of
indomethacin across nude mouse skin[122], vii) LFS (20 kHz) and 14 different chemical
enhancers (the best of which was 5% citral in 1:1 ethanol:PBS) on the transdermal permeation of
tizanidine hydrochloride across mouse skin,[123], and viii) LFS (20 kHz) and liposomes/SLS to
deliver antigens through in vitro and in vivo rat skin,[124] among others.
1.4.2.1 Synergism of LFS and Surfactants
The synergism between LFS and surfactants has been shown to be quite significant. For
example, Mitragotri et al. showed that by adding a common anionic surfactant, SLS, to the LFS
coupling medium (20 kHz), skin permeability to mannitol increased 200-fold over 90 minutes of
treatment, while for LFS and SLS treatments alone, only 3-fold and 8-fold enhancements were
observed, respectively. [10] Furthermore, these authors showed that the energy density threshold
required to observe any skin permeability enhancement decreased by nearly an order of
magnitude from 141 J/cm2 to 18 J/cm 2, with the inclusion of SLS in the LFS coupling medium.
In addition, Mitragotri et al. demonstrated that skin permeability enhancement is linearly
proportional to SLS concentration, in the range 0 - 1 wt% SLS, and is also proportional to the
LFS intensity and exposure time, but independent of duty cycle.[10] In a following study, Tezel
et al. studied the synergism between LFS (20 kHz) and a series of eleven surfactants.[50] The
study included surfactants with a variety of "head" groups (cationic, anionic, nonionic, and
zwitterionic) and "tail" groups (linear alkanes containing 8-16 carbons). In 10 minutes of LFS
treatment, using a surfactant concentration of 1 wt% in the coupling medium, tetradecyltrimethyl
ammoniumbromide (TDAB), SLS, and hexadecyltrimethyl ammoniumbromide (HDAB) yielded
the highest skin conductivity enhancement ratios of 35.4, 24.5, and 15.9, respectively, of all the
single surfactant solutions considered. However, when multiple surfactants were mixed, both
synergistic and antagonistic effects were observed. For example, a 50:50 mixture of TDAD and
HDAB (total concentration of 1 wt%) yielded an enhancement ratio of 42.8 (greater than using
either single surfactant alone at a concentration of 1 wt%), thus exhibiting synergism. On the
other hand, a 50:50 mixture of SLS and glycolic acid ethoxylate 4-tert-butyl phenyl ether (ether)
only showed an enhancement ratio of 1.6, much lower than the enhancement ratio corresponding
to either single surfactant solution (enhancement ratio for ether alone was 5.5), thus exhibiting
extreme antagonism. No mechanism was suggested to rationalize why synergistic or antagonistic
effects were observed in the binary surfactant formulations. Tezel et al. concluded that ionic
surfactants are better than nonionic surfactants at increasing skin conductivity, and that the
optimum surfactant tail length to attain synergistic skin permeability enhancement with LFS is
14 carbons, compared to 12 carbons for passive enhancement. [50]
The effects of a surfactant present in the coupling medium during sonophoretic treatment can be
broadly classified into two types: (i) the effect of the surfactant on ultrasound-related
phenomena, and (ii) the effect of ultrasound on surfactant penetration, dispersion, and
partitioning in the skin. Although these two mechanisms are strongly coupled, for simplicity,
they will be discussed separately. Surfactants can affect cavitation through several mechanisms.
Because of their preferential adsorption at interfaces, surfactants tend to reduce the surface
tension of aqueous solutions. Surface tension has its greatest effect on the oscillation of a
cavitation bubble at the beginning of its expansion and at the end of its compression, causing an
increase in the rate of expansion and a decrease in the rate of compression as the surface tension
decreases.[74] In general, sonochemical activity is favored in liquids possessing higher surface
tensions because it leads to more violent collapse of bubbles, and consequently, more
sonochemical related phenomena take place.[125] However, in addition to decreasing the
surface tension, surfactants also play a role in stabilizing cavitation bubbles by inhibiting bubble
coalescence and growth, especially in the case of charged surfactants (due to the electrostatic
repulsions between charged bubbles). Therefore, the addition of surfactants to the coupling
medium leads to a larger population of smaller cavitation bubbles.[84] If the ultrasound field is
pulsed, some of these smaller bubbles have a tendency to dissolve back into the solution when
the ultrasound is off due to the Laplace pressure of the bubble (see Section 1.2.1.2).[84] The
interplay between cavitation bubble growth and coalescence inhibition depends on the surfactant
concentration. Usually, in LFS-mediated transdermal drug delivery experiments, 1% w/v SLS is
used in the coupling medium. At this SLS concentration, experiments have shown that shielding
and stabilization effects play a more significant role than surface tension effects.[84] As a result,
it is observed that when 1% w/v SLS is present in the coupling medium during LFS treatment,
transient cavitation activity decreases when compared to experiments performed when SLS is not
present in the coupling medium, due to the existence of a population of smaller less energetic
cavitation bubbles in the presence of SLS. For example, Mitragotri et al. measured transient
cavitation events by aluminum foil pitting and found that when 1% w/v SLS in PBS solution was
used instead of just a PBS solution, the number of pits decreased from 73+20 pits, in 20 seconds,
to 6±4 pits. [10] These authors also found that the average pit diameter decreased when 1% w/v
SLS was present in the coupling medium. Therefore, it does not appear that a change in
cavitation activity would favor synergism between LFS and surfactants, but instead, may actually
inhibit it. Therefore, there must be some other mechanism to explain the synergism between
surfactants and sonophoresis.
Chemical enhancers, such as surfactants, are known to increase the rate of transdermal drug
delivery by: i) increasing the stratum corneum lipid fluidity, ii) changing lipid organization,[ 126]
iii) decreasing the path length and tortuosity across the stratum coreum, iv) increasing the skin
diffusion coefficient, and v) increasing the coupling medium-to-skin partition coefficient.[127,
128] However, the barrier properties of the skin inhibit the extent to which surfactants can
diffuse into and perturb the skin passively in a reasonable amount of time. Therefore, it is
believed that the main role of the synergism between LFS and the surfactant is the ability of LFS
to increase the concentration and dispersion of the surfactant inside the stratum comeum.[46] By
carrying out a series of experiments in which skin was soaked in a solution of 1% w/v SLS for
various durations between 1 minute and 24 hours, followed by the application of LFS/SLS for 10
minutes, Mitragotri et al. found that as the skin soaking time increased, the ratio of skin
conductivity after ultrasound treatment to skin conductivity prior to ultrasound treatment
decreased.[10] This result shows that the effect of LFS treatment is diminished with increased
passive exposure time to SLS. From these results, the authors argued that synergism between
LFS and SLS is due to the increased penetration and dispersion of the surfactant in the skin
induced by LFS.[10] Another study suggested that pH changes induced in the skin during LFS
may explain the synergism between LFS and SLS.[63] However, it is not clear whether the pH
changes in the skin are merely a consequence of the combined LFS/SLS treatment or, in fact,
play a role in the observed synergism. In spite of the findings above, no convincing physical
mechanism has been proposed to date to explain why LFS causes increased uptake of
surfactants. Therefore, this important topic is still an area of active research (see Chapter 4).
1.4.3 Synergism of Sonophoresis with Other Physical Enhancers
Early research using HFS showed that when an injection of hydrocortisone was followed by
ultrasound treatment at 1 MHz, the effects of the combined treatment were superior to those of
the injection alone,[26] essentially showing synergism between the injection and the therapeutic
ultrasound treatment. Later, Kost et al. investigated synergism between HFS and electroporation,
which is the process of increasing skin permeability by applying a high-voltage pulsed electric
field across the skin.[129] In this study, the transport of two model permeants, calcein and
sulforhodamine, were investigated in response to 10-150 V electric pulses (1 millisecond every
minute) in combination with 1 MHz HFS. Although HFS alone did not increase the skin
permeability to either model permeant, the combination of HFS and electroporation increased the
flux of calcein by a factor of 2 and of sulforhodamine by a factor of 3, compared to the
enhancement observed by electroporation alone. In addition, the lag time to steady state was
decreased by 40%, relative to the case of electroporation alone, from 15 minutes to 9 minutes.
However, when 3 MHz ultrasound was applied, very little synergism was observed. This led the
authors to conclude that the mechanism of synergism between HFS and electroporation was
cavitation-induced disordering of the skin's lipid bilayers and convection across the skin,
because cavitational effects are inversely proportional to ultrasound frequency. Furthermore,
convection-induced enhancement was dependent on the properties of the permeant considered.
For example, the electric field played a larger role in the flux enhancement of the more highly-
charged calcein (total charge of -4) than in the transport of sulforhodamine (total charge of -1)
across the skin.[129]
The most common type of physical enhancer that has been studied in combination with LFS is
iontophoresis, the process of increasing skin permeability by continuously applying a low
voltage electric field across the skin. Le et al. studied the synergism of LFS at 20 kHz, through a
coupling medium containing 1 wt% SLS or dodecyl pyridinium chloride (DPC), with
iontophoresis applied at an energy density of 0.45 mA/cm2 .[45] Utilizing heparin, a negatively-
charged biopolymer with average molecular weight of 10 kDa, as a model drug, these authors
found that the skin permeability was over two-fold higher with the combination of LFS and
iontophoresis (through an SLS coupling medium) than when utilizing either physical enhancer
alone. Subsequently, by utilizing the positively-charged surfactant DPC, the authors were able to
show that the initial (first hour) flux of the negatively-charged heparin was nearly twice that
corresponding to the SLS treatment case.[45] The authors reasoned that this was due to the fact
that when the negatively-charged SLS was utilized, both SLS and heparin competed for the same
current, while the opposite charges of DPC and heparin would negate this effect. However, the
steady-state heparin permeability induced by SLS, in combination with LFS and iontophoresis,
was still slightly higher than that attained using the same treatment with DPC. This suggests that
the combined LFS treatment with SLS caused greater sustained skin perturbation than DPC. The
authors concluded that the synergistic enhancement observed with LFS and iontophoresis was
practically significant because it: i) allowed the delivery of a macromolecule at therapeutic
levels, ii) required reduced voltage/current to achieve the desired flux, and iii) allowed for active
control of transdermal transport. [45] In another study, Fang et al. also found that LFS (20 kHz),
when combined with iontophoresis (0.5 mA/cm2), increased permeation of sodium nonivamide
acetate across nude mouse skin in a synergistic manner.[130] In a more recent study using an
intermediate ultrasound frequency (270 kHz), Watanabe et al. demonstrated that the combined
application of iontophoresis (20 V, 0.45-1.0 mA) with ultrasound can increase the delivery of
hydrophilic model compounds across hairless mouse skin in a synergistic manner.[109]
Specifically, despite minimal enhancing effects when ultrasound and iontophoresis were used
separately, their combination increased delivery of antipyrine and sodium salicylate 10-fold. The
authors suggested that the mechanism of enhancement was loosening of the connections of the
stratum corneum by ultrasound, followed by increased electroosmotic flow due to
iontophoresis.[109] In another study utilizing intermediate ultrasound, Hikima et al. studied the
mechanisms of synergistic delivery of seven model permeants, ranging in size from 122-1485
Da, utilizing 300 kHz ultrasound and iontophoresis (0.32 mA/cm2).[131] The study found that
chemicals that were non-ionized or greater than 1000 Da in molecular weight showed synergistic
enhancement with the combined ultrasound and iontophoresis application, whereas ionized drugs
showed similar profiles in response to the iontophoretic treatment alone. The authors also
conducted simulations that showed that the synergistic effect between ultrasound and
iontophoresis occurred due to increased electroosmosis in the stratum corneum. Consequently,
the synergistic mechanism was a result of increased skin diffusivity due to the action of
ultrasound on the skin, followed by increased electroosmotic flow induced by
iontophoresis. [131] Finally, Liu et al. demonstrated that pretreatment of rat skin with
laurocapram and LFS (20 kHz), followed by electroporation of the skin samples, increased
penetration of cyclosporin A by a factor of 15.[114]
Recently, LFS has also been utilized in conjunction with other physical enhancers in a clinical
setting. For example, Spierings et al. investigated the ability of LFS, in the form of the FDA
approved SonoPrep@ device (Echo Therapeutics, Franklin, MA), to act synergistically with low-
voltage iontophoresis, in the form of the FDA approved Phoresor PM700@ device (Iomed
Incorporated, Salt Lake City, UT), in delivering the topical anesthetic Iontocaine@ (Abbot
Laboratories, Chicago, IL).[19] The study showed that a pretreatment with LFS, followed by 2
minutes of low-voltage iontophoresis, provided statistically similar pain relief as 10 minutes of
standard high-voltage iontophoresis. A similar study with higher ultrasound frequencies found
that the combined treatment of iontophoresis (5 mA) and HFS (1 MHz) to deliver cortisol was
effective in decreasing subjective pain complaints of patients with mild to intermediate stages of
carpal tunnel syndrome.[132] Finally, a recent clinical study reported the use of
microdermabrasion treatment, followed by the application of sonophoresis through a complex
containing hyaluronic acid, retinol, and peptide.[133] The authors showed that the combination
of the two physical skin penetration enhancement methods had beneficial effects in
photorejuvenation of the skin, such as enhanced vascularity in the dermis and increased type I
and III collagen formation.[133]
1.5 Scope of Transdermal Delivery Utilizing Sonophoresis
1.5.1 High-Frequency Sonophoresis
The use of therapeutic frequencies of ultrasound to increase the cutaneous penetration of cortisol,
a topical steroid, was first demonstrated by Fellinger and Schmid in 1954.[25] Additional
research on sonophoresis during the same time period showed beneficial effects of therapeutic
ultrasound after injection of drugs[26, 134, 135] and the treatment of localized disorders with
ultrasound treatment alone, such as in the treatment of pain, scars, arthritis, epicondylitis, keloid
growth, and bursitis.[136-141] The popularity of delivering therapeutic compounds with
ultrasound increased over the following decades, with at least 150 independent reports to-date
describing the use of ultrasound frequencies greater than 0.7 MHz in the delivery of permeants
transdermally. These studies are summarized in Table 1-1.
Nearly all studies involving HFS have utilized the simultaneous treatment protocol, that is, the
drug being delivered is included in the coupling medium (typically a gel) during ultrasound
treatment. Therefore, in addition to cavitational effects within the skin[34] that can increase skin
permeability, thermal and convective effects can also play a role in increasing solute partitioning
into the stratum corneum of the skin and subsequent mobility therein (see Section 1.3 for more
details). The additional enhancement resulting from this combination of mechanisms is
beneficial, because enhancement by HFS is usually modest (1- to 10-fold) when compared to
enhancements observed with LFS.[20, 27, 29, 30] However, this level of enhancement may be
sufficient for the applications that HFS has been used for, which usually entail topical or regional
delivery of therapeutics (for example, topical steroids for inflammatory conditions or arthritic
joints, see Table 1-1). Systemic delivery is not a common goal with HFS. Furthermore, most
compounds delivered by HFS are small molecules, with only a handful of drugs having
molecular weights greater than 1000 Da tested (see Table 1-1). This is consistent with the
assertion that HFS does not change the structure of the skin greatly, and therefore, can only
operate by increasing the penetration of molecules that would likely penetrate the skin in lesser
amounts under passive conditions. Nevertheless, the fact that HFS does not induce large changes
to the skin barrier is also a strength of this treatment method, as it is generally considered to be a
very safe technology, and is frequently utilized in other widespread applications, such as in
sports and physical therapy. Furthermore, because many ultrasound devices that operate in the
range 0.7 - 3.0 MHz are FDA approved, it is much easier to initiate human trials of such
Table 1-1. Molecules that have been delivered transdermally with therapeutic and high-
frequency ultrasound.
Molecule
Aloe vera gel
Aminopyrine
Amphotericin B
Arnica montana extract
Ascorbic acid
Benzene
Benzocaine,
benzethonium mixture
Benzydamine
Benzyl nicotinate
Biomycin
Bufexamac
Butanol
Caffeine
Calcein
Calcium
Chymotrypsin
Corticosterone
Cortisol (hydrocortisone)
MW (Da) Log Ko/w" Freq.(MHz)
- - 1.0
231 1.00 3.5
924 -2.80 2.64
- - 1.0
176 -1.85 0.88, 5
78 2.13 1.0-3.0
165
448
309
213
451
223
74
194
623
42
25k
346
362
1.86
4.00
4.21
2.40
-3.60
2.08
0.88
-0.07
-0.57
1.94
1.61
1.1
C
0.75-3.0
3.0
C
3.0
1.0-3.0
1.0-3.0
1.0-3.0
1.0-3.0
1.0
C
1.0-3.0
C
0.5-1.0
0.09-3.6
Amp.(W/cm2)
0.5
0.1-2.0,
1.0
0.5
0.3-1.0
0-2.0
0.25
C
0-3.0
0.2-1.0
C
0.1-3.0
0-2.0
0-2.0
0.01-2.0
1.4
0.3
C
0-2.0
C
0-3.0
1.0-3.0
Skin Modelb Ref.
in vivo rat
in vitro
in vivo
in vivo
in vivo
in vitro
rat FTS
gp
rat
human
h FTS
in vivo human
in vivo
in vivo
in vivo
in vivo
in vivo
in vitro
in vitro
in vitro
in vitro
in vivo
in vivo
in vitro
in vivo
in vivo
in vivo
in vivo
human
human
human
human
human
h FTS
h FTS
m FTS
h FTS
mouse
human
h FTS
human
human
pig
rabbit
[94]
[143]
[144]
[145]
[146, 147]
[34]
[148]
[149, 150]
[151]
[152]
[153, 154]
[155]
[34]
[34]
[104, 156]
[129]
[157]
[158]
[34, 112]
[25, 159-180]
[132, 181-186]
[187-190]
[191-194]
in vivo dog [195, 196]
1.1
1.1-3.5
1.0
C
Dexamethasone
Dibucaine (cinchocaine)
Diclofenac
Digoxin
Dimethyl sulfoxide
Ethyl nicotinate
EMLA (lidocaine,
prilocaine mixture)
Estradiol
Fibrinolysin
Flufenamic acid
Fluocinolone acetonide
(sinalar)
Fluocinonide
392
343
296
781
78
151
234
220
272
13.8k
281
452
495
1.5
0.1-2.5
3.0
C
1.83
4.40
4.51
1.26
-1.35
1.32
2.44
2.11
4.01
5.25
2.48
3.19
-0.89
0.87
1.0-3.0
1.0
1.0
1.1
1.0-3.0
0.8
3.3
1.0
3.0
0.75-3.0
1.0
1.0-3.0
C
0.8, 1.0
0.8, 1.0
C
0.87
1.0
1.0
1.5
1.4
0.25
0.5-1.5
0.5-3.0
1.0, 3.0
0.8
1.0
0.25-1.5
2.0
0-2.0
C
0.0-1.5
0.0-1.5
0.2
2.0
1.5
in vitro
in vitro
in vitro
in vitro
in vivo
in vivo
in vivo
in vivo
in vitro
in vivo
in vivo
in vitro
in vitro
in vitro
in vivo
in vivo
in vivo
in vivo
in vitro
in vivo
in vivo
in vitro
in vivo
in vivo
in vivo
h FTS
rat FTS
m FTS
frog
human
human
human
pig
h FTS
human
human
r FTS
h FTS
m FTS
rat
human
human
rat
h FTS
human
human
h FTS
rat
human
human
[197]
[113, 143]
[197]
[198, 199]
[200, 201]
[202]
[203, 204]
[186]
[112]
[148]
[205-209]
[210]
[211]
[142]
[212]
[148, 213]
[214]
[34, 112, 197]
[215]
[216, 217]
[216]
[218-220]
[221]
[222]
3.5 0.1-2.0
0.87-1.0 0.5-2.75
5-Fluorouracil 130 in vitro rat FTS [143, 223]
Glucosamine
Glucose
Glycerol
Heparinoid
Hexyl nicotinate
Hyaluronan
Ibuprofen
Indomethacin
Inulin
lodex pomade (Iodine,
methyl salicylate mixture)
Ketoprofen
Ketorolac tromethamine
Lappaconitine HBr
Lanthanum hydroxide
Lidocaine
Linoleic acid
Mannitol
Menthol
179
180
92
5-40k'
207
1-3k
206
358
5k
127
152
254
255
666
190
234
280
182
156
-4.23
-3.24
-1.76
3.51
3.97
4.27
2.49
2.55
3.12
2.32
2.44
7.05
-3.10
3.40
1.0
10
1.0
C
3.0
1.0
1.0
1.0
0.8
1.0
1.0
C
1.0-3.0
1.0
0.8-1.0
10,16
0.87
0.5-1.0
C
1.0
1.0
1.0
1.1
3.5
10
1.0-3.0
0.3
0.2, 2.0
f
C
1.0
0.4
1.0
1.0
0.5-3.0
0.25-2.5
1.5-3.0
1.5
1.0-1.5
1.0-3.0
0.7-0.75
0.2
C
2.0
2.0
1.4
1.4
1.5-3.0
1.5
0.1-2.0
0.2, 2.0
1.5
in vivo
in vitro
in vitro
in vivo
in vivo
in vivo
in vivo
in vitro
in vitro
in vivo
in vivo
human
p FTS
p FTS
human
human
rabbit
human
h HSS
r FTS
rat
gp, rat
in vivo human
in vivo
in vitro
in vitro
in vitro
in vivo
in vivo
in vivo
in vitro
in vitro
in vivo
in vitro
in vitro
in vitro
in vivo
human
rat FTS
rat FTS
gp FTS
human
human
rabbit
h FTS
h FTS
gp, rat
h FTS
rat FTS
p FTS
human
[224]
[57]
[225]
[226]
[212]
[227]
[228]
[102]
[95, 210]
[229, 230]
[33]
[231]
[93, 209, 232]
[115, 233]
[234]
[28]
[202]
[235, 236]
[237]
[112]
[112]
[33]
[197]
[143]
[57]
[238]
Mepivacaine
Metamizole (analgin)
Methyl nicotinate
Morphine
Niacinamide
Niflumic acid
Nimesulide
Oxygen gas
Panax notoginseng
Panthenol
Paraaminohippuric acid
Penicillamine (cuprenil)
Penicillin
Phenylbutazone
Physostigmine
Piroxicam
Prednisolone
Prednisolone acetate
Progesterone
Radioiodine
Reparil (mix of Aescin,
Diethylamine salicylate)
Salicylic acid
246
333
137
285
122
282
308
32
205
194
149
334
308
275
331
360
402
314
131
1131
211
138
1.95
-4.76
0.83
0.89
-0.37
4.43
2.60
0.65
-1.92
-0.89
-1.78
1.83
3.16
1.58
3.06
1.62
2.40
3.87
2.49
2.26
4 *C
3.0
1.5-3.0
5.0
3.0
1.0
0.97
1.0
3.0
C
1.0
0.01-2.0
0.7
0.1-3.0
1.0
1.0-2.0
0.5
0.1
C
3.0 0.1-3.0
1.0
3.0
1.0-3.0
0.8-0.87
1.0
1.0
1.0-3.0
C
C
2.0-16
1.0
1.5-3.0
0.5
1.0-2.0
0.5-3.0
1.50-4.32
1.50-4.32
0-2
C
C
0.2
3.0
in vivo human
in vivo human
in vivo human
in vitro m FTS
in vivo human
in vivo human
in vivo human
in vitro frog
in vivo rat
in vitro p FTS
in vitro m FTS
in vivo human
in vivo human
in vivo human
in vivo human
in vivo gp, rat
in vivo human
in vitro h FTS
in vitro r FTS
in vitro m FTS
in vitro m FTS
in vitro h FTS
in vivo human
in vivo human
in vivo gp
in vitro m FTS
[239]
[240]
[212], [241]
[156]
[147]
[155]
[92]
[242]
[243]
[244]
[245]
[179]
[246]
[155]
[158, 247]
[33]
[96]
[248]
[210, 249]
[250, 251]
[250]
[34]
[252]
[253]
[103]
[104]
Scopolamine 303 0.98 C C in vivo human [254]
Sinomenine 329 1.05 0.8 C in vitro r FTS [121]
Silver Chloride 143 - 1.0-3.0 1.0, 2.2 in vivo fish [255]
Silver Nitrate 170 - 0.79-2.9 0.5 in vivo rat [256]
Streptomycin 582 -7.53 C C in vivo rabbit [257]
Sucrose 342 -3.70 3.5 0.1-2.0 in vitro rat FTS [143]
Sulforhodamine 101 607 - 1.0-3.0 1.4 in vitro h FTS [129]
Tannic acid 1.7k -0.19 1.0 1.0 in vivo human [258-260]
Testosterone 288 3.32 1.0-3.0 0-2.0 in vitro h FTS [34, 112]
1.0 0.5 in vitro rat FTS [261]
Tetracycline 444 -1.30 C C in vivo cow [262]
in vivo rabbit [263]
Thiamin 337 -3.93 0.88 0.3-1.0 in vivo human [146]
Triamcinolone acetonide 434 2.53 1.0-3.0 1.0-2.5 in vivo rat
[264, 265]
in vitro mouse
Trilon B (Na4EDTAe) 380 -13.2 C C in vitro frog [266, 267]
Trolamine salicylate 287 - 1.0 0.5-1.5 in vivo human [268]
Urea 60 -2.11 1.0 1.0 in vivo human [258-260]
Zidovudine 266 0.05 1.1 1.5 in vitro h FTS
[269]
in vitro m FTS
Zinc Sulfate 65 -0.47 1.0 1.0 in vivo human [258-260]
a from Syracuse Research Corporation physical property database.[270]
b legend: h = human, p = pig, r = rabbit, m = mouse, gp = guinea pig, FTS full-thickness skin, and HSS = heat-
stripped skin.
not available or not specified.
d estimated from references or other sources.
e ethylenediaminetetraacetate tetrasodium salt.
600 kPa, not reported in W/cm2.
therapies, as evidenced by the large number of in vivo human studies presented in Table 1-1 (in
comparison, far fewer in vivo studies are summarized in Table 1-2 in the case of LFS).
Therefore, as evidenced by the nearly 90 compounds tested with HFS listed in Table 1-1, the use
of therapeutic and high-frequency ultrasound for skin penetration enhancement has a rather large
scope, with interest in the technology continuing to the present day.[92-96, 142]
1.5.2 Low-Frequency Sonophoresis
LFS is at a disadvantage relative to HFS in that it has been studied extensively only over the past
two decades. Therefore, LFS has been investigated in fewer studies and currently lacks the
historical track record of safety that HFS enjoys. The first investigations devoted solely to the use
of LFS for transdermal delivery were conducted by Tachibana and Tachibana in the early
1990s,[100, 271, 272] and involved the use of 48 kHz and 105 kHz ultrasound for the delivery of
insulin and lidocaine to mice and rabbits. Surprisingly, a review of the literature shows that
Griffen et al. used LFS at 90 kHz, in 1965,[190] and demonstrated that the penetration of cortisol
into subcutaneous pig nerves was higher for the 90 kHz treatments than those at 1MHz.
However, frequencies in the range 20 - 100 kHz were seemingly forgotten for the next 25 years,
until the aforementioned publications by Tachibana and Tachibana.[100, 271, 272] These
studies were followed by work done by Mitragotri et al., who showed that macromolecules even
larger than insulin could be delivered transdermally at therapeutic levels, including interferon-y
(17 kDa) and erythropoietin (48 kDa).[20] A subsequent investigation demonstrated that LFS is
up to three orders of magnitude more effective at increasing skin penetration enhancement of
compounds transdermally than HFS.[30] From these beginnings, research on low-frequency
Table 1-2. Molecules that have been delivered transdermally by low-frequency ultrasound.
Molecule
Acetic acid
Aldosterone
Aminopyrine
Antipyrine
Ascorbic acid
Azelaic acid
Benzoate ion
Betamethasone valerate
Bovine serum albumin
Butanol
Caffeine
Calcein
Clobetasol propionate
Corticosterone
Cortisol
Cyclobarbital
Cyclosporin
Daniplestim
Dextran
Deuterium oxide
Epinephrine
MW (Da)
60
360
231
188
176
188
121
477
66k
74
194
Log Ko/wa
-0.17
1.08
1.00
0.38
-1.85
1.57
-2.27
3.60
0.88
-0.07
623
467
346
362
236
1.2k
13k
70k
20
183
3.50
1.94
1.61
1.77
2.92
-1.38
-1.37
Skin Modelb Ref.
in vitro p FTS [273]
Freq. (kHz)
58
20
150
150
25
25
150
36
20
20
20
40
20
41-445
20
20
58
90
150
25
20
55
58, 20
41-445
Amp. (W/cm2)
1.08
0.125
0.111
0.111
0.05-0.1
0.05-0.1
0.111
2.72
9
0.125
2.5
0.13-0.44
1-15
0.06-0.30
d
0.125
1.08
1.0
0.111
0.05-0.1
0.4-1.2
:515
1.08, 7.0
0.06-0.24
<15 in vivo human
in vitro
in vitro
in vitro
in vivo
in vivo
in vitro
in vivo
in vitro
in vivo
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vivo
in vitro
in vivo
in vitro
in vivo
in vitro
in vitro
h HSS
rat FTS
rat FTS
human
human
rat FTS
human
rat FTS
rat
h HSS
rat FTS
m FTS
p FTS
rat FTS
m FTS
h HSS
p FTS
pig
rat FTS
human
rat FTS
rat
p FTS
rat FTS
[30]
[105, 274]
[105]
[275]
[275]
[276]
[277]
[124]
[30]
[278]
[156]
[14, 15, 43, 51]
[62, 69, 279]
[280]
[30]
[273]
[190]
[105, 274]
[275]
[114]
[281]
[61, 65]
[105, 274, 279]
[19]
Erythropoeitin
Estradiol
Fentanyl
FITC-dextran'
Fluorescein
5-Fluorouracil
Flurbiprofen
Glucose
Gold nanoparticles
Heparin
Heparin (Low-Molecular
Weight)
Histamine
lbuprofen
Indomethacin
Interferon - y
Insulin
48k
272
336
4.4k, 38k
332
130
244
180
5 nm
10k - 19kf
3.0k - 8.0k
111
206
358
17k
5.8k
4.01
4.05
3.35
-0.89
4.16
-3.24
-0.70
3.97
4.27
20
20
20
20
41,150
20
150
150
20
20
20
20
20
55
36
150
20
20
48
20
20, 32, 105
20
20
20
0-0.225
0.125
2.5
4.4
0.06-0.30
0.008-0.024
0.111
0.111
9
7.5
7.0, 7.4
7.0
7.0
15
2.72-3.5
0.111
0.2
0.0125-0.225
e
0-10.0
0.05-0.1,
0.1, 2.5
0.0125-1.0
0.173
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
in vivo
in vivo
in vitro
in vitro
in vivo
in vitro
in vitro
in vitro
in vivo
in vivo
in vivo
in vivo
in vitro
in vitro
h HSS
h HSS
rat FTS
p FTS
rat FTS
h FTS
rat FTS
rat FTS
p FTS
p FTS
p 700
p FTS
rat
rat
p FTS
rat FTS
human
rat FTS
m FTS
h HSS
mouse
rat
rabbit
pig
h HSS
h FTS
[20]
[30]
[278]
[44]
[69, 105]
[282]
[105]
[105]
[57]
[56]
[45, 65]
[65]
[65]
[65]
[283]
[284]
[105]
[122]
[20]
[272]
[20, 285-287]
[271, 288, 289]
[287, 290]
[20, 291]
[292]
Inulin 5.0k
Iron oxide particles
Isosorbide dinitrate
Ketoprofen
Kojic acid
Lanthanum nitrate
LHRH
Lidocaine
Lipid particles
Liposomes
Mannitol
Methylprednisolone
Microparticles
Morphine
Nile red
Oligonucleotides
poly-l-lysine-FITCc
5 - 10 nm
236
254
142
433
1.3k
234
-100 nmf
0.08 pm,
4.6 pm
182
374
1.5-173 pm"
285
318
7k - 10kg
51k
1.31
3.12
-0.64
2.44
-3.10
1.82
0.89
20
58, 20
20
25
150
150
25
35
58
55
48
150
20
20
20
20
20
20
20
19-93
55
20
40
20
20
20
1.6
1.08, 7.0
7.2
0.8
0.111
0.111
0.05-0.1
0.80
1.08
:515
0.17
0.111
2.5-5.0
9
1.6
6.5
1.6, 6.5
7.2
6.5
1.08-14
:515
19
0.13-0.44
15
2.4
2-50
in vivo
in vitro
in vitro
in vivo
in vitro
in vitro
in vivo
in vivo
in vitro
in vivo
in vivo
in vitro
in vitro
in vitro
in vivo
in vivo
in vivo
in vitro
in vitro
in vitro
in vitro
in vivo
in vitro
in vitro
in vitro
in vitro
in vitro
in vitro
rat
p FTS
h FTS
mouse
rat FTS
rat FTS
human
mouse
p FTS
human
mouse
rat FTS
rat FTS
rat FTS
rat
rat
pig
h HSS
h FTS
p 700
p FTS
human
h HSS
h FTS
m FTS
p FTS
p FTS
h HSS
[47]
[61, 65]
[53, 55]
[58]
[105]
[105]
[275]
[58]
[61]
[17-19, 293-295]
[100]
[105]
[261]
[124]
[47]
[48]
[21, 48]
[53, 55]
[48]
[10. 12, 21,48, 49,81, 273
[275]
[296]
[156]
[43]
[66]
[296]
Quantum dots 10-22 nm
Octa-l-lysine-4-FITCc
Polymer nanoparticles
Prilocaine
Raffinose
Rhodamine B
Rhod. B hexyl ester
Salicylic acid
siRNA-liposomes
Sodium nonivamide acet.
Sucrose
2.5k
200 nm
220
504
479
627
138
2.11
-6.76
1.95
2.26
7.5, 2.4
2-50
8
s15
7.2
in vitro p FTS
in vitro h HSS
in vivo rat
in vivo human
in vitro h FTS
41 0.06-0.30 in vitro rat FTS
7.2 in vitro h FTS
0.125
50 nm
373
342
0.05
0.20
-3.70
in vivo mouse
in vitro h HSS
in vivo mouse
in vitro m FTS
20 0.125, 1.6 in vitro h HSS
7.5 in vitro p 700
Sulforhodamine B
Testosterone
Tetanus Toxoid
Tizanidine
Urea
Vasopressin
559
288
150k
254
60
1.1k
Water
-0.01
3.32
20, 58
20
20
-2.11
-8.37
-1.38
1.6, 7.5
0-7.5
2.5-5.0
2.4, g
10
in vitro p FTS [14, 21, 56]
in vitro p FTS
in vitro rat FTS
in vivo mouse
in vitro mouse
7.2 in vitro h FTS
0.1-1.0
0.125
in vitro h HSS
in vitro h HSS
41 0.06-0.30 in vitro rat FTS
1.08 in vitro p FTS
[13]
[261]
[67, 300]
[123]
[53, 55]
[291]
[30]
[69]
[273]
a from Syracuse Research Corporation physical property database.[270]
b Legend: h = human, p = pig, r = rabbit, m = mouse, gp = guinea pig, FTS = full-thickness skin, 700 = dermatomed
700 pm skin, and HSS = heat-stripped skin.
c FITC = Fluorescein isothiocyanate.
d estimated from references or other sources.
e Intensity was reported as 3000 - 8000 Pa.
Molecular weight or size were estimated from references.
g A setting of 10-70% was reported (VCX 400 or 500, Sonics and Materials, USA).
h Particles larger than 25 pm in diameter were not observed to penetrate the skin.
[52, 56]
[296]
[298]
[18]
[53, 55]
[62, 69]
[13]
[30]
[299]
[130]
[21, 30]
[14, 56]
20 7.5 in vitro p700 [56, 297]
ultrasound-mediated transdermal drug delivery has exploded, with dozens of different groups
working on applications of this technology (see Table 1-2). All types of permeants, from small
hydrophobic compounds, such as salicylic acid, to highly hydrophilic compounds, such as
vasopressin, to proteins, such as insulin, and even vaccines or nanoparticles, have been delivered
transdermally with LFS. All the permeants that have been delivered by LFS through varying
skin models, to-date, are listed in Table 1-2. Note the wide range of molecules that have been
delivered by LFS, including those that are either hydrophilic (negative octanol-water partition
coefficient, log Ko/,) or hydrophobic (positive log Ko/w), and those that are low-molecular weight
(< 1000 Da molecular weight, MW) or high-molecular weight (2 1000 Da MW). LFS has truly
increased both the type and the extent to which molecules can be delivered through the skin at
therapeutic levels, compared to HFS, which is typically limited to lower molecular weight
compounds. Therefore, the scope of LFS may be even greater than that of HFS, although LFS
faces more regulatory hurdles than HFS treatments, due to the current lack of historical
precedence of safety.
1.6 Delivery of Hydrophilic Permeants and Macromolecules with LFS
1.6.1 Delivery of Hydrophilic Permeants
1.6.1.1 The Aqueous Porous Pathway Model
Although traditional transdermal transport models have typically utilized molecular weight and
octanol-water partition coefficients (log K0 1a) to describe solute transport through the skin,
including transport of hydrophilic permeants,[312, 313] an improved mechanistic understanding
of hydrophilic permeant transport through LFS-treated skin was made possible by the
development of the aqueous porous pathway model (APPM).[21] By assuming that hydrophilic
permeants traverse the stratum corneum along the same pathways as the current carrying ions,
the APPM derives a quantitative relationship between the skin permeability of hydrophilic
permeants, P, and the skin electrical resistivity, R. Specifically, by utilizing relations from
hindered-transport theory for the diffusion of permeants through confined pores,[314] the APPM
demonstrates that a linear regression of log P versus log R should yield a slope of -1.[21]
Moreover, by substituting the values of known parameters associated with the bulk solution, the
skin membrane, and the diffusing permeant (hydrodynamic radius), one can calculate important
structural parameters of the skin utilizing the APPM, including the average skin aqueous pore
radius and the skin porosity to tortuosity ratio. The APPM has been applied to a broad class of
hydrophilic permeants (see Table 1-3), for both small molecules and macromolecules, diffusing
through LFS-treated skin.[12, 14, 15, 21, 51, 53, 55, 56, 61] Although the APPM assumes a
single average pore radius, it can be extended to include: (i) a distribution of aqueous pore
radii,[61] and (ii) lipophilic pathways.[273] There is strong evidence that there is a distribution
of skin pore radii, as reflected by the fact that the size of the permeant used in the context of the
APPM affects the average pore radius calculated.[53, 61] In other words, larger permeants can
only travel through aqueous pores that are larger than their hydrodynamic radius. Therefore,
macromolecules can only sample the upper tail of the aqueous pore radius distribution, while
smaller permeants have access to a wider range of pore radii. In addition to the apparent pore
radius depending on the size of the permeant used, the ultrasound amplitude also plays an
important role. An examination of Table 1-3 shows that most studies conducted in the range 7.2
- 7.5 W/cm 2 at 20 kHz calculated the average skin aqueous pore radius to be close to 100 A. On
the other hand, studies which utilized 1.0 - 1.6 W/cm 2 at 20 kHz generally calculated average
skin aqueous pore radii which are smaller than 35 A (comparable to the radius of native skin
pores). It is also worth noting that at lower LFS intensities (1.08 W/cm 2), no frequency
dependence of the pore radii was observed.[61] On the other hand, at higher LFS intensities (7.5
W/cm 2), pore radii were affected significantly by the applied ultrasound frequency (see Chapter
2).[14, 15] The observed intensity and frequency dependence of pore radii are both likely due to
the formation of larger LTRs at higher ultrasound intensities. Indeed, it is known that large
aqueous pores are formed almost exclusively within LTRs due to cavitational processes,[14, 15,
51, 273] and that LTR area is inversely proportional to skin resistivity (skin samples with lower
skin resistivities generally possess larger LTRs).[14, 15, 51] Therefore, given that the log R
values in Table 1-3 are lower for the samples treated at higher LFS intensities (7.2 - 7.5 W/cm2),
the larger pores and the observed frequency dependence of pore radii in these skin samples is due
to an increase in LTR area and to a higher level of skin perturbation in these samples, with
respect to samples treated at LFS intensities of 1.0 - 1.6 W/cm2.
The APPM has been very useful to extract information about how various LFS treatment
regimens, both in the presence and absence of chemical enhancers, affects the structural state of
the skin. For example, the mechanistic investigation presented in Chapter 2 will investigate the
pore radii within LTRs and non-LTRs of LFS-treated skin.[14, 15] It will be shown that the pore
radii within LTRs correlate strongly with the applied LFS frequency, while the pore radii within
non-LTRs are frequency independent, useful conclusions about the enhancement mechanisms
operating within each skin region will be drawn (see Section 2.4.1).[14, 15] In addition, utilizing
the APPM, Seto et al. have recently shown that the response of different skin models to the
LFS/SLS treatment is not necessarily the same. Specifically, it was demonstrated that, although
Table 1-3. Hydrophilic molecules that have been investigated in the context of the aqueous porous pathway model (APPM) for LFS-treated skin.
MW
Molecule (Da)
Mannitol 182
Mannitol 182
Mannitol 182
Mannitol 182
Mannitol 182
Mannitol 182
Mannitol 182
Mannitol 182
Mannitol 182
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Sucrose 342
Raftinose 504
Raltinose 504
Calcein 623
Calcein 623
Calcein 623
LHRH* 1311
Inulin 5000
inulin 5000
Inulin 5000
Dextra 70000
Ultrasound Parameters
Freq. Amplitude Skin-to-Horn log R
(kHz) (W/cm2 ) Distance (mm) Range Duty Cycle
1.08
1.08
1.08
1.08
1.08
1.6
1.6
7.2
72
1.6
1.6
7.5
7.5
7.5
7.5
7.5
7.5
7.5
7.5
7.5
7.2
7.2
7.5
7.5
7.5
1.08
1.08
7.2
7.2
1.08
0.3to 1.7
0.2to 1.6
0.1 to 1.9
0.6to 1.9
0.6to 1.9
-1.0to 04
-. 4 to 1.6
0.6to 0.8
-1 1 to -0.9
-1.0to 0.1
-0.2to 1.7
0.0 to 1.6
-0.4to 1.6
-02to 1.6
-0.3to 1.4
-0.210 1.4
-0.3to 1.5
-0.1 to 1.3
0.Oto 1,3
0.010 1.3
0.6to 0.8
-1.110 -0.9
-0.2to -0.8
-0210 -0.8
-0.2to -0.9
0.010 1.7
0.1 to 1.8
0.610 0.8
-1.1 to -0.9
0.21o 1.6
100%
100%
100%
100%
100%
10%
10%
50%
50%
10%
10%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
100%
100%
50%
50%
100%
Co-
Enhancer
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
none
none
1% SLS
1% SLS
none
none
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
none
none
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
1% SLS
Skin
Model'
p FTS
p FTS
p FTS
p FTS
p FTS
h HSS
p FTS
h FTS
h FTS
h HSS
p FTS
h FTS
h 700
h 250
p FTS
p 700
p FTS
p 700
p FTS
p 70 0
h FTS
h FTS
p FTS
p FTS
p FTS
p FTS
p FTS
h FTS
h FTS
p FTS
APPM Results
Pore
Slope log Cb Radius (A)*
- -2.92 28 ± 10
-0.85 -2.93 23± 13
- -2.91 29± 9
- -2.92 28 t12
- -2.94 26± 8
-0.95 -2.50 > 92
-087 -298 22±20
-
-
41d
-
-
57d
-0.88 2.61 > 125
-1.05 -3.21 23± 10
-1.08 -3.05 39
-1.04 -2.91 >120
-1.09 -2.69 >120
-1.07 -2.95 113
-1.07 -2.89 113
-1.08 -2.96 >120
-1.07 -2.90 >120
-0.98 -2.96 >120
-1.02 -2.68 >120
- 8 8 d
- - 98
-0.92 -3.14 105
-1-02 -3.19 73.9
-1.08 -3.26 50.7
-0.74 -3.42 28±4
-0.65 -3.86 34± 4
- - 111
- -
95 d
-0-44 -4.40 58 ±3
' All skin models are in-vitro. Legend: p = pig, h = human, FTS = fiil-thickness skin, HSS = heat-stripped skin 700 = 700-pm dermatomed skin, and 250 = 250-pm dermatomed
skin.
b log C is equivalent to the y-intercept in a plot of log P vs. log R, where the slope is required to be equal to the APPM theoretical value of -I
Publications after 2008 utilized an updated form of the hindrance-factor expression in pore radius calculations.
d Pore radii were calculated by comparing permeant permeability to urea permeability, rather than to ion permeablity (R).
LHRH = hiteinizing-hormone-releasmg hormone.
Ref.
[12]
[61]
[12]
[12]
[12]
[21]
[21]
[53]
[53]
[21]
[21]
[56]
[46]
[46]
[56]
[56]
[14]
[14]
[14]
[14]
[53]
[53]
[151
[15]
[151
[61]
[61]
[53]
[53]
[61]
.. . .. . ..
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full-thickness and split-thickness pig skin models respond in an equivalent manner to the
LFS/SLS treatment, human skin models of varying thickness do not respond in an identical
fashion.[56] In general, the APPM provides a useful tool to understand and analyze the transport
of hydrophilic permeants across the skin, as well as to analyze the structural state of the skin
following LFS treatment.
1.6.1.2 LFS-Mediated Transdermal Transport of Hydrophilic Permeants
The ability of LFS to increase skin permeability to hydrophilic permeants has been well
established through research done with the APPM. Simple sugars, such as sucrose and raffinose
(see Table 1-3), having log octanol-water partition coefficients (log Ko/w) less than -3,[270] and
even larger water soluble fibers, such as inulin, have been shown to penetrate through skin in
appreciable amounts following LFS treatment.[14, 15, 21, 53, 56, 61] In addition to allowing the
delivery of hydrophilic permeants, LFS skin treatment has also been shown to allow the
extraction of hydrophilic analytes, such as blood glucose (log Ko/w = -3.24[270]).[22, 23, 310,
315] Strict glycemic control is critical for proper care of diabetic patients. By increasing the
permeability of the skin using LFS, followed by the application of a transdermal glucose sensor,
it has been shown that blood-glucose levels can be monitored continuously for up to 24
hours.[16, 309] The delivery and extraction of hydrophilic permeants in clinical use will be
discussed further in Section 1.6.3.
1.6.2 Delivery of Macromolecules Utilizing LFS
The delivery of proteins, biopolymers, nanoparticles, and other high-molecular weight drugs or
particles has received considerable attention during the past few years. However, this
application of LFS is not just a recent trend, but dates back to some of the earliest studies with
LFS.[20, 271] The benefit of transdermal protein delivery is that it bypasses the harsh
environment of the gastro-intestinal tract, which can induce protein denaturation, enzymatic
degradation, and loss of therapeutic activity. Moreover, compared to injections, it allows for
controlled release profiles (not just a bolus), and displays possible compliance and safety benefits
due to the elimination of needles from the delivery process.[1, 2] Therefore, it is not surprising
that when LFS was established as a feasible means of delivering high-molecular weight proteins,
some of the first molecules that were tested included proteins, such as insulin and interferon-
y.[20, 271] However, delivery of high-molecular weight molecules by LFS is not only limited
to proteins, but includes high-molecular weight drugs, hormones, fibers, biopolymers,
oligonucleotides, liposomes, nanoparticles, and even vaccines (see Table 1-4).
The most widely studied protein, with respect to transdermal delivery by LFS, is insulin (see
Table 1-4), because of its implications in the treatment of diabetes. After Tachibana et al.
showed the feasibility of transdermal insulin delivery with LFS,[271] Mitragotri et al. conducted
the first comprehensive study comparing LFS-mediated insulin delivery with subcutaneous
injection.[20] These authors showed that, above a threshold ultrasound intensity and treatment
time, LFS-mediated insulin delivery was as effective at lowering blood glucose levels as
subcutaneous injection, including lowering blood glucose levels of diabetic rats to normal
levels.[20] More recently, there has been extensive research on insulin delivery using a light,
Table 1-4. High molecular weight molecules (>1000 g/mol) and particles that have been delivered transdermalI with LFS.
Ultrasound Parameters
Molecule
Vasopressin
Cyclosponn A
LHRH
Octa-lysine4-FITCc
FITC-dextran*
Inulin
Inulin
Inulin
Dextran
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Low-Molecular
Weight Heparin
Oligonucleotides
Daniplestim
Interferon - y
Heparin
FITC-dextranc
Erythropoeitin
poly-l-lysine-FITC*
Bovine serum albumin
Dextran
Dextran
Tetanus Toxoid
Tetanus Toxoid
MW (kDA)
1.1
1.2
1.3
2.5
4.4
5.0
5.0
5.0
5.0
5.8
5.8
5.8
5.8
5.8
5.8
5.8
5.8
5.8
5.8
< 8.0'
7 - lot
13
17
10-19
38
48
51
66
70
70
150
150
Frequency
(kHz)
20
20
58
20
41
58
20
20
20
20
20
20
20
20
20, 32
20
20
48
105
20
20
55
20
20
41
20
20
20
58
20
20
20
Amplitude
(W/cm2)
0.1 -1.0
0. -1-2
1.08
2-50
0.06 - 0.30
1.08
7.2
7.0
7.0
0.0125 - 0.225
2.5 - 10.0
0.173
0.1
0.1
0.05
0.1
0.1 -1.0
e
e
7.0
2.4
15
0.0125 - 0.225
7.0
0.06 - 0.30
0.0125 - 0.225
2 -50
9
1.08
7.0
2.4
9
Skin-to-Horn US ON
Distance (m)
10
5
3
2-4
3
3
3
10
10
10
10
5
10
10
13
10
10
2
2
1
33
7.5
10
10
3
10
53
10
5
7.5
Duty
Cycle
10%
50%
100%
5%
100%
100%
50%
50%
50%
10%
Co-Enhancer
hydrogel
various
1% SLS
none
none
1% SLS
1% SLS
1% SLS
1% SLS
none
Skin Modet* Ref.
in vitro h HSS [2911
in vitro rat FTS [1141
in vitro p FTS [611
in vitro h HSS [317]
in vitro rat FTS [69
in vitro p FTS [611
in vitro h FTS [53]
in vitro p FTS [65]
in vitro p FTS [651
in vitro h HSS [20
in vivo rat
Time (min)
12 -30
5-30
b
0.05-3
120
1 -24
6 - 18
60.0
12
12
12
12
12-30
5
45
*
10
1.5
24
d
120
24.0
0.05 -0.5
2
b
1.3
0.75
rat
h HSS
mouse.
rabbit
p FTS
rat
P FTS
rat
h HSS
p FTS
rat
rat FTS
h HSS
h HSS
rat FTS
rat
p FTS
p FTS
10-30%
20%
20%
20%
20%
20%
10%
100%
50%
50%
50%
100%
10%
50%
100%
10%
5%
50%
100%
50%
50%
10- 20%
[286]
[2921
[290]
[288]
[289]
[2851
[291]
L.AliJ
[271]
[65]
[661
[281]
[201
[65]
[691
[20]
[317]
[124]
1611
[651
[671
[300]
none
none
none
none
none
none
hydrogel
none
none
1% SLS
1% SLS
1% SLS
none
1% SLS
none
none
none
0 - 1% SLS
1% SLS
1% SLS
1% SLS
0 - 1% SLS
in vivo mouse
In vivo mouse
in vivo rat
in vitro h FTS
in vivo pig
in vivo rabbit
in vivo rabbit
in vivo
in vitro
in vivo
in vivo
in vitro
in vivo
in vitro
in vivo
in vitro
in vitro
in viv
in vitro
in vitro
in vitro
in vitro
in vivo
in vitro
in vitro
Particles
Gold nanoparticles
Iron oxide particles
Quantum dots
Quantum dots
Diameter
5 nm
5- 10 nm
10 -22 nm
20 nm
Quantum dots 20 nm
siRNA-iposome 50 nm
complex
Testosterone in solid -100 nm'
lipid microparticles
Lidocaine in polymer 200 nm
nanopartices
Liposomes 0.08 pm,
Microparticles
Ultrasound Parameters
Skin-to-Horn
Frequency Amplitude distance US ON Duty
(kHz) (W/cm2) (mm) Time (min) Cycle
20 7.5 3 -3r 50%
0.8
7.5
7.5
2.4
0.05
20 2.5-5.0
4.6 pm
1 - 173 pm'
5
~311
~3"
3
3
100%
50%
50%
50%
20%
Co-Enhancer
1% SLS
0.
5 6-15 20-50%
1 10 100%
2 50%
6 0.25-1.5 20-100%
in vitro
3 M oleic acid in vivo
1% SLS in vitro
1% SLS invio
in vio
0 - 1% SLS in vitro
none in vitro
in vivo
1% dodecyl- in vitro
amine
none
*Legend: p = pig, h = human, FTS = full-thickness skin, HSS = heat-stripped skin, and 700 = 700-sm dermatomed skn.
b No treatment times were specified, see log R values in Table I for relative extents of skin perturbation.
c FITC = fluorescem isothiocyanate.
d No treatment times were specified; skin was treated to a skin conductivity of 0.6 (kohm-cm) 1.
* Amplitude was not reported in W/cm2 ; reported intensity was 3000-8000 Pa.
Molecular weight or size were not reported, but was instead estimated from the paper's references.
g Amplitude was not reported in W/cm2; a setting of 20-30% on the machine was reported (VCX 500, Sonics and Materials, USA).
h Approxinate treatment time, skin was treated to attain a specified range of skm resistivity values.
'Particles as large as 25 pm in diameter were observed to penetrate the skin, but larger particles did not.
Skin Model'
in vitro P- FTS
p 700
mice
p 700
p FTS
p 700
p FTS
cel fines
mouse
rat FTS
Ref.
[56]
[58]
12971
[56]
[521
[2991
[2611
[298]
[124]
[317]
in vivo rats
0 - 1% SLS in vitro
in vivo
none in vtro
in vito
rat FTS
rat
h HSS
h FTS
.. .......... .. . -
portable cymbal array device, which operates at 20 kHz and intensities between 50 - 100
mW/cm2.[285, 289, 290, 292] The novelty of the cymbal array is in its compact size, being only
3 mm in thickness and varying in surface dimensions between 3 cm x 3 cm and 6 cm x 6 cm,
which allows the device to be worn during treatment. This could potentially lead to a closed-
loop system, where one wearable device could house both a glucose sensor and the ultrasound
transducer, allowing the delivery of insulin on demand in response to glucose readings. The
feasibility of both insulin delivery[285, 289, 290, 292] and glucose sensing[310] using the
cymbal array device has been tested and validated.
1.6.2.1 Transdermal Vaccination
In addition to insulin, another research area that is gaining increased attention is transdermal
vaccination. Transdermal vaccination would provide many advantages over current injection-
based methods of vaccination, because it would completely eliminate safety concerns involving
the use of needles, especially with regards to misuse and improper re-use in lower-income areas
and nations. Furthermore, using a patch vaccine formulation, it may be possible to expose the
body to a lower concentration of antigens for a longer period of time, which could provide a
similar, or stronger, immune response by targeting the Langerhans cells within the skin, while
having the added safety benefit associated with lower concentrations of antigen encountered by
the immune system. [306, 316] The first study of LFS-mediated vaccine delivery was conducted
by Tezel et al., and involved the delivery of tetanus toxoid (TT) into an in vivo mouse model
following pretreatment with 20 kHz LFS and 1% SLS.[67] The study found that TT IgG titers
increased with increasing LFS energy density (LFS energy density = LFS amplitude x LFS
treatment time), and that the titers obtained with 1.3 ptg of TT delivered by LFS were similar to
those obtained by subcutaneous injection of 10 ptg of TT (note that subcutaneous injection of 5
jig of TT is sufficient for immunity to tetanus toxin). Therefore, the authors concluded that LFS
not only elicits an enhanced immune response because of the increased delivery of TT to the
Langerhans cells, but also through LFS-induced activation of Langerhans cells. In fact, LFS
alone, in the absence of antigen, was found to induce activation of Langerhans cells in these
studies.[67] Other studies have also shown the ability of high-amplitude LFS (5-7 W/cm2) to
induce an increased immune response, when compared to low-amplitude LFS (0.15 W/cm 2) and
negative controls.[308] These findings demonstrate the significant potential of LFS to act as a
physical adjuvant, and motivate further investigation of LFS-mediated transdermal
immunization. A more recent study investigated the level of TT antibody titers in mice treated
with LFS, while varying SLS concentrations and ultrasound parameters. [300] This study found
that 0.5% SLS provided an immune response superior to that of 1% SLS, despite causing less
skin perturbation. Similarly, a 10% duty cycle produced higher antibody titers than a 20% duty
cycle, in spite of again causing less skin damage.[300] Therefore, it is clear that the
mechanisms of immune response by LFS are not well understood, and more research is needed
in order to optimize protocols for transdermal vaccination using LFS.
1.6.2.2 Delivery of Nanoparticles
In addition to the delivery of simple molecules, the delivery of nanoparticles and molecules in
liposomal formulations have also been tested with LFS (see Table 1-4). With respect to
mechanistic investigations, quantum dots (QDs) have been utilized in several studies, because it
is possible to tune their size and surface chemistry in a controlled fashion.[52, 56, 297] A recent
study by Lopez et al. investigated the delivery of QDs (10-22 nm in diameter), with varying
surface charge (cationic, neutral, and anionic), in order to evaluate LFS treatment to enhance
skin penetration of transdermal carriers.[297] Lopez et al. found that the LFS treatment
increased the amount of QDs penetrating past the epidermis by 500-1300%. Interestingly,
however, the highest charged cationic QD did not penetrate the most, as originally expected,
suggesting that there is an optimal cationic surface charge for designing transdermal
carriers.[297] Other studies have considered the delivery of metallic nanoparticles into LFS-
treated skin, including gold nanoparticles[56] and iron oxide nanoparticles.[58] The latter study,
utilizing iron oxide nanoparticles, was conducted using zero clearance between the skin surface
and the ultrasound horn, which is not typical of treatment protocols involving LFS. In general, it
is advisable to leave some clearance between the skin and the ultrasound horn, even if it is a
small distance (2-3 mm), to avoid the creation of pockets of air/coupling solution between the
skin and the ultrasound horn. Without any clearance, small solution volumes trapped between
the skin and the ultrasound horn, which are restricted from mixing with the bulk solution, could
heat rapidly. This heating can cause thermal effects that are unaccounted for and could lead to
difficulty in the interpretation of the mechanisms of enhancement.
Larger particles have also been delivered through LFS-treated skin, the majority of which are
liposomal formulations. Liposomal formulations are a natural delivery vehicle in the context of
LFS-mediated transdermal delivery, because formulations of lidocaine within liposomes are
already clinically used for topical anesthesia, which will be discussed further in Section 1.6.3
(see Table 1-5). An interesting application of liposomal formulations has been reported by Tran
et al. for the delivery of siRNA-liposome complexes for treatment of melanoma. [299] The study
showed that the application of LFS enabled the delivery of loaded cationic liposomes throughout
the epidermis and the dermis of skin reconstructs, as well as in an in vivo mouse model, which
led to a decrease of melanoma by a statistically significant amount.[299] Other studies have
examined the delivery of liposomes or microparticles as large as 173 Im in diameter,[124, 317]
and have shown that particles as large as 25 tm in diameter can penetrate the skin.[317]
However, the study involving the delivery of microparticles as large as 173 pm was conducted at
extremely high amplitudes, approximately 3 - 7-fold higher (19 - 49 W/cm 2) than the highest
amplitudes commonly used for LFS-mediated transdermal delivery (7 - 8 W/cm 2). Therefore,
although particles as large as 25 gm in diameter were delivered through heat-stripped skin,
microscopy showed macroscopic holes in the skin,[317] which casts significant concern with
regards to the safety of this treatment protocol. Under typical LFS conditions, which have been
tested for safety, it is generally believed that particles no larger than ~100 nm can penetrate LFS-
treated skin as intact entities (see Table 1-4).
1.6.3 Clinical Applications of LFS
LFS has been utilized in many clinical applications for the delivery and extraction of different
types of drugs and analytes (see Table 1-5), in addition to being used for cosmetic purposes in
skin rejuvenation and cellulite remediation. Here, I will focus solely on clinical applications
relevant to drug delivery and analyte extraction. The first clinical application of LFS involved
the delivery of liposomal lidocaine, or lidocaine/prilocaine (both are small, hydrophobic
molecules), to decrease the time of onset for local anesthesia. [18] This application has been well
documented, with multiple pilot and clinical trials showing that LFS decreases the onset to
anesthesia with lidocaine, from 30-60 minutes passively, to less than 5 minutes with LFS
pretreatment. This technology is FDA approved for use in both adults and children for local
Figure 1-7. Low-frequency ultrasound treatment in a clinical setting with the SonoPrep@ device
(Echo Therapeutics, Franklin, MA). The patient holds a conductive polymer hand-piece and the
device automatically stops when the skin impedance is decreased to the desired treatment level.
Usual treatment times are on the order of 10 seconds.
anesthesia prior to hypodermic injection, IV cannulation, and blood donation (SonoPrep@, Echo
Therapeutics, Franklin, MA, see Figure 1-7).[17, 18, 293-295] The device has also been tested
for use in combination with iontophoresis, which results in an even shorter time to onset of
anesthesia (2 minutes).[19] Other applications of the device involve the extraction of interstitial
fluid for blood-glucose and lactate monitoring, which is currently in the process of attaining
FDA approval.[16, 309]
Other studies have investigated the delivery of hydrophilic molecules in clinical applications (see
log K0oW values in Table 1-5), including the delivery of histamine,[284] kojic acid,[275] ascorbic
acid,[275] and epinephrine.[19] Additionally, cyclosporine solution (MW = 1203 kDa) has been
utilized in combination with LFS for the treatment of alopecia areata.[275] In all cases, the drugs
delivered were reported to have the desired effect. For complete experimental details of clinical
trials, refer to Table 1-5.
1.6.4 Safety of LFS
The safety of LFS for use in animals and humans has been evaluated rather rigorously for single
dose applications. Clinical studies with the SonoPrep@ device have shown that, following a
single treatment (10 seconds), there are usually minimal or no adverse reactions, with the most
common side effect being mild erythema.[17, 18, 293-295] As stated above, the SonoPrep@ has
therefore been FDA approved for use in children and adults for decreasing the onset time to local
anesthesia. The effect of LFS on animal models and cultured cell lines has also shown that the
use of low ultrasound intensities is safe, causing no changes in skin pathology and cell
viability. [20, 23, 30, 308, 318] In general, for single application treatments, thermal effects
Table 1-5. Drugs that have been tested in clinical (in vivo human) settings, including experimental details.
Experimental Details
Equipment
Drug MW log Device Manufact(Da) Ko/W urer Purpose
SonoPrepb Echo/ Skin resistivitySontrac reduction
Recovery time of
aEcho/ skin barrierSontra"
Histamine 111 -0.70 Mesothe ape Tran'
Transdermal
histamine
delivery with LFS
Accurately
180 -3-24 w e Echol monitor blood10-3 Sontra" glucose through
LFS-treated skin
Accurately
Echo/ monitor blood
180 -3.24 SonoPrep Sontra glucose through
LFS and
abraded skin
Treatment of
NS melasma and
solar lentigo
Ability of LFS to
234 2.44 SonoPrepb Echo/ decrease onsetSontra" of lidocaine to 5
minutes
Echol234 2.44 SonoPrepb Eo/
Ability of LFS to
decrease onset
of lidocaine to 5
minutes in
children
Metric Utilized
Electrical
current
Electrical
current)
Method Participants
~ Bnded TotaI IFS
nuzed S
No No
No No
Results
Benefit Conclusion
LFS led to an immediate
10 10 Yes decrease in skin impedence,
which lasted for 24 hours.
LFS caused increased and
sustained skin penneaby for up
10 10 Yes to 48 hours uder occlusion Skin
baprier popeuties remcovered
rapidly alter occiusion rmoxval.
Increase in skin
impedance
Increase in skin
impanfce
Papule
formation
caused by
histamine,
patient pain
score
Comparson of
transdenal
blood glucose
readings to
controls
Comparison of
transdermal
blood glucose
readings to
controls
Skin color and
luminosity index
Patients' pain
scores during IV
cannulation, skin
irritation
Children's and
parents' pain
scores with IV
placement
90% of patients showed papule
formation with LFS, compared to
Yes Yes 10 10 Yes none without LFS. Pain scores
with LFS were similar to pain
scores for pin prick tests.
Transdermal glucose monitoring
was found to be safe and
No No 10 10 Yes effective, with a correlationcoefficient of 0.84 between the
transdermal and conrol blood
glucose measurements.
Good agreement was observed
between the transdermal (both
Yes Yes 24 24 Yes LFS and abraded skin) and
control blood glucose
measurements.
Treatnent with emulsion and LFS
resulted in complete
NS NS 48 32 Yes depigmentation in 75% of
melasma cases and 43% total
remission in solar lentigo cases.
91% of LFS-treated patients
Yes Yes 94 45 Yes reported pain scores less than 5,compared to 43% in the controls.
Skin Irritation was similar in both.
Both children's (2.29 vs. 3.23)
and parents' (2.47 vs. 3.39) pain
Yes Yes 77 38 Yes scores decreased significantly
with LFS/lidocaine treatment,
compared to controls.
Glucose
extraction
Glucose
extraction
Azelaic acid,
ascorbic acid,
and kojic acid
(emulsion)
Liposomal
lidocaine
creamf
Liposomal
lidocaine
cream
188, 1.57,
176, -1.85,
142 -0.64
25 klz,
50-100
mW/cm2
-- snow''
Ref.
[318]
[319]
[284]
[161
[3091
[2751
[17]
[293]
Ability of LFS to
b Echo/ decrease pain234 2.44 SonoPrep Eo/o associated withSontra venipuncture in
children
Ability of LFS to
234 2.44 SonoPrepb Echo/ decrease painSontra" associated with
blood donation
Lidocaine, 234, 2.44,
epinephrineO 183 -1.37
Ability of LFS, in
Echo/ combination withSonoPrepb Sontra" iontophoresis, to
decrease onset
to 2 minutes
Ability of LFS to
SonoPrepb Echol decrease onsetSontra" of EMLA cream
to 5 minutes
25 kHz, 50 -374 1.82 100 mW/cm 2  NS
477 3-60 ddefranvs-Ulkrasonored derma
25 kHz, 50 -1203 2.92 100 mW/cm2 NS
Treatment of
alopecia areata
Efficacy of
topical steroids
for
vasoconstiction
Treatment of
alopecia areata
Liposomal
lidocaine
creamy
posomal
lidocaine
fcream
Childrens' and
parents' pain
scores with IV
placement
Patients' pain
scores) during
blood donation,
skin irritation
Patients' pain
scores upon
needle prick
Patients! pain
scores upon
needle prick
Hair re-growth
(total, partial,
none)
Color of skin
evaluated by
chromometer
and Visual
inspection
Hair re-growth
(total, partial,
none)
NS = not specified
a Log octanol-water partition coefficients reported from Ref 270 (Syracuse Research Corporation Physical Property Database).
b Operating frequency = 55 kHz, Amplitude 515 W/cm, transduce-to-skm distance = 0.5 cm, duty cycle = 100%, couplng medium = 1.0% SLS, and treatment times = -10
seconds.
* Echo Therapeutics (Franklin, MA) merged with Smotra in 2007.d Operating frequency = 36 kHz, Amplitude =2.72-3.5 W/cm2, transducer-to-skin distance = 0.5 cm, duty cycle = 29-38% coupling medium = saline, and treatment time = 5
minutes.
e Transderma Systems (Tours, France)-
'Femdale Laboratoies (Ferndale, MI).
5Iontocaine (Abbot Laboratories, Chicago, IL).
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29% of patients had total re-
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caused by LFS are of most consequence to the skin if not monitored properly, causing potentially
serious side effects such as bums, epidermal detachment, epidermal or dermal necrosis, and, on a
cellular level, keratinocyte apoptosis.[308, 318] However, these types of side effects are easily
mitigated by minimizing the duration and intensity of the LFS treatment utilized.
Although LFS has been generally accepted as safe for single dose uses, there have been no
significant studies of the prolonged or repeated use of such treatments. These types of studies
will need to be conducted to establish the safety of LFS in the treatment of chronic diseases. For
example, the current application of non-invasive blood glucose monitoring would require daily
LFS treatment, as would other drug delivery applications. Therefore, sustained in vivo safety
studies are needed to understand the potential skin toxicities involved with repeated LFS
treatment.
1.7 Emerging Trends in Sonophoresis
1.7.1 High-Frequency Sonophoresis
The future of HFS appears to be very similar to its past, that is, in its utilization for the treatment
of topical or regional disorders. A review of publications in the last two years reveals that the
most common types of drugs delivered with HFS are anti-inflammatory medications for joint and
muscle pain, as well as ointments for local skin or muscle conditions. However, while
historically the most common types of anti-inflammatory medications used with HFS have been
topical steroids, such as cortisol, dexamethasone, or prednisolone (see Table 1-1), a shift has
been seen in recent years to non-steroidal anti-inflammatory drugs (NSAIDs). These include: i)
diclofenac, used to alleviate knee pain or arthritis,[209, 210], ii) ibuprofen, used to treat pain and
inflammation in arthritis and other ailments,[95, 210] iii) ketoprofen, used in treating pain of the
knee and temporomandibular joints,[93], iv) ketorolac, used for post-operative pain and
inflammation,[233] v) nimesulide, used for acute pain, such as that associated with
osteoarthritis,[92] and vi) piroxicam, used to treat symptoms of arthritis.[96, 210, 249] This
trend is likely due to the fact that oral NSAIDs commonly cause gastrointestinal (GI) side-
effects, such as nausea, heartburn, GI ulcers, GI inflammation, nonspecific colitis, relapse of
inflammatory bowel disease, and GI bleeding, among others.[301, 302] Meanwhile, common
uses of oral NSAIDs include local joint conditions such as arthritis, that may be equally, or more,
effective if administered topically, while greatly mitigating systemic side-effects.[303] In fact, it
has been shown that treating GI-related side-effects of NSAID usage adds, on average, nearly
46% to the total cost of patient care.[304, 305] Therefore, creating a dependable and usable
topical NSAID treatment method is clearly an area of need, and is a current and emerging trend
with HFS.
Other recent studies that have utilized HFS for increased percutaneous absorption to treat local
ailments include: i) aloe vera, a common skin moisturizer or skin healing agent,[94] ii) Arnica
montana, a plant extract used to treat inflammatory muscle lesions,[145] iii) dimethylsulfoxide,
for the treatment of local muscle damage and oxidative stress,[142] panax notoginseng, an herbal
extract used to increase strength of local ligament repair,[243] and v) sinomenine, a morphinan
derivative used in the treatment of rheumatism and arthritis.[121] In nearly all of these studies,
the combination of HFS treatment with the active agent showed increased benefit over passive
treatment with the drug alone. Therefore, because of its track-record of safety and its ability to
increase the epidermal penetration of topical ointments, it is likely that HFS will continue to
emerge as a viable method for the delivery of low-molecular weight drugs (<1000 Da) for local
and regional ailments.
1.7.2 Low-Frequency Sonophoresis
Unlike HFS, LFS is not restricted as severely by the size of the molecules that it can deliver,
since proteins, vaccines, and even nanoparticles have been demonstrated to be deliverable by
LFS (see Table 1-2). Therefore, emerging trends with LFS include the delivery of therapeutics
for systemic, regional, or local conditions. Arguably the most exciting application is the use of
LFS for transdermal vaccination. Transcutaneous administration of vaccines is already known to
act as an immunization adjuvant, by targeting the Langerhans cells of the viable epidermis.[306,
307] Even ultrasound itself, without exposure to an antigen, has been shown to elicit an immune
response and to activate Langerhans cells.[67, 308] Furthermore, it has been demonstrated that
LFS can be utilized to deliver high-molecular weight vaccines, such as tetanus toxoid, and can
offer equal protection as intramuscular injection.[67, 300] Therefore, it is of no surprise that
transdermal vaccination by LFS is an area of increased research interest. Transdermal
vaccination has the added safety benefits of decreased risk of needle misuse, abuse, or re-use,
especially in lower income areas and nations where these types of issues can be a problem.[1, 2]
Moreover, an equal immune response can be achieved by transdermal application of antigens, as
injection, but with the body being exposed to a far smaller concentration of antigen. For
example, Tezel et al. have shown that just 1.3 ptg of tetanus toxoid delivered to the Langerhans
cells after LFS treatment elicited an immune response equivalent to that of 10 ptg injected
subcutaneously in mouse models.[67] This clearly demonstrates the ability of LFS to deliver
vaccines effectively.
Another interesting area of research is the use of LFS to transdermally deliver drug carriers,
which could be used for targeted or systemic delivery of agents. For example, several groups
have recently shown the ability of LFS to deliver nanoparticles as large as ~100 nm through the
stratum corneum, the primary barrier of the skin, into the viable epidermal and dermal skin
layers.[52, 56, 58, 297] Specifically, Lopez et al. have utilized functionalized quantum dots
(QDs), to mimic drug delivery vehicles, in order to understand optimum surface chemistry for
the delivery of nano-carriers through LFS-treated skin. [297] Their findings showed that cationic,
neutral, and anionic QDs, ranging in size from 10 - 22 nm, could be delivered into the dermal
layers of LFS-treated skin. They found that, unexpectedly, the cationic-functionalized QD with
the highest charge did not penetrate to the greatest extent through LFS-treated skin. Therefore, it
is likely that an optimal cationic surface charge exists when designing transdermal drug delivery
vehicles.[297] Therefore, with further research in this area, one could design drug delivery
carriers that could be administered through LFS-treated skin for applications such as transdermal
vaccination, the delivery of drugs for treatment of skin disorders, or even for systemic delivery.
Other areas in which LFS has been utilized in emerging technologies include: i) blood glucose
monitoring,[16, 22, 23, 47, 309-311], protein delivery,[235, 281, 285, 288, 289], and in clinical
allergy testing.[284] Glucose-monitoring, coupled with transdermal insulin delivery,[235, 285,
288, 289] is especially exciting because it may permit the creation of a closed-loop system that
allows for on-demand delivery of insulin, based on a patient's continuous blood-glucose
measurements. [311] The miniaturization of LFS horns, to the size of 3 - 6 cm wearable devices,
has brought this goal even closer to reality. [285, 288-290, 292, 299, 310, 311] Needless to say,
there are many emerging LFS technologies on the horizon that may change how doctors
administer, and patients receive, drug therapies in the future.
1.8 Thesis Objectives
Although the field of low-frequency sonophoresis has progressed considerably over the past
decade, there are still many unanswered questions concerning phenomena that occur in response
to LFS treatment (see Sections 1.4.1 and 1.4.2). In order to address these unanswered questions
and advance current understanding of the field of LFS, the following three research areas will be
investigated in this thesis: i) understanding the role of cavitation in low-frequency sonophoresis
(LFS), with specific emphasis to its role in inducing heterogeneous skin perturbation, ii) the role
of chemical penetration enhancers (CPEs), primarily surfactants, in causing skin perturbation
with LFS, and iii) the synergism between CPEs and cavitation in LFS treatment.
The first research area investigates the role of cavitation, particularly acoustic cavitation
microjets, in the heterogeneous transport observed in LFS-treated skin (see Figure 1-6). In
general, it is not well understood why highly-perturbed regions, LTRs, and less-perturbed
regions, non-LTRs, are formed on skin samples treated with LFS. Therefore, it is not known
what role cavitation, or other enhancement mechanisms, may be playing in the formation of each
of these discrete skin regions. A deeper understanding of the transport pathways within these
regions could lead to a deeper mechanistic understanding of the formation of LTRs and,
therefore, allow for the exploitation of this mechanism to create larger LTR areas, which would
permit not only achieving greater skin permeabilities but also more control of the extent of skin
perturbation with LFS-treatment. Specifically, the research objectives in this area are to: i) better
characterize the transport pathways through LTRs and non-LTRs by independently determining
the permeabilities and the effective aqueous pore radii in LTRs and non-LTRs, and ii) explain
mechanisms of enhancement within LTRs and non-LTRs.
The second research area explores the role of surfactants in inducing skin perturbation when
applied simultaneously with LFS. In particular, the role of traditional and non-traditional
surfactants in causing skin perturbation with LFS is not well understood, especially with regards
to their role in causing permeability enhancement within LTRs and non-LTRs of LFS-treated
skin. In addition, non-traditional surfactants, such as dyes, are often utilized in LFS coupling
solutions, with little known about how their inclusion affects the resulting skin permeability
enhancement. Therefore, it is very important to understand how these additives affect LFS
treatment protocols. This motivates the following important goals of this research area: i)
understanding the role of surfactants in skin perturbation in LTRs and non-LTRs, and ii)
elucidating the role of non-traditional surfactants, such as dyes that are added to typical LFS
coupling solutions, on skin permeability enhancement.
The third research area ties together the first two research areas, by investigating the synergism
between chemical penetration enhancers (CPEs), such as surfactants, and LFS. Specifically, in
spite of previous work showing that LFS increases the penetration and dispersion of CPEs in the
skin, no mechanism for this increased penetration has previously been proposed. Furthermore,
the effect of a simultaneous treatment of skin with LFS and surfactants is not understood from
the perspective of the structural changes which result from combined LFS/surfactant treatment.
Therefore, little is known about how simultaneous skin treatment with LFS and surfactants can
affect important characteristics associated with LFS treatment, including reproducibility and
predictability of permeability enhancement. Accordingly, the significant aims of this research
area involve: i) explaining the mechanism of increased penetration and dispersion of CPEs, and
specifically surfactants, in LFS-treated skin, ii) elucidating how the extent of skin perturbation
differs between skin samples treated with LFS/surfactants and LFS, iii) understanding how skin
structural parameters differ between skin samples treated with LFS/surfactants and LFS, iv)
explaining how the extent of mechanical support (i.e., the thickness of the dermis in the skin
model considered) affects the extent of skin perturbation in samples treated with LFS/surfactants
and LFS, and v) elucidating how the reproducibility and predictability of skin permeability
enhancement and treatment times of skin samples treated with LFS/surfactants compares to those
of skin samples treated solely with LFS.
Investigating the three research areas discussed above will have a significant impact in furthering
the current mechanistic understanding of low-frequency ultrasound-mediated transdermal drug
delivery. Additionally, the insights provided by the proposed research could lead to the
development of optimized LFS treatment protocols and improved LFS coupling solution
formulations. This would permit attaining the desired skin permeability using milder LFS
treatment conditions and smaller skin treatment areas. This could also lead to lower power
requirements of LFS devices, thereby leading to miniaturization of devices and the creation of
more commercially-viable LFS equipment.
1.9 Thesis Overview
The remainder of this thesis is devoted to an in-depth investigation of the role of cavitation,
ultrasound, and their synergism in ultrasound-mediated transdermal drug delivery, especially
with respect to previously poorly understood phenomena outlined in Section 1.8.
Chapter 2 provides a detailed study of the transport pathways present in the LTRs and non-LTRs
of LFS-treated skin and elucidates the mechanisms that lead to these differences. Specifically,
by utilizing the APPM and by treating skin at three LFS frequencies (20, 40, and 60 kHz),
average pore radii for LTRs, non-LTRs, and total skin samples are calculated as a function of
ultrasound frequency. This allows one to understand the role of cavitation, which is known to be
a frequency-dependent process, as well as of other enhancement mechanisms, on skin
perturbation within each skin region. In addition, the role of CPEs, such as the surfactant sodium
lauryl sulfate (SLS), in causing skin perturbation within non-LTRs is examined.
Chapter 3 investigates the role of traditional and non-traditional surfactants in causing skin
perturbation when applied simultaneously with LFS. In this chapter, the role of a commonly
utilized fluorescent dye, sulforhodamine B (SRB), in affecting bulk and interfacial solution
properties is investigated. SRB has been commonly used in the past as a colorimetric dye with
LFS treatment in order to visualize LTRs, without investigating whether the dye itself could play
a role in skin perturbation. These studies investigate explicitly the role of SRB in causing skin
perturbation both passively and when combined with LFS. Additionally, I investigate how the
combination of SRB with other CPEs, such as SLS, can have unintended consequences on the
extent of skin perturbation produced.
Chapters 4 and 5 investigate the synergism between LFS and CPEs. Chapter 4 ties together
many of the elements of the previous chapters of this thesis, especially Chapter 2, by proposing a
physical mechanism by which LFS induces increased penetration of all CPEs into the LTRs of
LFS-treated skin. In addition, a physical mechanism is proposed to explain why amphiphilic
CPEs, specifically, should exhibit even greater synergism with LFS. These studies answer the
important question of how the synergism between LFS and CPEs actually occurs, and
specifically why this synergism is so pronounced with amphiphilic CPEs. Chapter 5 builds upon
current understanding of the synergism between LFS and CPEs, specifically SLS, by
investigating how skin treated solely with LFS compares to that treated with LFS/SLS from the
viewpoint of skin structural perturbation. In Chapter 5, I investigate how the skin responds to
treatment with LFS and LFS/SLS, including its implications on important metrics for
transdermal delivery, such as reproducibility and predictability of the skin permeability
enhancement.
Chapter 6 concludes this thesis by: (i) providing a summary of the important findings and
conclusions of the research presented, (ii) presenting a critical analysis of the current and future
prospects of LFS, and (iii) proposing future research directions in this area.
1.10 References
[1] M. Prausnitz, R. Langer, Transdermal drug delivery. Nat Biotechnol 26(11) (2008) 1261-
1268.
[2] M. Prausnitz, S. Mitragotri, R. Langer, Current status and future potential of transdermal
drug delivery. Nat Rev Drug Discov 3(2) (2004) 115-124.
[3] J. Bos, M. Meinardi, The 500 Dalton rule for the skin penetration of chemical compounds
and drugs. Exp Dermatol 9(3) (2000) 165-169.
[4] R. Langer, New methods of drug delivery. Science 249(4976) (1990) 1527.
[5] B.W. Barry, Novel mechanisms and devices to enable successful transdermal drug
delivery. Eur J Pharm Sci 14(2) (2001) 101-114.
[6] M.R. Prausnitz, The effects of electric current applied to skin: A review for transdermal
drug delivery. Adv Drug Deliver Rev 18(3) (1996) 395-425.
[7] S. Jacques, D. McAuliffe, I. Blank, J. Parrish, Controlled removal of human stratum
corneum by pulsed laser. J Invest Dermatol 88(1) (1987) 88-93.
[8] A. Arora, M.R. Prausnitz, S. Mitragotri, Micro-scale devices for transdermal drug
delivery. Int J Pharm 364(2) (2008) 227-236.
[9] S. Mitragotri, J. Farrell, H. Tang, T. Terahara, J. Kost, R. Langer, Determination of
threshold energy dose for ultrasound-induced transdermal drug transport. J Control Release 63(1 -
2) (2000) 41-52.
[10] S. Mitragotri, D. Ray, J. Farrell, H. Tang, B. Yu, J. Kost, D. Blankschtein, R. Langer,
Synergistic effect of low-frequency ultrasound and sodium lauryl sulfate on transdermal
transport. J Pharm Sci 89(7) (2000) 892-900.
[11] T. Terahara, S. Mitragotri, J. Kost, R. Langer, Dependence of low-frequency
sonophoresis on ultrasound parameters; distance of the horn and intensity. Int J Pharm 235(1-2)
(2002) 35-42.
[12] A. Tezel, A. Sens, S. Mitragotri, A theoretical analysis of low-frequency sonophoresis:
dependence of transdermal transport pathways on frequency and energy density. Pharm Res
19(12) (2002) 1841-1846.
[13] J. Kushner, D. Kim, P. So, D. Blankschtein, R. Langer, Dual-channel two-photon
microscopy study of transdermal transport in skin treated with low-frequency ultrasound and a
chemical enhancer. J Invest Dermatol 127(12) (2007) 2832-2846.
[14] B.E. Polat, J.E. Seto, D. Blankschtein, R. Langer, Application of the aqueous porous
pathway model to quantify the effect of sodium lauryl sulfate on ultrasound-induced skin
structural perturbation. J Pharm Sci 100(4) (2011) 1387-1397.
[15] B.E. Polat, P.L. Figueroa, D. Blankschtein, R. Langer, Transport pathways and
enhancement mechanisms within localized and non-localized transport regions in skin treated
with low-frequency sonophoresis and sodium lauryl sulfate. J Pharm Sci 100(2) (2011) 512-529.
[16] H. Chuang, E. Taylor, T. Davison, Clinical evaluation of a continuous minimally invasive
glucose flux sensor placed over ultrasonically permeated skin. Diabetes Technol The 6(1) (2004)
21-30.
[17] B. Becker, S. Helfrich, E. Baker, K. Lovgren, P. Minugh, J. Machan, Ultrasound with
topical anesthetic rapidly decreases pain of intravenous cannulation. Acad Emerg Med 12(4)
(2005) 289-295.
[18] N. Katz, D. Shapiro, T. Herrmann, J. Kost, L. Custer, Rapid onset of cutaneous
anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Anesth
Analg 98(2) (2004) 371.
[19] E. Spierings, J. Brevard, N. Katz, Two-minute skin anesthesia through ultrasound
pretreatment and iontophoretic delivery of a topical anesthetic: A feasibility study. Pain Med
9(1) (2008) 55-59.
[20] S. Mitragotri, D. Blankschtein, R. Langer, Ultrasound-mediated transdermal protein
delivery. Science 269(5225) (1995) 850-853.
[21] H. Tang, S. Mitragotri, D. Blankschtein, R. Langer, Theoretical description of
transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis. J
Pharm Sci 90(5) (2001) 545-568.
[22] J. Kost, S. Mitragotri, R. Gabbay, M. Pishko, R. Langer, Transdermal monitoring of
glucose and other analytes using ultrasound. Nat Med 6(3) (2000) 347-350.
[23] S. Mitragotri, M. Coleman, J. Kost, R. Langer, Transdermal extraction of analytes using
low-frequency ultrasound. Pharm Res 17(4) (2000) 466-470.
[24] S. Mitragotri, Sonophoresis: a 50-year journey. Drug Discov Today 9(17) (2004) 735-
736.
[25] K. Fellinger, J. Schmid, Klinik und Therapie des chronischen Gelenkrheumatismus,
Maudrich, Vienna, Austria, 1954.
[26] M. Newman, M. Kill, G. Frampton, Effects of ultrasound alone and combined with
hydrocortisone injections by needle or hypo-spray. Amer J Physical Med 37(4) (1958) 206 - 209.
[27] P. Tyle, P. Agrawala, Drug delivery by phonophoresis. Pharm Res 6(5) (1989) 355-361.
[28] D. Bommannan, G. Menon, H. Okuyama, P. Elias, R. Guy, Sonophoresis. II.
Examination of the mechanism (s) of ultrasound-enhanced transdermal drug delivery. Pharm Res
9(8) (1992) 1043-1047.
[29] N. Byl, The use of ultrasound as an enhancer for transcutaneous drug delivery:
phonophoresis. Phys Ther 75(6) (1995) 539.
[30] S. Mitragotri, D. Blankschtein, R. Langer, Transdermal drug delivery using low-
frequency sonophoresis. Pharm Res 13(3) (1996) 411-420.
[31] R. Apfel, Acoustic cavitation: a possible consequence of biomedical uses of ultrasound.
Br J Cancer Suppl 5 (1982) 140-146.
[32] J. Kost, D. Levy, R. Langer, Ultrasound effect on transdermal drug delivery. International
Symposium Controlled Release 1986, pp. 177-178.
[33] D. Levy, J. Kost, Y. Meshulam, R. Langer, Effect of ultrasound on transdermal drug
delivery to rats and guinea pigs. J Clin Invest 83(6) (1989) 2074.
[34] S. Mitragotri, D. Edwards, D. Blankschtein, R. Langer, A mechanistic study of
ultrasonically-enhanced transdermal drug delivery. J Pharm Sci 84(6) (1995) 697-706.
[35] W. Gaertner, Frequency Dependence of Ultrasonic Cavitation. J Acoust Soc Am 26(6)
(1954) 977-980.
[36] B. Baroli, Penetration of nanoparticles and nanomaterials in the skin: Fiction or reality? J
Pharm Sci 99(1) (2010) 21-50.
[37] G. Cevc, U. Vierl, Nanotechnology and the transdermal route:: A state of the art review
and critical appraisal. J Control Release 141(3) (2010) 277-299.
[38] B.E. Polat, D. Blankschtein, R. Langer, Low-frequency sonophoresis: application to the
transdermal delivery of macromolecules and hydrophilic drugs. Expert Opin Drug Del 7(12)
(2010) 1415-1432.
[39] T. Leighton, What is ultrasound? Prog Biophys Mol Bio 93(1-3) (2007) 3-83.
[40] A. Pointon, Piezoelectric devices. IEE Proc-A 129(5) (1982) 285-307.
[41] A. Boucaud, J. Montharu, L. Machet, B. Arbeille, M. Machet, F. Patat, L. Vaillant,
Clinical, histologic, and electron microscopy study of skin exposed to low-frequency ultrasound.
Anat Rec Part A 264(1) (2001) 114-119.
[42] H. Tang, C. Wang, D. Blankschtein, R. Langer, An investigation of the role of cavitation
in low-frequency ultrasound-mediated transdermal drug transport. Pharm Res 19(8) (2002) 1160-
1169.
[43] R. Alvarez-Romin, G. Merino, Y. Kalia, A. Naik, R. Guy, Skin permeability
enhancement by low frequency sonophoresis: lipid extraction and transport pathways. J Pharm
Sci 92(6) (2003) 1138-1146.
[44] L. Wolloch, J. Kost, The importance of microjet vs shock wave formation in
sonophoresis. J Control Release (in press) (2010).
[45] L. Le, J. Kost, S. Mitragotri, Combined effect of low-frequency ultrasound and
iontophoresis: applications for transdermal heparin delivery. Pharm Res 17(9) (2000) 1151-1154.
[46] S. Mitragotri, Synergistic effect of enhancers for transdermal drug delivery. Pharm Res
17(11) (2000) 1354-1359.
[47] S. Mitragotri, J. Kost, Low-frequency sonophoresis: a noninvasive method of drug
delivery and diagnostics. Biotechnol Prog 16(3) (2000) 488-492.
[48] H. Tang, D. Blankschtein, R. Langer, Effects of low-frequency ultrasound on the
transdermal permeation of mannitol: comparative studies with in vivo and in vitro skin. J Pharm
Sci 91(8) (2002) 1776-1794.
[49] T. Terahara, S. Mitragotri, R. Langer, Porous resins as a cavitation enhancer for low-
frequency sonophoresis. J Pharm Sci 91(3) (2002) 753-759.
[50] A. Tezel, A. Sens, J. Tuchscherer, S. Mitragotri, Synergistic effect of low-frequency
ultrasound and surfactants on skin permeability. J Pharm Sci 91(1) (2002) 91-100.
[51] J. Kushner, D. Blankschtein, R. Langer, Experimental demonstration of the existence of
highly permeable localized transport regions in low-frequency sonophoresis. J Pharm Sci 93(11)
(2004) 2733-2745.
[52] S. Paliwal, G. Menon, S. Mitragotri, Low-frequency sonophoresis: ultrastructural basis
for stratum corneum permeability assessed using quantum dots. J Invest Dermatol 126(5) (2006)
1095-1101.
[53] J. Kushner, D. Blankschtein, R. Langer, Evaluation of the porosity, the tortuosity, and the
hindrance factor for the transdermal delivery of hydrophilic permeants in the context of the
aqueous pore pathway hypothesis using dual-radiolabeled permeability experiments. J Pharm Sci
96(12) (2007) 3263-3282.
[54] J. Kushner, D. Blankschtein, R. Langer, Heterogeneity in skin treated with low-frequency
ultrasound. J Pharm Sci 97(10) (2008) 4119-4128.
[55] J. Kushner, D. Blankschtein, R. Langer, Evaluation of hydrophilic permeant transport
parameters in the localized and non-localized transport regions of skin treated simultaneously
with low-frequency ultrasound and sodium lauryl sulfate. J Pharm Sci 97(2) (2008) 906-918.
100
[56] J. Seto, B. Polat, R. Lopez, D. Blankschtein, R. Langer, Effects of ultrasound and sodium
lauryl sulfate on the transdermal delivery of hydrophilic permeants: Comparative in vitro studies
with full-thickness and split-thickness pig and human skin. J Control Release 145(1) (2010) 26-
32.
[57] G. Merino, Y. Kalia, M. Delgado-Charro, R. Potts, R. Guy, Frequency and thermal
effects on the enhancement of transdermal transport by sonophoresis. J Control Release 88(1)
(2003) 85-94.
[58] S. Lee, K. Choi, G. Menon, H. Kim, E. Choi, S. Ahn, S. Lee, Penetration Pathways
Induced by Low-Frequency Sonophoresis with Physical and Chemical Enhancers: Iron Oxide
Nanoparticles versus Lanthanum Nitrates. J Invest Dermatol 130(4) (2010) 1063-1072.
[59] A. Tezel, S. Mitragotri, Interactions of inertial cavitation bubbles with stratum corneum
lipid bilayers during low-frequency sonophoresis. Biophys J 85(6) (2003) 3502-3512.
[60] A. Tezel, A. Sens, S. Mitragotri, Investigations of the role of cavitation in low-frequency
sonophoresis using acoustic spectroscopy. J Pharm Sci 91(2) (2002) 444-453.
[61] A. Tezel, A. Sens, S. Mitragotri, Description of transdermal transport of hydrophilic
solutes during low-frequency sonophoresis based on a modified porous pathway model. J Pharm
Sci 92(2) (2003) 381-393.
[62] H. Ueda, M. Mutoh, T. Seki, D. Kobayashi, Y. Morimoto, Acoustic Cavitation as an
Enhancing Mechanism of Low-Frequency Sonophoresis for Transdermal Drug Delivery. Biol
Pharm Bull 32(5) (2009) 916-920.
[63] I. Lavon, N. Grossman, J. Kost, The nature of ultrasound-SLS synergism during
enhanced transdermal transport. J Control Release 107(3) (2005) 484-494.
101
[64] I. Lavon, N. Grossman, J. Kost, E. Kimmel, G. Enden, Bubble growth within the skin by
rectified diffusion might play a significant role in sonophoresis. J Control Release 117(2) (2007)
246-255.
[65] S. Mitragotri, J. Kost, Transdermal delivery of heparin and low-molecular weight heparin
using low-frequency ultrasound. Pharm Res 18(8) (2001) 1151-1156.
[66] A. Tezel, S. Dokka, S. Kelly, G. Hardee, S. Mitragotri, Topical delivery of anti-sense
oligonucleotides using low-frequency sonophoresis. Pharm Res 21(12) (2004) 2219-2225.
[67] A. Tezel, S. Paliwal, Z. Shen, S. Mitragotri, Low-frequency ultrasound as a
transcutaneous immunization adjuvant. Vaccine 23(29) (2005) 3800-3807.
[68] A. Tezel, A. Sens, J. Tuchscherer, S. Mitragotri, Frequency dependence of sonophoresis.
Pharm Res 18(12) (2001) 1694-1700.
[69] Y. Morimoto, M. Mutoh, H. Ueda, L. Fang, K. Hirayama, M. Atobe, D. Kobayashi,
Elucidation of the transport pathway in hairless rat skin enhanced by low-frequency sonophoresis
based on the solute-water transport relationship and confocal microscopy. J Control Release
103(3) (2005) 587-597.
[70] M. Brown, G. Martin, S. Jones, F. Akomeah, Dermal and transdermal drug delivery
systems: current and future prospects. Drug Deliv 13(3) (2006) 175-187.
[71] H. Tang, D. Blankschtein, R. Langer, Prediction of steady-state skin permeabilities of
polar and nonpolar permeants across excised pig skin based on measurements of transient
diffusion: Characterization of hydration effects on the skin porous pathway. J Pharm Sci 91(8)
(2002) 1891-1907.
[72] S. Ghosh, D. Blankschtein, The role of sodium dodecyl sulfate (SDS) micelles in
inducing skin barrier perturbation in the presence of glycerol. Int J Cosmetic Sci 30 (2007) 73.
102
[73] C. Brennen, Cavitation and bubble dynamics, Oxford University Press, USA, 1995.
[74] M. Margulis, Sonochemistry and Cavitation, Taylor & Francis, 1995.
[75] L. Crum, Sonochemistry and sonoluminescence, Springer Netherlands, 1999.
[76] S. Fong, E. Klaseboer, C. Turangan, B. Khoo, K. Hung, Numerical analysis of a gas
bubble near bio-materials in an ultrasound field. Ultrasound Med Biol 32(6) (2006) 925-942.
[77] T. Leighton, A. Walton, M. Pickworth, Primary Bjerknes forces. Eur J Phys(1) (1990) 47.
[78] T. Leighton, An introduction to acoustic cavitation. Med Sci Ser (1998) 199-223.
[79] J. Simonin, On the mechanisms of in vitro and in vivo phonophoresis. J Control Release
33(1) (1995) 125-141.
[80] D. Hsieh, M. Plesset, Theory of Rectified Diffusion of Mass into Gas Bubbles. J Acoust
Soc Am 33(2) (1961) 206-215.
[81] A. Eller, H. Flynn, Rectified diffusion during nonlinear pulsations of cavitation bubbles. J
Acoust Soc Am 37 (1965) 493.
[82] A. Naji Meidani, M. Hasan, Mathematical and physical modelling of bubble growth due
to ultrasound. Appl Math Model 28(4) (2004) 333-351.
[83] S. Jones, G. Evans, K. Galvin, Bubble nucleation from gas cavities -- a review. Adv
Colloid Interfac 80(1) (1999) 27-50.
[84] J. Lee, S. Kentish, T. Matula, M. Ashokkumar, Effect of surfactants on inertial cavitation
activity in a pulsed acoustic field. J. Phys. Chem. B 109(35) (2005) 16860-16865.
[85] T. Mason, D. Peters, Practical sonochemistry: Uses and applications of ultrasound,
Horwood Publishing Limited, 2002.
[86] N. Pelekasis, A. Gaki, A. Doinikov, J. Tsamopoulos, Secondary Bjerknes forces between
two bubbles and the phenomenon of acoustic streamers. J Fluid Mech 500 (2004) 313-347.
103
[87] R. Mettin, I. Akhatov, U. Parlitz, C.D. Ohl, W. Lauterborn, Bjerknes forces between
small cavitation bubbles in a strong acoustic field. Phys Rev E 56(3) (1997) 2924.
[88] R. Mettin, P. Koch, W. Lauterborn, D. Krefting, Modeling acoustic cavitation with
bubble redistribution. Sixth International Symposium on Cavitation, Wageningen, The
Netherlands, 2006.
[89] R. Mettin, D. Krefting, J. Appel, P. Koch, W. Lauterborn, Stereoscopic high- speed
recording of bubble structures. Proceedings of the 3rd Conference on Ultrasound in Processing,
Paris, France, 2001, pp. 199-203.
[90] J. Appel, P. Koch, R. Mettin, D. Krefting, W. Lauterborn, Stereoscopic high-speed
recording of bubble filaments. Ultrason Sonochem 11(1) (2004) 39-42.
[91] M. Ogura, S. Paliwal, S. Mitragotri, Low-frequency sonophoresis: current status and
future prospects. Adv Drug Deliv Rev 60(10) (2008) 1218-1223.
[92] P. Barja, D. Veloso, Photoacoustic study of the penetration kinetics of nimesulid into
human skin. International Conference on Photoacoustic and Photothermal Phenomena, IOP
Publishing, 2010, p. (214) 012017.
[93] K. Kaya, S. Delialouglu, M. Babadag, D. Duleroglu, S. Ozel, C. Culha, S. Gorgun,
Combined Physiotherapy in Patients with Arthrogenous Pain of Temporomandibular Joint. J
PMR Sci 13 (2010) 6-14.
[94] A.L.M. Maia Filho, A.B. Villaverde, E. Munin, F. Aimbire, R. Albertini, Comparative
Study of the Topical Application of Aloe Vera Gel, Therapeutic Ultrasound and Phonophoresis
on the Tissue Repair in Collagenase-Induced Rat Tendinitis. Ultrasound Med Biol 36(10) (2010)
1682-1690.
104
[95] M. Meshali, H. Abdel-Aleem, F. Sakr, S. Nazzal, Y. El-Malah, Effect of gel composition
and phonophoresis on the transdermal delivery of ibuprofen: In vitro and in vivo evaluation.
Pharm Dev Technol (in press) (2010).
[96] F. Silveira, P. Barja, D. Acosta-Avalos, Photoacoustic evaluation of the penetration of
piroxicam gel applied with phonophoresis into human skin. International Conference on
Photoacoustic and Photothermal Phenomena, IOP Publishing, 2010, p. (214) 012022.
[97] P. Riesz, T. Kondo, Free radical formation induced by ultrasound and its biological
implications. Free Radical Bio Med 13(3) (1992) 247-270.
[98] V. Meidan, A. Walmsley, W. Irwin, Phonophoresis is it a reality? Int J Pharm 118(2)
(1995) 129-149.
[99] T. Julian, G. Zentner, Mechanism for ultrasonically enhanced transmembrane solute
permeation. J Control Release 12(1) (1990) 77-85.
[100] K. Tachibana, S. Tachibana, Use of ultrasound to enhance the local anesthetic effect of
topically applied aqueous lidocaine. Anesthesiology 78(6) (1993) 1091.
[101] I. Lenart, D. Auslander, The effect of ultrasound on diffusion through membranes.
Ultrasonics 18(5) (1980) 216-218.
[102] R. Brucks, M. Nanavaty, D. Jung, F. Siegel, The effect of ultrasound on the in vitro
penetration of ibuprofen through human epidermis. Pharm Res 6(8) (1989) 697-701.
[103] D. Bommannan, H. Okuyama, P. Stauffer, R. Guy, Sonophoresis. I. The use of high-
frequency ultrasound to enhance transdermal drug delivery. Pharm Res 9(4) (1992) 559-564.
[104] M. Machluf, J. Kost, Ultrasonically enhanced transdermal drug delivery. Experimental
approaches to elucidate the mechanism. J Biomat Sci-Polym E 5(1-2) (1993) 147-156.
105
[105] H. Ueda, K. Sugibayashi, Y. Morimoto, Skin penetration-enhancing effect of drugs by
phonophoresis. J Control Release 37(3) (1995) 291-297.
[106] D. Skauen, G. Zentner, Phonophoresis. Int J Pharm 20(3) (1984) 235-245.
[107] J. Sundaram, B. Mellein, S. Mitragotri, An experimental and theoretical analysis of
ultrasound-induced permeabilization of cell membranes. Biophys J 84(5) (2003) 3087-3101.
[108] J. Isselin, A. Alloncle, M. Autric, On laser induced single bubble near a solid boundary:
Contribution to the understanding of erosion phenomena. J Appl Phys 84 (1998) 5766.
[109] S. Watanabe, S. Takagi, K. Ga, K. Yamamoto, T. Aoyagi, Enhanced transdermal drug
penetration by the simultaneous application of iontophoresis and sonophoresis. Drug Del Sci
Tech 19(3) (2009) 185-189.
[110] A. Joshi, J. Raje, Sonicated transdermal drug transport. J Control Release 83(1) (2002)
13-22.
[111] M. Pahade, M. Jadhav, M. Kadam, Sonophoresis: An Overview. Int J Pharm Sci Res 3(2)
(2010) 24-32.
[112] M. Johnson, S. Mitragotri, A. Patel, D. Blankschtein, R. Langer, Synergistic effects of
chemical enhancers and therapeutic ultrasound on transdermal drug delivery. J Pharm Sci 85(7)
(1996) 670-679.
[113] V. Meidan, M. Docker, A. Walmsley, W. Irwin, Phonophoresis of hydrocortisone with
enhancers: an acoustically defined model. Int J Pharm 170(2) (1998) 157-168.
[114] H. Liu, S. Li, W. Pan, Y. Wang, F. Han, H. Yao, Investigation into the potential of low-
frequency ultrasound facilitated topical delivery of Cyclosporin A. Int J Pharm 326(1-2) (2006)
32-38.
106
[115] S. Tiwari, R. Pai, N. Udupa, Influence of ultrasound on the percutaneous absorption of
ketorolac tromethamine in vitro across rat skin. Drug Deliv 11(1) (2004) 47-51.
[116] X. Xu, Q. Zhu, C. Sun, Combined effect of ultrasound-SLS on skin optical clearing.
IEEE Photonic Tech L 20(24) (2008) 2117-2119.
[117] X. Xu, Q. Zhu, C. Sun, Assessment of the effects of ultrasound-mediated alcohols on skin
optical clearing. J Biomed Opt 14(3) (2009) 034042.
[118] X. Xu, Q. Zhu, C. Sun, Assessment of the effects of ultrasound-mediated alcohols on skin
optical clearing. J Biomed Opt 14 (2009) 034042.
[119] H. Zhong, Z. Guo, H. Wei, L. Guo, C. Wang, Y. He, H. Xiong, S. Liu, Synergistic Effect
of Ultrasound and Thiazone-PEG 400 on Human Skin Optical Clearing In Vivo. Photochem
Photobiol 86(3) (2010) 732-737.
[120] H. Zhong, Z. Guo, H. Wei, C. Zeng, H. Xiong, Y. He, S. Liu, In vitro study of ultrasound
and different-concentration glycerol--induced changes in human skin optical attenuation assessed
with optical coherence tomography. J Biomed Opt 15(3) (2010) 036012.
[121] L. Li-an, W. Hong, L. Xin-Ping, G. Jian-Qing, Effect of Sonophoresis Combined with
Chemical Enhancer on Transdermal Delivery of Sinomenine Hydrochloride Gel in Vitro. Chin
Arch Trad Chin Med (2009).
[122] J. Fang, C. Fang, C. Hong, H. Chen, T. Lin, H. Wei, Capsaicin and nonivamide as novel
skin permeation enhancers for indomethacin. Eur J Pharm Sci 12(3) (2001) 195-203.
[123] S. Mutalik, H. Parekh, N. Davies, N. Udupa, A combined approach of chemical
enhancers and sonophoresis for the transdermal delivery of tizanidine hydrochloride. Drug Deliv
16(2) (2009) 82-91.
107
[124] A. Dahlan, H. Alpar, S. Murdan, An investigation into the combination of low frequency
ultrasound and liposomes on skin permeability. Int J Pharm 379(1) (2009) 139-142.
[125] Y. Shah, A. Pandit, V. Moholkar, Cavitation reaction engineering, Plenum Pub Corp,
1999.
[126] G. Golden, J. McKie, R. Potts, Role of stratum corneum lipid fluidity in transdermal drug
flux. J Pharm Sci 76(1) (1987) 25-28.
[127] B. Yu, C. Dong, P. So, D. Blankschtein, R. Langer, In vitro visualization and
quantification of oleic acid induced changes in transdermal transport using two-photon
fluorescence microscopy. J Invest Dermatol 117(1) (2001) 16-25.
[128] B. Yu, K. Kim, P. So, D. Blankschtein, R. Langer, Visualization of oleic acid-induced
transdermal diffusion pathways using two-photon fluorescence microscopy. J Invest Dermatol
120(3) (2003) 448-455.
[129] J. Kost, U. Pliquett, S. Mitragotri, A. Yamamoto, R. Langer, J. Weaver, Synergistic effect
of electric field and ultrasound on transdermal transport. Pharm Res 13(4) (1996) 633-638.
[130] J. Fang, T. Hwang, Y. Huang, Y. Tsai, Transdermal iontophoresis of sodium nonivamide
acetate: V. Combined effect of physical enhancement methods. Int J Pharm 235(1-2) (2002) 95-
105.
[131] T. Hikima, S. Ohsumi, K. Shirouzu, K. Tojo, Mechanisms of Synergistic Skin
Penetration by Sonophoresis and Iontophoresis. Biol Pharm Bull 32(5) (2009) 905-909.
[132] A. Dakowicz, R. Latosiewicz, The value of iontophoresis combined with ultrasound in
patients with the carpal tunnel syndrome. Rocz Akad Med Bialymst 50 (2005) 196-198.
108
[133] J. Dudelzak, M. Hussain, R. Phelps, G. Gottlieb, D. Goldberg, Evaluation of histologic
and electron microscopic changes after novel treatment using combined microdermabrasion and
ultrasound induced phonophoresis of human skin. J Cosmet Laser Ther 10(4) (2008) 187-192.
[134] E. Coodley, Bursitis and post-traumatic lesions: management with combined use of
ultrasound and intra-articular hydrocortisone. Am Pract 11 (1960) 181 -187.
[135] 0. Mune, K. Thorseth, Ultrasonic treatment of subcutaneous infiltrations after injections.
Acta Orthop Scand 33(1-4) (1963) 347-349.
[136] J. Aldes, Ultrasonic radiation in the treatment of epicondylitis. GP 13(6) (1956) 89.
[137] J. Aldes, W. Jadeson, Ultrasonic therapy in the treatment of hypertrophic arthritis in
elderly patients. Ann West Med Surg 6(9) (1952) 545.
[138] J. Aldes, T. Klaras, Use of ultrasonic radiation in the treatment of subdeltoid bursitis with
and without calcareous deposits. West J Surg Obstet Gynecol 62(7) (1954) 369-376.
[139] W. Bierman, Ultrasound in the treatment of scars. Arch Phys Med Rehabil 35(4) (1954)
209-214.
[140] J. Kuitert, M. Davis, A. Brittis, J. Aldes, Control of keloid growth with ultrasonic energy;
a report of two cases. Am J Phys Med 34(3) (1955) 408-412.
[141] 0. Mune, K. Thorseth, Ultrasonic Treatment of Cicatricalgia. Acta Orthop Scand 33(1-4)
(1963) 342-346.
[142] P. Silveira, E. Victor, D. Schefer, L. Silva, E. Streck, M. Paula, R. Pinho, Effects of
Therapeutic Pulsed Ultrasound and Dimethylsulfoxide (DMSO) Phonophoresis on Parameters of
Oxidative Stress in Traumatized Muscle. Ultrasound Med Biol 36(1) (2010) 44-50.
109
[143] V. Meidan, M. Docker, A. Walmsley, W. Irwin, Low intensity ultrasound as a probe to
elucidate the relative follicular contribution to total transdermal absorption. Pharm Res 15(1)
(1998) 85-92.
[144] I. Romanenko, R. Aravi ski Comparative levels of amphotericin B in the skin and
subcutaneous fatty tissue after cutaneous application of amphotericin ointment by phonophoresis
and with preliminary treatment by dimethyl sulfoxide. Antibiot Khimioter 36(9) (1991) 29.
[145] P. Alfredo, C. Anaruma, A. Pido, S. Joio, R. Casarotto, Effects of phonophoresis with
Arnica montana onto acute inflammatory process in rat skeletal muscles: An experimental study.
Ultrasonics 49(4-5) (2009) 466-471.
[146] L. Glushchenko, Phonophoresis of thiamin and ascorbic acid. Zdravookhr Beloruss 11
(1977) 80-81.
[147] T. Hakozaki, H. Takiwaki, K. Miyamoto, Y. Sato, S. Arase, Ultrasound enhanced skin-
lightening effect of vitamin C and niacinamide. Skin Res Technol 12(2) (2006) 105-113.
[148] A.R. Williams, Phonophoresis: An in vivo evaluation using three topical anaesthetic
preparations. Ultrasonics 28(3) (1990) 137-141.
[149] D. Chatterjee, A double-blind clinical study with benzydamine 3% cream on soft tissue
injuries in an occupational health centre. J Int Med Res 5(6) (1977) 450 - 458.
[150] H. Benson, J. McElnay, J. Whiteman, R. Harland, Lack of effect of ultrasound on the
percutaneous absorption of benzydamine. J Pharm Pharmacol 38 (1986).
[151] H. Benson, J. McElnay, R. Harland, Use of ultrasound to enhance percutaneous
absorption of benzydamine. Phys Ther 69(2) (1989) 113.
[152] D. Hofmann, F. Moll, The effect of ultrasound on in vitro liberation and in vivo
penetration of benzyl nicotinate. J Control Release 27(3) (1993) 185-192.
110
[153] P. Indkevich, Experience in the treatment of hidradenitis with biomycin phonophoresis.
Vestn Dermatol Venerol(44) (1971) 75 - 77.
[154] P. Indkevich, Use of biomycin phonophoresis in the treatment of suppurative skin
diseases. Vestn Dermatol Venerol(37) (1972) 266 - 267.
[155] J. Famaey, Sonophoresis with non-steroidal antiinflammatory drugs. A survey of the
problem (author's transl). J Belge Rhumatol Med Phys 30(3) (1975) 129 - 141.
[156] D. Monti, R. Giannelli, P. Chetoni, S. Burgalassi, Comparison of the effect of ultrasound
and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless
mouse skin in vitro. Int J Pharm 229(1-2) (2001) 131-137.
[157] E.H. Choi, M.J. Kim, B.-I. Yeh, S.K. Ahn, S.H. Lee, Iontophoresis and Sonophoresis
Stimulate Epidermal Cytokine Expression at Energies That Do Not Provoke a Barrier
Abnormality: Lamellar Body Secretion and Cytokine Expression Are Linked to Altered
Epidermal Calcium Levels. J Invest Dermatol 121(5) (2003) 1138-1144.
[158] G. Wanet, N. Dehon, Clinical study of ultrasonophoresis with a topical preparation
combining phenylbutazone and alpha-chymotrypsin. J Belge Rhumatol Med Phys 31(2) (1976)
49 - 58.
[159] S. Gatev, E. Vatsov, Attempt to treat essential pruritus vulvae and some inflammatory
gynecologic diseases with hydrocortisone phonophoresis. Akush Ginekol 5(2) (1966) 123.
[160] S. Safiulina, A. Pushkareva, Experience in the phonophoresis treatment with
hydrocortisone of patients with diseases of the musculoskeletal system. Vopr Kurortol Fizioter
Lech Fiz Kult 32(6) (1967) 485 - 488.
111
[161] E. Nagovitsyn, Comparative evaluation of the effectiveness of hydrocortisone injections
and phonophoresis in the treatment of diseases of the support-motor apparatus. Vestn Khir Im I I
Grek 104(3) (1970) 54 - 55.
[162] E. Nagovitsyn, I. Vakhatova, Hydrocortisone phonophoresis for various diseases of the
locomotor apparatus. Vopr Kurortol Fizioter Lech Fiz Kult 36(2) (1971) 180.
[163] E. Bel'ts, M. Bondarenko, The use of ultrasound and phonophoresis with hydrocortisone
in chronic psoriasis. Vestn Dermatol Venerol(45) (1971) 70-72.
[164] T. Burgudzhieva, The treatment of pruritus vulvae essentialis with ultrasound and
hydrocortisone ointment as well as phonophoresis with hydrocortisone ointment. Akush Ginekol
10(3) (1971) 231 - 234.
[165] T. Burgudzhieva, Comparative data on histological changes in the external genitalia in
patients with pruritus vulvae essentialis before and after treatment by phonophoresis with
unguentum hydrocortisone. Akush Ginekol 10(16) (1971) 477 - 482.
[166] T. Burgudzhieva, Histological changes in external genital organs in patients with
kraurosis vulvae, treated by phonophoresis and hydrocortisone ointment. Akush Ginekol 10(4)
(1971) 287 - 291.
[167] T. Burgudzhieva, Comparative study of treatment of kraurosis vulvae (lichen
scleroatrophicus vulvae) with ultrasound, hydrocortisone ointment and phonophoresis with
hydrocortisone ointment. Akush Ginekol 11(3) (1972) 246 - 251.
[168] T. Burgudzhieva, Effect of ultrasonics, hydrocortisone ointment and phonophoresis of
hydrocortisone ointment on indices of sensory chronaximetry of kraurosis vulvae, lichen
scleroatrophicus vulvae and pruritis vulvae essentialis. Vopr Kurortol Fizioter Lech Fiz Kult(3)
(1974) 267 - 269.
112
[169] A. Grinshtein, S. Shevchenko, Rheoencephalographic studies of facial neuritis in
treatment by ultrasonics and hydrocortisone phonophoresis. Vopr Kurortol Fizioter Lech Fiz
Kult 38(3) (1973) 230.
[170] A. Grinshtein, A. Tolmacheva, V. Khriptulov, The effectiveness of hydrocortisone
phonophoresis in facial nerve neuritis according to strength-duration findings. Vopr Kurortol
Fizioter Lech Fiz Kult 36(6) (1971) 528 - 530.
[171] T. Bioarintseva, I. Grushlavski, Hydrocortisone phonophoresis treatment of various
diseases of the weight bearing-locomoter apparatus. Vrach Delo(1 1) (1972) 119-120.
[172] N. Blinova, M. Ishchenko, The effect of hydrocortisone phonophoresis in the androgenic
and glucocorticoid function of the adrenal cortex in patients with lumbosacral radiculitis. Vopr
Kurortol Fizioter Lech Fiz Kult(37) (1972) 220-223.
[173] M. Antropova, Use of hydrocortisone phonophoresis in the treatment of facial nerve
neuritis. Zh Nevropatol Psikhiatr Im S S Korsakova(7) (1974) 506 - 511.
[174] A. Komienko, Use of hydrocortisone phonophoresis in the treatment of allergic rhinitis.
Vestn Otolorinolaringol(1) (1974) 55 - 57.
[175] M. Braginski Treatment of certain dermatoses by hydrocortisone phonophoresis. Sov
Med(7) (1975) 145.
[176] E. Bratslavskaia, S. Vitushkina, Hydrocortisone phonophoresis in trauma and diseases of
the locomotor system in athletes. Med Sestra 34 (1975) 34 - 36.
[177] R. Kharitonov, V. Gol'dblat, A. Anisimov, Hydrocortisone phonophoresis in complex
conservative treatment of arthrosis deformans of the knee joint. Ortop Traumatol Protez(2)
(1975) 22 - 26.
113
[178] V. Artamonova, T. Nikitana, Use of ultrasound and hydrocortisone phonophoresis in the
complex treatment of children with rheumatoid arthritis. Vopr Kurortol Fizioter Lech Fiz
Kult(42) (1977) 29 - 33.
[179] V. Dozhanskaia, Hydrocortisone and cuprenil phonophoresis in the therapy of
scleroderma. Vestn Dermatol Venerol.(10) (1980) 50 - 51.
[180] F. Pottenger, B. Karalfa, Utilization of hydrocortisone phonophoresis in United States
Army Physical Therapy Clinics. Mil Med 154(7) (1989) 355.
[181] J. Griffin, J. Echternach, R. Price, J. Touchstone, Patients treated with ultrasonic driven
hydrocortisone and with ultrasound alone. Phys Ther 47(7) (1967) 595 - 601.
[182] A. Bare, M. McAnaw, A. Pritchard, J. Struebing, M. Smutok, D. Christie, M. Domenech,
M. Bare, M. Bloodworth, L. Seal, Phonophoretic delivery of 10% hydrocortisone through the
epidermis of humans as determined by serum cortisol concentrations. Phys Ther 76(7) (1996)
738.
[183] P. Koeke, N. Parizotto, P. Carrinho, A. Salate, Comparative study of the efficacy of the
topical application of hydrocortisone, therapeutic ultrasound and phonophoresis on the tissue
repair process in rat tendons. Ultrasound Med Biol 31(3) (2005) 345-350.
[184] J. Kleinkort, F. Wood, Phonophoresis with 1 percent versus 10 percent hydrocortisone.
Phys Ther 55(12) (1975) 1320 - 1324.
[185] A. Kuntz, C. Griffiths, J. Rankin, C. Armstrong, T. McLoughlin, Cortisol concentrations
in human skeletal muscle tissue after phonophoresis with 10% hydrocortisone gel. J Athl
Training 41(3) (2006) 321.
[186] N. Byl, A. McKenzie, B. Halliday, T. Wong, J. O'Connell, The effects of phonophoresis
with corticosteroids: a controlled pilot study. J Orthop Sports Phys Ther 18(5) (1993) 590.
114
[187] J. Griffin, J. Touchstone, Ultrasonic movement of cortisol into pig tissues. I. Movement
into skeletal muscle. Amer J Physical Med 42 (1963) 77 - 85.
[188] J. Griffin, J. Touchstone, Low-intensity phonophoresis of cortisol in swine. Phys Ther
48(12) (1968) 1336.
[189] J. Griffin, J. Touchstone, Effects of ultrasonic frequency on phonophoresis of cortisol
into swine tissues. Amer J Physical Med 51(2) (1972) 62 - 78.
[190] J. Griffin, J. Touchstone, A. Liu, Ultrasonic movement of cortisol into pig tissue. II.
Movement into the paravertebral nerve. Amer J Physical Med 44 (1965) 20 - 25.
[191] N. Popov, V. Kudriashov, L. Pristupa, 17-oxycorticosteroids in levels in blood and skin
of rabbits after hydrocortisone phonophoresis. Voprosy kurortologii, fizioterapii, i lechebnoA
fizicheskoA kultury 35(4) (1970) 295 - 297.
[192] V. Tsitlanadze, Changes in the metabolism of trace elements and the comparative
effectiveness of treating infectious non-specific polyarthritis with ultrasound and hydrocortisone
phonophoresis. Vopr Kurortol Fizioter Lech Fiz Kult 36(2) (1971) 158 - 161.
[193] V. Tsitlanadze, Morphohistochemical changes during experimental arthritis in rabbits
caused by hydrocortisone phonophoresis. Soobshch Akad Nauk Gruz SSR(63) (1971) 237 - 240.
[194] V. Tsitlanadze, The mechanism of action of hydrocortisone phonophoresis in rabbits with
adjuvant arthritis. Voprosy revmatizma 12(4) (1973) 19 - 22.
[195] J.P. Davick, R.K. Martin, J.P. Albright, Distribution and Deposition of Tritiated Cortisol
Using Phonophoresis. Phys Ther 68(11) (1988) 1672-1675.
[196] W. Muir, F. Magee, J. Longo, R. Karpman, P. Finley, Comparison of ultrasonically
applied vs. intra-articular injected hydrocortisone levels in canine knees. Orthop Rev 19(4)
(1990)351.
115
[197] L. Machet, N. Cochelin, F. Patat, B. Arbeille, M. Machet, G. Lorette, L. Vaillant, In vitro
phonophoresis of mannitol, oestradiol and hydrocortisone across human and hairless mouse skin.
Int J Pharm 165(2) (1998) 169-174.
[198] S. Safiulina, G. Proskurova, Phonophoresis of hydrocortisone. Vopr Kurortol Fizioter
Lech Fiz Kult 35(4) (1970) 293 - 295.
[199] S. Gatev, Effect of ultrasonic phonophoresis on passage of hydrocortisone through the
skin of Rana ridibunda. Eksp Med Morfol 11(4) (1972) 231 - 236.
[200] W. Quillin, Ultrasonic phonophoresis. Phys Sportsmed 10 (1982) 211.
[201] T. Conner-Kerr, M. Franklin, J. Kerr, S. Smith, R. Franklin, Phonophoretic delivery of
dexamethasone to human transdermal tissues: a controlled pilot study. Eur J Phys Rehab Med
8(1) (1998) 19-23.
[202] M. Moll, A new approach to pain: lidocaine and decadron with ultrasound. USAF Med
Serv Dig 30 (1979) 8-11.
[203] H. Darrow, S. Schulthies, D. Draper, M. Ricard, G. Measom, Serum dexamethasone
levels after Decadron phonophoresis. J Athl Training 34(4) (1999) 338.
[204] S. Saliba, D. Mistry, D. Perrin, J. Gieck, A. Weltman, Phonophoresis and the Absorption
of Dexamethasone in the Presence of an Occlusive Dressing. J Athl Training 42(3) (2007) 349.
[205] S. Alballa, Effect of phonophoretic application of diclofenac gel on localized
musculoskeletal disorders. Curr Ther Res 55(11) (1994) 1382-1390.
[206] P. Barja, D. Acosta-Avalos, P. Rompe, F. Dos Anjos, F. Marciano, M. da Silva, In vivo
evaluation of drug delivery after ultrasound application: A new use for the photoacoustic
technique. J. Phys. IV France 125 (2005) 789-791.
116
[207] G. Rosim, C. Barbieri, F. Langas, N. Mazzer, Diclofenac phonophoresis in human
volunteers. Ultrasound Med Biol 31(3) (2005) 337-343.
[208] Y.-L. Hsieh, Effects of Ultrasound and Diclofenac Phonophoresis on Inflammatory Pain
Relief: Suppression of Inducible Nitric Oxide Synthase in Arthritic Rats. Phys Ther 86(1) (2006)
39-49.
[209] D. Sharma, M. Hanesh, A. Yahya, M. Mohamed, Phonophoresis with Diclofenac versus
Ketoprofen for Knee Joint
Injuries. Middle East J Int Med 2(2) (2009) 9 - 12.
[210] M. Meshali, H. Abdel-Aleem, F. Sakr, S. Nazzal, Y. El-Malah, In vitro phonophoresis:
effect of ultrasound intensity and mode at high frequency on NSAIDs transport across cellulose
and rabbit skin membranes. Pharmazie 63(1) (2008) 49-53.
[211] L. Machet, J. Pinton, F. Patat, B. Arbeille, L. Pourcelot, L. Vaillant, In vitro
phonophoresis of digoxin across hairless mice and human skin: Thermal effect of ultrasound.
International Journal of Pharmaceutics 133(1-2) (1996) 39-45.
[212] H.A.E. Benson, J.C. McElnay, R. Harland, J. Hadgraft, Influence of Ultrasound on the
Percutaneous Absorption of Nicotinate Esters. Pharm Res 8(2) (1991) 204-209.
[213] H.A.E. Benson, J.C. McElnay, R. Harland, Phonophoresis of lignocaine and prilocaine
from Emla cream. Int J Pharm 44(1-3) (1988) 65-69.
[214] Y. Wu, W. Chen, J. Luh, F. Chong, Thermal Effect of Sonophoresis for Accelerating the
Analgesic Effect of Local Anesthetics on Rat Tail Nerve. International IEEE EMBS Conference,
Vancouver, BC, 2008, pp. 2504-2507.
[215] E. Vainshtein, L. Lutsker, L. Zobina, A. Tartakovskaia, Electro-and phonophoresis of
fibrinolysin. Vestn Oftalnol(4) (1975) 74 - 76.
117
[216] M. Hippius, C. Uhlemann, U. Smolenski, U. Schreiber, S. Reissig, A. Hoffmann, In vitro
investigations of drug release and penetration: enhancing effect of ultrasound on transmembrane
transport of flufenamic acid. Int J Clin Pharm Th 36(2) (1998) 107-111.
[217] C. Uhlemann, S. ReiBig, M. Hippius, U. Smolenski, T. Schreiber, Phonophorese mit
Flufenaminsaure in Abhangigkeit von Parametern der Ultraschalldosis Phonophoresis of
flufenamin acid dependent on parameters of dose of ultrasound. Phys Rehab Kur Med 10 (2000)
86-93.
[218] A. Chirkin, V. Kozin, Enzymatic activity of the pentosephosphate pathway of
carbohydrate conversion in the experimental therapy of dermatitis in rats. Vopr Med Khim 22(4)
(1976) 448 - 451.
[219] V. Kozin, Morphological changes in the skin of rats under experimental therapy for
dermatitis. Zdravookhr Beloruss(4) (1976) 81 - 82.
[220] V. Kozin, A. Chirkin, I. Griaditski Histamine and serotonin content in the blood and skin
in experimental therapy of dermatitis in rats. Fiziol Zh 22(3) (1976) 390 - 394.
[221] J.C. McElnay, T.A. Kennedy, R. Harland, The influence of ultrasound on the
percutaneous absorption of fluocinolone acetonide. International Journal of Pharmaceutics 40(1-
2) (1987) 105-110.
[222] M. Klaiman, J. Shrader, J. Danoff, J. Hicks, W. Pesce, J. Ferland, Phonophoresis versus
ultrasound in the treatment of common musculoskeletal conditions. Med Sci Sport Exer 30(9)
(1998)1349.
[223] V. Meidan, A. Walmsley, M. Docker, W. Irwin, Ultrasound-enhanced diffusion into
coupling gel during phonophoresis of 5-fluorouracil. Int J Pharm 185(2) (1999) 205-213.
118
[224] P. Kafas, Ghicosaminoglycan Phonophoresis of the TMJ in the Symptomatic Treatment
of Internal Derangement. J Med Sci 7(1) (2007) 158-160.
[225] D. Park, J. Yoon, J. Park, B. Jung, H. Park, J. Seo, Transdermal Drug Delivery Aided by
an Ultrasound Contrast Agent: An In Vitro Experimental Study. Open Biomed Eng J 4 (2010)
56-62.
[226] V. Klare, W. KURY, On phonophoresis treatment with hirudoid. Wien Med Wschr 110
(1960) 701 - 702.
[227] S.R. Park, K.W. Jang, S.-H. Park, H.S. Cho, C.Z. Jin, M.J. Choi, S.I. Chung, B.-H. Min,
The effect of sonication on simulated osteoarthritis. Part I: Effects of 1 MHz ultrasound on
uptake of hyaluronan into the rabbit synovium. Ultrasound Med Biol 31(11) (2005) 1551-1558.
[228] E. Kozanoglu, S. Basaran, R. Guzel, F. Guler-Uysal, Short term efficacy of ibuprofen
phonophoresis versus continuous ultrasound therapy in knee osteoarthritis. Swiss Med Wkly
133(23-24) (2003) 333-338.
[229] J. Asano, F. Suisha, M. Takada, N. Kawasaki, S. Miyazaki, Effect of pulsed output
ultrasound on the transdermal absorption of indomethacin from an ointment in rats. Biol Pharm
Bull 20(3) (1997) 288-291.
[230] S. Miyazaki, H. Mizuoka, Y. Kohata, M. Takada, External control of drug release and
penetration. VI. Enhancing effect of ultrasound on the transdermal absorption of indomethacin
from an ointment in rats. Chem Pharm Bull 40(10) (1992) 2826.
[231] G. Bunin, F. Can, Effects of iontophoresis and phonophoresis methods on pain in cases
with shoulder periarthritis. Pain Clinic 13(2) (2001) 159-162.
119
[232] B. Cagnie, E. Vinck, S. Rimbaut, G. Vanderstraeten, Phonophoresis Versus Topical
Application of Ketoprofen: Comparison Between Tissue and Plasma Levels. Phys Ther 83(8)
(2003) 707-712.
[233] J.-H. Yang, T.-Y. Kim, J.-H. Lee, S.-W. Yoon, K.-H. Yang, S.-C. Shin, Anti-
hyperalgesic and anti-inflammatory effects of Ketorolac Tromethamine gel using pulsed
ultrasound in inflamed rats. Arch Pharm Res 31(4) (2008) 511-517.
[234] L. Wei, L. Xinping, W. Gang, Sonophoresis Induces the Enhanced Permeation of Drug
and Its Effect on Stratum Comeum. Chin JMAP 26(6) (2009) 510 - 513.
[235] J. McElnay, M. Matthews, R. Harland, D. McCafferty, The effect of ultrasound on the
percutaneous absorption of lignocaine. Brit J Clin Pharmaco 20(4) (1985) 421.
[236] T. Kim, D. Jung, Y. Kim, J. Yang, S. Shin, Anesthetic effects of lidocaine hydrochloride
gel using low frequency ultrasound of 0.5 MHz. J Pharm Pharm Sci 10(1) (2007) 1-8.
[237] E. Novak, Experimental Transmission of lidocaine through intact skin by ultrasound.
Arch Phys Med Rehab 45 (1964) 231 - 232.
[238] D. Ashton, D. Draper, J. Myrer, Temperature rise in human muscle during ultrasound
treatments using Flex-All as a coupling agent. J Athl Training 33(2) (1998) 136.
[239] B. Cameroy, Ultrasound enhanced local anesthesia. Am J Orthaped 8(47) (1966).
[240] L. Glushchenko, Quantitative study of analgin phonophoresis. Vopr Kurortol Fizioter
Lech Fiz Kult(41) (1976) 20 - 23.
[241] J.C. McElnay, H.A.E. Benson, R. Harland, J. Hadgraft, Phonophoresis of Methyl
Nicotinate: A Preliminary Study to Elucidate the Mechanism of Action. Pharmaceutical research
10(12) (1993) 1726-173 1.
120
[242] A. Mortimer, B. Trollope, E. Villeneuve, 0. Roy, Ultrasound-enhanced diffusion through
isolated frog skin. Ultrasonics 26(6) (1988) 348-35 1.
[243] G.Y.F. Ng, R.Y.F. Wong, Ultrasound Phonophoresis of Panax Notoginseng Improves the
Strength of Repairing Ligament: A Rat Model. Ultrasound Med Biol 34(12) (2008) 1919-1923.
[244] V. Zague, M. Polacow, M. Pires-de-Campos, G. Leonardi, Evaluation of the ultrasound
influence in the cutaneous penetration of d-panthenol: test in vitro. J Cosmet Dermatol 4(1)
(2005) 29-33.
[245] J. Kost, K. Leong, R. Langer, Ultrasonically controlled drug delivery in vivo. Proc. Int.
Symp. Controlled Release Bioact. Mater, Vol. 14, Controlled Release Society, 1987, pp. 186-
187.
[246] T. Dynnik, A. Garbar, Use of antibiotic phonophoresis in purulent inflammatory skin
diseases. Vrach Delo(8) (1977) 115 -116.
[247] W. Brondolo, Phenylbutazone with ultrasonics in some cases of arthrosynovitis of the
knee. Arch Orthoped(73) (1960) 532 - 540.
[248] K. Chung, Y. Kim, J. Yang, Phonophoretic delivery of piroxicam. J Korean Pharm Sci
32(4) (2002) 259-266.
[249] M. Shiran, M. Motevalian, R. Ravanfar, S. Bohlouli, The effect of bubble surface charge
on phonophoresis: implications in transderaml piroxicam delivery. Iran J Pharm Ther 7(1) (2008)
15-19.
[250] T. Hikima, Y. Hirai, K. Tojo, Effect of Ultrasound Application on Skin Metabolism of
Prednisolone 21-Acetate. Pharmaceutical research 15(11) (1998) 1680-1683.
[251] A. Yamashita, Y. Hirai, K. Tojo, Effect of ultrasound on rate of drug absorption through
skin. j Chem Eng Jpn 29(5) (1996) 812-816.
121
[252] J. Dohnalek, I. Hrazdira, J. Cecava, F. Novak, J. Svoboda, Penetration of radioiodine
through the skin enhanced by ultrasonics. Cesk Derm 40 (1965) 173 - 178.
[253] V. Klare, Experiences with Reparil. Iontophoretic, phonophoretic and oral application.
Ther Ggw 107(2) (1968) 240.
[254] I. Doweck, Z. Nachum, S. Dachir, 0. Spitzer, C. Gordon, A. Gonen, A. Levy, A. Shupak,
Enhancement of transdermal scopolamine absorption using sonophoresis. International Congress
of Aviation and Space Medicine, Jerusalem, Israel, 1996.
[255] V. Frenkel, E. Kimmel, Y. Iger, Ultrasound-facilitated transport of silver chloride (AgCl)
particles in fish skin. Journal of Controlled Release 68(2) (2000) 251-261.
[256] M.C. Fyfe, L.A. Chahl, The effect of ultrasound on experimental oedema in rats.
Ultrasound Med Biol 6(2) (1980) 107-111.
[257] S. Ragelis, Penicillin and streptomycin penetration into tissue by a modified
electrophoretic method. Antibiotiki 26(9) (1981) 699 - 703.
[258] T. Brawner, J. Senne, M. Fahim, A combined chemical-physical treatment for herpes
simplex lesions in guinea pigs. Arch Dermatol Res 265(1) (1979) 71-77.
[259] M. Fahim, T. Brawner, D. Hall, New treatment for herpes simplex virus type 2
[ultrasound and zinc, urea and tannic acid ointment]. Part II: Female patients. J Med 11(2-3)
(1980) 143 - 167.
[260] M. Fahim, T. Brawner, L. Millikan, M. Nickell, D. Hall, New treatment for herpes
simplex virus type 2 [ultrasound and zinc, urea, and tannic acid ointment]. Part I--Male patients.
J Med 9(3) (1978) 245 - 264.
122
[261] A. El-Kamel, I. Al-Fagih, I. Alsarra, Effect of sonophoresis and chemical enhancers on
testosterone transdermal delivery from solid lipid microparticles: an in vitro study. Curr Drug
Deliv 5(1) (2008) 20-26.
[262] V. Parikov, Injection of tetracyline into the tissues of cow udders by ultrasonics.
Veterinariia 43(6) (1966) 88 - 91.
[263] S. Ragelis, Tetracycline penetration into tissue by modified electro-and phonophoretic
methods. Antibiotiki 26(9) (1981) 699.
[264] J. Yang, D. Kim, T. Kim, G. Kim, S. Shin, Anti-inflammatory effects by transdermal
application of triamcinolone acetonide gel using phonophoresis in rats. Int J Pharm 302(1-2)
(2005) 39-46.
[265] J. Yang, D. Kim, M. Yun, T. Kim, S. Shin, Transdermal delivery system of triamcinolone
acetonide from a gel using phonophoresis. Arch Pharm Res 29(5) (2006) 412-417.
[266] A. Grinshtein, A. Tolmacheva, V. Khriptulov, Phonophoresis of Trilon B. Vopr Kurortol
Fizioter Lech Fiz Kult 37(3) (1972) 223 - 225.
[267] L. Kamrash, M. Mal'tseva, V. Tigeev, Trylon B phonophoresis in the rehabilitation of
patients with stable contractures of extremity joints. Ortop Traumatol Protez(9) (1974) 79 - 80.
[268] C.D. Ciccone, B.G. Leggin, J.J. Callamaro, Effects of Ultrasound and Trolamine
Salicylate Phonophoresis on Delayed-Onset Muscle Soreness. Phys Ther 71(9) (1991) 666-675.
[269] C. Pelucio-Lopes, L. Machet, L. Vaillant, F. Patat, M. Lethiecq, Y. Furet, L. Pourcelot,
G. Lorette, Phonophoresis of azidothymidine (AZT). Int J Pharm 96(1-3) (1993) 249-252.
[270] SyracuseResearchCorporation, Interactive PhysProp Database Demo.
http://www.syrres.com/what-we-do/databaseforms.aspx?id=386.
123
[271] K. Tachibana, Transdermal Delivery of Insulin to Alloxan-Diabetic Rabbits by
Ultrasound Exposure. Pharm Res 9(7) (1992) 952-954.
[272] K. Tachibana, S. Tachibana, Transdermal delivery of insulin by ultrasonic vibration. J
Pharm Pharmacol 43(4) (1991) 270-271.
[273] A. Tezel, A. Sens, S. Mitragotri, Incorporation of lipophilic pathways into the porous
pathway model for describing skin permeabilization during low-frequency sonophoresis. J
Control Release 83(1) (2002) 183-188.
[274] H. Ueda, R. Isshiki, M. Ogihara, K. Sugibayashi, Y. Morimoto, Combined effect of
ultrasound and chemical enhancers on the skin permeation of aminopyrine. Int J Pharm 143(1)
(1996) 37-45.
[275] P. Santoianni, M. Nino, G. Calabro, Intradermal drug delivery by low-frequency
sonophoresis (25 kHz). Dermatol Online J 10(2) (2004) 24.
[276] H. Ueda, M. Ogihara, K. Sugibayashi, Y. Morimoto, Change in the electrochemical
properties of skin and the lipid packing in stratum corneum by ultrasonic irradiation. Int J Pharm
137(2) (1996) 217-224.
[277] A. Maruani, A. Boucaud, E. Perrodeau, D. Gendre, B. Giraudeau, L. Machet, Low-
frequency ultrasound sonophoresis to increase the efficiency of topical steroids: A pilot
randomized study of humans. Int J Pharm 395 (2010) 84-90.
[278] A. Boucaud, L. Machet, B. Arbeille, M. Machet, M. Sournac, A. Mavon, F. Patat, L.
Vaillant, In vitro study of low-frequency ultrasound-enhanced transdermal transport of fentanyl
and caffeine across human and hairless rat skin. Int J Pharm 228(1-2) (2001) 69-77.
124
[279] M. Mutoh, H. Ueda, Y. Nakamura, K. Hirayama, M. Atobe, D. Kobayashi, Y. Morimoto,
Characterization of transdermal solute transport induced by low-frequency ultrasound in the
hairless rat skin. J Control Release 92(1-2) (2003) 137-146.
[280] J.-Y. Fang, C.-L. Fang, K.C. Sung, H.-Y. Chen, Effect of low frequency ultrasound on
the in vitro percutaneous absorption of clobetasol 17-propionate. Int J Pharm 191(1) (1999) 33-
42.
[281] S. Katikaneni, G. Li, A. Badkar, A. Banga, Transdermal delivery of a- 13 kDa protein-
an in vivo comparison of physical enhancement methods. J Drug Target 18(2) (2010) 141-147.
[282] L. Cancel, J. Tarbell, A. Ben-Jebria, Fluorescein permeability and electrical resistance of
human skin during low frequency ultrasound application. J Pharm Pharmacol 56(9) (2004) 1109-
1118.
[283] S. Lanke, C. Kolli, J. Strom, A. Banga, Enhanced transdermal delivery of low molecular
weight heparin by barrier perturbation. Int J Pharm 365(1-2) (2009) 26-33.
[284] A. Maruani, E. Vierron, L. Machet, B. Giraudeau, A. Boucaud, Efficiency of low-
frequency ultrasound sonophoresis in skin penetration of histamine: A randomized study in
humans. Int J Pharm 385(37-41) (2010).
[285] E. Park, J. Dodds, N. Smith, Dose comparison of ultrasonic transdermal insulin delivery
to subcutaneous insulin injection. Int J Nanomed 3(3) (2008) 335.
[286] A. Boucaud, M. Garrigue, L. Machet, L. Vaillant, F. Patat, Effect of sonication
parameters on transdermal delivery of insulin to hairless rats. J Control Release 81(1-2) (2002)
113-119.
125
[287] A. Boucaud, L. Machet, M. Garrigue, L. Vaillant, F. Patat, A Practical Use of Low
Frequency Ultrasound For Rapid and Reproducible Transdermal Delivery of Insulin. IEEE
Ultrasonics Symposium, Vol. 2, Atlanta, GA, 2001, pp. 1327 - 1330.
[288] S. Lee, B. Snyder, R. Newnham, N. Barrie Smith, Noninvasive ultrasonic transdermal
insulin delivery in rabbits using the light-weight cymbal array. Diabetes Technol The 6(6) (2004)
808-815.
[289] J. Luis, E.J. Park, J.R.J. Meyer, N.B. Smith, Rectangular cymbal arrays for improved
ultrasonic transdermal insulin delivery. J Acoust Soc Am 122(4) (2007) 2022-2030.
[290] E. Park, J. Werner, N. Smith, Ultrasound mediated transdermal insulin delivery in pigs
using a lightweight transducer. Pharm Res
24(7) (2007) 1396-1401.
[291] I. Zhang, K. Shung, D. Edwards, Hydrogels with enhanced mass transfer for transdermal
drug delivery. J Pharm Sci 85(12) (1996) 1312-1316.
[292] N. Smith, S. Lee, E. Maione, R. Roy, S. McElligott, K. Shung, Ultrasound-mediated
transdermal transport of insulin in vitro through human skin using novel transducer designs.
Ultrasound Med Biol 29(2) (2003) 311-317.
[293] S. Skarbek-Borowska, B.M. Becker, K. Lovgren, A. Bates, P.A. Minugh, Brief Focal
Ultrasound With Topical Anesthetic Decreases the Pain of Intravenous Placement in Children.
Pediatr Emerg Care 22(5) (2006) 339-345.
[294] C.P. Stowell, M.Q. Trieu, H. Chuang, N. Katz, C. Quarrington, Ultrasound-enabled
topical anesthesia for pain reduction of phlebotomy for whole blood donation. Transfusion 49(1)
(2009) 146-153.
126
[295] W. Zempsky, B. Robbins, K. McKay, Reduction of topical anesthetic onset time using
ultrasound: a randomized controlled trial prior to venipuncture in young children. Pain Med 9(7)
(2008) 795-802.
[296] L. Weimann Jr, J. Wu, Ultrasound induced enhancement of skin permeability to Octa L
Lysine. J Acoust Soc Am 106 (1999) 2230.
[297] R.F.V. Lopez, J.E. Seto, D. Blankschtein, R. Langer, Enhancing the transdermal delivery
of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate.
Biomaterials 32(3) (2011) 933-941.
[298] M. Gou, L. Wu, Q. Yin, Q. Guo, G. Guo, J. Liu, X. Zhao, Y. Wei, Z. Qian, Transdermal
Anaesthesia with Lidocaine Nano-Formulation Pretreated with Low-Frequency Ultrasound in
Rats Model. J Nanosci Nanotechno 9(11) (2009) 6360-6365.
[299] M. Tran, R. Gowda, A. Sharma, E. Park, J. Adair, M. Kester, N. Smith, G. Robertson,
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous
melanocytic lesion development. Cancer Res 68(18) (2008) 7638.
[300] A. Dahlan, H. Alpar, P. Stickings, D. Sesardic, S. Murdan, Transcutaneous immunisation
assisted by low-frequency ultrasound. Int J Pharm 368(1-2) (2009) 123-128.
[301] I. Bjarnason, J. Hayllar, A. MacPherson, A. Russell, Side effects of nonsteroidal anti-
inflammatory drugs on the small and large intestine in humans. Gastroenterology 104(6) (1993)
1832.
[302] K.D. Rainsford, Profile and mechanisms of gastrointestinal and other side effects of
nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107(6, Supplement 1) (1999) 27-3 5.
[303] C. Heyneman, C. Lawless-Liday, G. Wall, Oral versus topical NSAIDs in rheumatic
diseases: a comparison. Drugs 60(3) (2000) 555-574.
127
[304] B. Bloom, Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-
inflammatory drugs. Arch Intern Med 149(5) (1989) 1019-1022.
[305] B.S. Bloom, Direct medical costs of disease and gastrointestinal side effects during
treatment for arthritis. Am J Med 84(2, Supplement 1) (1988) 20-24.
[306] P. Karande, S. Mitragotri, Transcutaneous immunization: an overview of advantages,
disease targets, vaccines, and delivery technologies. Annu Rev Chem Biomol Eng 1 (2010) 175-
201.
[307] J. Mikszta, J. Alarcon, J. Brittingham, D. Sutter, R. Pettis, N. Harvey, Improved genetic
immunization via micromechanical disruption of skin-barrier function and targeted epidermal
delivery. Nat Med 8(4) (2002) 415-419.
[308] C. Scarponi, F. Nasorri, F. Pavani, S. Madonna, R. Sestito, M. Simonacci, 0. De Pita, A.
Cavani, C. Albanesi, Low-Frequency Low-Intensity Ultrasounds Do Not Influence the Survival
and Immune Functions of Cultured Keratinocytes and Dendritic Cells. J Biomed Biotechnol
(2009).
[309] H. Chuang, M. Trieu, J. Hurley, E. Taylor, M. England, S. Nasraway Jr, Pilot Studies of
Transdermal Continuous Glucose Measurement in Outpatient Diabetic Patients and in Patients
during and after Cardiac Surgery. J Diabetes Sci Technol 2(5) (2008) 595-602.
[310] E. Park, J. Werner, J. Beebe, S. Chan, N. Smith, Noninvasive Ultrasonic Glucose Sensing
with Large Pigs ( 200 Pounds) Using a Lightweight Cymbal Transducer Array and Biosensors. J
Diabetes Sci Technol 3(3) (2009) 517 - 523.
[311] M. Pishko, N. Smith, R. Gabbay, J. Werner, Closed-Loop Noninvasive Ultrasound
Glucose Sensing and Insulin Delivery. Storming Media, 2006.
128
[312] S. Mitragotri, Modeling skin permeability to hydrophilic and hydrophobic solutes based
on four permeation pathways. J Control Release 86(1) (2003) 69-92.
[313] G. Moss, J. Dearden, H. Patel, M. Cronin, Quantitative structure-permeability
relationships (QSPRs) for percutaneous absorption. Toxicol In Vitro 16(3) (2002) 299-317.
[314] P. Dechadilok, W. Deen, Hindrance factors for diffusion and convection in pores. Ind
Eng Chem Res 45(21) (2006) 6953-6959.
[315] D. Li, X. Huang, H. Yu, Z. Zhang, F. Huang, K. Xu, X. Hu, A Novel Minimally Invasive
Method to Detect Glucose Concentration without Blood Extraction. 1st IEEE International
Conference on Nano/Micro Engineered and Molecular Systems, Zhuhai 2006, pp. 1185-1189.
[316] S. Naito, J. Maeyama, T. Mizukami, M. Takahashi, I. Hamaguchi, K. Yamaguchi,
Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin
of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant.
Vaccine 25(52) (2007) 8762-8770.
[317] L. Weimann, J. Wu, Transdermal delivery of poly-l-lysine by sonomacroporation.
Ultrasound Med Biol 28(9) (2002) 1173-1180.
[318] A.J. Singer, C.S. Homan, A.L. Church, S.A. McClain, Low-frequency Sonophoresis:
Pathologic and Thermal Effects in Dogs. Acad Emerg Med 5(1) (1998) 35-40.
[319] A. Farinha, S. Kellogg, K. Dickinson, T. Davison, Skin impedance reduction for
electrophysiology measurements using ultrasonic skin permeation: initial report and comparison
to current methods. Biomed Instrum Techn 40(1) (2006) 72-77.
[320] J. Gupta, M. Prausnitz, Recovery of skin barrier properties after sonication in human
subjects. Ultrasound Med Biol 35(8) (2009) 1405-1408.
129
130
Chapter 2
Transport Pathways and Enhancement Mechanisms
within Localized and Non-Localized Transport
Regions in Skin Treated with Low-Frequency
Sonophoresis and Sodium Lauryl Sulfate
2.1 Introduction
The use of ultrasound to increase skin permeability, referred to as sonophoresis, has generated
considerable interest and gained much use over the past few decades.[1] Initial research in the
field was conducted at therapeutic frequencies, 1-3 MHz,[2-4] while more recent research efforts
have focused on low-frequency sonophoresis (LFS), in the range 20-100 kHz. This shift in
frequencies was prompted by the discovery that cavitation is the primary mechanism responsible
for skin permeability enhancement.[5-9] The observed frequency dependence of cavitation
occurs because of the inverse relationship between the ultrasound frequency and the radii of the
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cavitation bubbles generated in the coupling medium between the ultrasound horn and the
skin.[10-12] As the ultrasound frequency decreases, the radii of the cavitation bubbles tend to
grow on average, resulting in more forceful collapses when cavitation bubbles approach the
surface of the skin. These transient cavitation events near the skin surface have been identified as
the primary mechanism of skin permeability enhancement in response to LF S treatment. [5, 6, 8]
In addition to uncovering the connection between cavitation and skin permeability enhancement,
recent research has revealed many additional interesting phenomena. First, it has been
demonstrated that when LFS and chemical enhancers, especially surfactants, are applied
simultaneously during skin treatment, a synergistic enhancement is observed.[6, 13] This
synergism can lead to an increase in skin conductivity or permeability by orders-of-magnitude
when compared to skin treated separately with LFS or chemical enhancers.[13-15] Second, it has
been shown that skin permeability enhancement by LFS and by LFS/SLS at 20 kHz is not
homogenous.[15-21] Instead, the LFS treatment generates discrete regions within the skin,
referred to as localized transport regions (LTRs), which are orders-of-magnitude more permeable
than the surrounding skin regions (non-LTRs) and native skin samples.[14] Furthermore, it has
been shown that the non-LTRs also exhibit increased skin permeability, with respect to native
skin, when treated with 20 kHz LFS in combination with the surfactant sodium lauryl sulfate
(SLS).[14, 17, 21] Accordingly, it was proposed that two levels of enhancement are present in
skin samples that are treated simultaneously with LFS at 20 kHz and a chemical enhancer, such
as SLS. The proposed existence of two levels of enhancement on a single skin sample in
response to LFS/SLS at 20 kHz suggests that separate mechanisms of enhancement may operate
within the LTRs and the non-LTRs, or that an enhancement mechanism that is significant within
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the LTRs does not play a role within the non-LTRs. This possibility motivates the need for a
deeper understanding of the transport pathways within LTRs and non-LTRs. In addition to
quantifying the relative extents of skin perturbation by measuring skin permeability and skin
resistivity, it is possible to utilize the aqueous porous pathway model (APPM)[22] and
previously published masking techniques[14] to independently probe the effective pore radii in
the LTRs and the non-LTRs. In doing so, one may be able to provide deeper insight into the
nature of the aqueous transdermal pathways that exist within LTRs and non-LTRs, including the
permeability enhancement mechanisms that are most significant in each of these skin regions.
Moreover, because acoustic cavitation bubble collapse on the skin surface is a frequency-
dependent process,[10-12] with the average cavitation bubble radius increasing with decreasing
ultrasound frequency, one would expect that the average pore radii in the skin regions where
such collapses occur would also increase with decreasing ultrasound frequency, if this
mechanism was present.
It is important to note that a previous study investigated the average pore radius of skin treated
with a range of LFS frequencies, in the context of the APPM.[19] However, because that study
did not independently study LTRs and non-LTRs, it is significantly different than the study
presented here. First, because the pore radii within LTRs and non-LTRs were not studied
separately, no direct conclusions could be reached about the nature of the transport pathways or
enhancement mechanisms within LTRs and non-LTRs. Second, the ultrasound intensity used in
the previous study was 1.08 W/cm 2 , which is significantly lower than the 7.5 W/cm2 ultrasound
intensity used in the experiments reported here. Note that the ultrasound intensity used here is
similar to those used in other recent papers discussing LTR formation using LFS/SLS.[14-17,
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23] Third, the range of skin electrical resistivities investigated here is lower than that of the
previous study, indicating that the skin samples considered here are perturbed to a greater extent
by the LFS/SLS treatment than those considered in the prior study. In fact, because LTR size is
closely related to the extent of skin perturbation, as measured by skin resistivity,[14] it is likely
that any LTRs that were formed would be much smaller than those observed in the study
reported here. Because the effects of the enhancement mechanisms are expected to be magnified
under the ultrasound skin treatment conditions used in this study, relative to those used
previously, the combination of a higher ultrasound intensity and a greater extent of skin
perturbation by the LFS/SLS treatment utilized here should facilitate gaining insight into the
enhancement mechanisms at play within LTRs and non-LTRs, including the effect of the
ultrasound frequency on the resulting transdermal pathways in each skin region.
With all of the above in mind, the goals of this study are four-fold: i) to demonstrate that at the
three ultrasound frequencies tested (20 kHz, 40 kHz, and 60 kHz), LTRs form on the surface of
the skin and exhibit increased permeability relative to both the non-LTRs and native skin, ii) to
demonstrate that at the three frequencies considered here there are two levels of skin
permeability enhancement relative to native skin when LFS and SLS are used simultaneously,
indicating that the non-LTRs also exhibit increased permeability relative to native skin, iii) to
better characterize the transport pathways through LTRs and non-LTRs by independently
determining the permeabilities and the effective aqueous pore radii in LTRs, non-LTRs, and total
skin samples in the context of the APPM, and iv) to propose mechanisms of enhancement within
LTRs and non-LTRs.
134
2.2 Materials and Methods
2.2.1 Materials
Phosphate buffer saline (PBS; 0.01 M phosphate, 0.137 M NaCl), calcein, and SLS were
obtained from Sigma Chemical Company (St. Louis, MO). The dye allura red (molecular weight
= 496 g/mol, water solubility = 225 g/L = 22.5 wt% at 25 0C, log K, =-0.550 [24]) was
obtained from TCI America (Portland, OR). C14-labeled SLS (specific activity of 55 mCi/mmol)
was obtained from American Radiolabeled Chemicals (St. Louis, MO). Soluene-350, a tissue
solubilizer, and Hionic-Fluor, a scintillation cocktail, were obtained from Perkin-Elmer
(Waltham, MA). All chemicals were used as received.
2.2.2 Skin Preparation
Previously published protocols were utilized for the storage and preparation of skin samples. [22]
A brief summary of these protocols follows. This procedure has been approved by the MIT
Committee on Animal Care. Skin was harvested from the back and flank of Female Yorkshire
pigs within 1 hour of sacrificing the animal. Subcutaneous fat was removed from the skin using
a razor blade and then sectioned into one-inch strips prior to storage at -85 'C for up to 6 months.
Before use in experiments, the skin was thawed for 1 hour in PBS and then excess hair was
trimmed using surgical scissors. The thawed skin was then cut into 25 mm by 25 mm samples.
Before mounting of the skin samples into the 15-mm inner diameter diffusion cells (PermeGear,
Hellertown, PA), high vacuum grease (Dow Corning, Midland, MI) was applied to the inner
flange of the donor and the receiver compartments in order to provide a water-tight seal between
the skin and the diffusion cell. For additional mechanical support, a 150-pm opening nylon
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mesh (Sefar Filtration, Depew, NY) was placed onto the top of the receiver chamber of the
diffusion cell. The receiver chamber was then filled with PBS, the skin sample was mounted
into the diffusion cell, and the diffusion cell was clamped tightly. The donor chamber was then
filled with the appropriate solution for treatment or permeation experiments.
2.2.3 Skin Electrical Resistivity Measurements
The skin electrical resistivity, R, has been shown to be an accurate and instantaneous indicator of
the structural state of the skin.[25, 26] Previously published methods were followed to measure
R[16, 23, 26] and are summarized next. A signal generator (Hewlett-Packard, model HP
33120A) was used to generate an AC voltage at 100 mV and 10 Hz. The voltage was applied
across the skin using two Ag/AgC1 electrodes (In Vivo Metrics, Healdsburgh, CA). The skin
electrical current was measured using a multimeter (Fluke Corporation, Model 189) and the skin
electrical resistance was calculated using Ohm's Law. The background resistance of the system
was accounted for by removing the skin sample from the diffusion cell and measuring the
resistance of the system (note that this resistance is a function of the area available for diffusion,
therefore the background resistances for the LTRs and the non-LTRs are not necessarily the
same as that for the total skin samples). Subsequently, the background resistance was subtracted
from the resistance measured for the total system, including the skin. R was then calculated by
multiplying the skin electrical resistance by the area of the skin sample. In order to ensure that
the skin was intact prior to experimentation, the initial R value of a skin sample was required to
be above 50 kOhm-cm 2 .[27-29] The electrical current measured, and the resulting resistivity
values, were calibrated by testing the electrical equipment with resistors of known resistance.
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2.2.4 Determination of Steady-State Calcein Permeability through Skin
Calcein was chosen as a model aqueous permeant because its concentration in aqueous solution
can be determined with relative ease using simple spectrophotometric methods, which minimizes
sample preparation time and the cost of sample analysis. Calcein has also been used in the past
to determine skin permeabilities in the context of the APPM.[14] The procedures described in
the following sub-sections were carried out on LTRs, non-LTRs, and total skin samples, as well
as on native skin and skin dermis.
2.2.4.1 Pre-Treatment of Skin Samples by LFS/SLS
LFS/SLS pre-treatment of skin samples was carried out according to previously published
methods, which are summarized next.[14-17, 22] Three separate ultrasound systems (Sonics and
Materials, Inc., Newtown, CT) were used in this study, each operating at a different frequency:
20 kHz (VCX 500), 40 kHz (VCX 130), and 60 kHz (custom order). The intensity of each horn
was calibrated using calorimetry, and the skin treatment with each system was carried out under
identical experimental conditions: intensity - 7.5 W/cm 2, duty cycle - 50% (5 s on, 5 s off), tip
displacement - 3 mm, and a coupling medium containing 1% (w/v) SLS and 0.025% (w/v) allura
red in PBS. Samples were treated with LFS until they reached pre-determined electrical current
thresholds of 225, 275, or 335 pA (±10%), which are similar to previously published thresholds
used when studying LTR formation.[14, 23] These thresholds were chosen in order to: i) create
LTRs that are sufficiently large to be quantifiable on a macroscopic scale (at least 5% coverage
of LTRs on the skin surface), and ii) study different levels of skin perturbation. After each
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minute of LFS treatment, the coupling medium was changed in order to minimize thermal effects
(maintain the temperature within 10 'C of room temperature), and the electrical current of the
skin samples was measured to determine if the target threshold had been reached. Upon
completion of the LFS treatment, samples were rinsed thoroughly with PBS, in order to remove
all excess SLS from the skin surface, and then the donor solution was replaced with 0.025%
(w/v) allura red in PBS for 1 hour. Because of the significantly higher permeability of LTRs,
relative to non-LTRs (see Results section), increased uptake of allura red occurs significantly
only within LTRs during the additional 1 hour soak, which aids in the subsequent digital imaging
of the LTRs.
2.2.4.2 Digital Imaging and Analysis of LTR Areas
Digital imaging and analysis of LTRs was conducted according to previously published
protocols, which are summarized next. [14] After the 1-hour soak in the allura red solution, the
skin samples were thoroughly rinsed with PBS and blotted dry. The skin samples were then
imaged in triplicate using a digital camera (HP Photosmart R967, 10 Megapixels, auto macro
setting) at a distance of approximately 8 inches above the sample. In order to correct for
fluctuations in laboratory lighting and infidelity of the charged coupled device, a red-colored
strip was included in each image as a standard (VWR, general-purpose laboratory labeling tape,
color "red"). Images were then analyzed using the Corel Photo-Paint 11 Software Package
(Corel Corporation, Ontario, Canada) according to the method published by Kushner et al.[14]
Briefly, first the red-colored tape strip in each image was isolated in order to measure the
average blue-channel levels for all of the isolated strips. Then, the blue level for each image was
shifted using the "Contrast Enhancement" function to the average blue level for all samples.
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After this standardization, the images were cropped to the size of the skin sample treated by LFS
(15 mm by 15 mm image size). Subsequently, the total number of pixels in the image was noted
using the "Histogram" function. In order to determine the size of the LTRs, the "Threshold"
function was used to tabulate the number of pixels having a blue-channel level below 50. The
reasons for the selection of these criteria are discussed further in Kushner et al.[14] It is
important to note that the blue level threshold used in the current study is different than that used
by Kushner et al., because allura red was utilized to visualize the LTRs instead of
sulforhodamine B (SRB).[14] SRB was not used in the present study because a fluorescent dye
was not required. It is then straightforward to calculate the area of the LTRs on the skin surface,
ALTR ,in terms of the number of LTR pixels, the total number of pixels in the image, and the total
area of the image (Aoai=1.5 cm by 1.5 cm = 2.25 cm 2). Specifically,
(LTR Pixels)
(Total Pixels)
2.2.4.3 Diffusion Masking Experiments
Diffusion masking is a previously published method[14] that allows one to probe the transport
properties of the LTRs and the non-LTRs separately. Use of this method allowed us to test three
groups of samples at each ultrasound frequency following pre-treatment with LFS/SLS: total,
LTR, and non-LTR samples. Skin samples in the total group were not masked (indicating that
the entire skin surface was available for calcein permeation). Skin samples in the LTR group
had the non-LTR regions masked in order to leave the LTR regions accessible for permeation of
calcein (see Figure 2-1 for an image of a skin sample showing LTRs and non-LTRs). Similarly,
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Figure 2-1. Porcine skin sample treated with LFS/SLS at 40 kHz. Regions of the skin dyed red
are LTRs, regions of the skin that are not dyed red are non-LTRs. The diameter of the circular
sample is 15 mm.
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skin samples in the non-LTR group had the LTR regions masked in order to leave the non-LTR
regions accessible for permeation of calcein. The masking technique involves applying vacuum
grease to either the LTR or the non-LTR regions, respectively. The vacuum grease does not
allow diffusion of hydrophilic permeants through the skin regions that are masked with vacuum
grease. This method has been validated previously by Kushner et al. [14]
2.2.4.4 Calculating Steady-State Calcein Permeability through the Skin
Following imaging and masking, all skin samples were remounted into clean, dry diffusion cells.
The receiver chamber of each sample was filled with PBS (12 mL) and the donor chamber was
filled with 2.5 mL of 0.2% (w/v) calcein in PBS solution. These experiments were conducted at
room temperature (25 'C), and the receiver chambers were magnetically stirred at 400 rotations
per minute. Samples were allowed sufficient time to reach steady-state (which has previously
been established for calcein through porcine skin[14]), and then were sampled at two-hour
intervals between 18 - 26 hours after initiation of the experiments. For each sample, a 1 mL
aliquot was withdrawn from the receiver chamber and immediately replaced with an equal
volume of PBS. In addition, at each time interval, a 20 pL aliquot was withdrawn from the
donor chamber and diluted to 2 mL (in order for the absorbance to be in the linear regime for
calcein). The concentration of calcein in each aliquot was determined using a UV/VIS
spectrophotometer (Beckman Coulter DU 800) to measure absorbance at k = 494 nm and,
subsequently, was converted to units of % (w/v) using a standard curve generated from known
concentrations of calcein.
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Finally, the permeability of calcein through the skin, P, was calculated at steady-state, infinite
sink conditions using the following equation:
P = (2.2)
ACd At
where A is the area of skin available for permeation (which can vary with LTR area for the
masked samples, with A = 1.77 cm 2 for the total skin samples), V is the volume of PBS in the
receiver chamber, Cd is the average calcein concentration in the donor chamber over the
sampling period, and (AC/At) is the rate of change of calcein concentration in the receiver
chamber (where replacement of the sampled aliquots by PBS is taken into account).
As previously noted, three main skin sample groups were studied: total samples, LTR samples,
and non-LTR samples. In addition, passive samples were also tested, which involved no
LFS/SLS pre-treatment, in order to compare the permeabilities of LTRs and non-LTRs to that of
native skin. Note that in the non-LTR and passive sample groups, it was necessary to account
for the background absorption of lipids in the receiver chamber in the spectrophotometric
analysis. It is well established that many epidermal and dermal components have broad range
absorption in the visible light range,[30-34] which justifies the need for this correction when the
absorption of calcein is of similar, or of lower, magnitude than the absorption of the skin
components in solution at the wavelength of interest. This procedure is described in Section 2.A.
Because there is a higher concentration of calcein present in the receiver chambers of LTR
samples, background absorption was found to be insignificant within these samples and,
therefore, there was no need to implement the procedure described in Section 2.A.
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2.2.4.5 Calcein Permeability through the Skin Dermis
The final group of samples consisted of skin that was first dermatomed (Zimmer Electric
Dermatome, Model 8821, Dover, OH) at a depth of 300 pm to completely remove the entirety of
the epidermis from the dermis. The epidermis was then discarded, and the calcein permeability
and skin electrical resistivity of the dermis were measured. Note that the calcein permeability
and skin electrical resistivity of the dermis are necessary in order to find the effective aqueous
pore radius of the dermis in the context of the APPM (see Section 2.3).[22]
2.2.5 Experiments with C14-Labeled SLS
In order to quantify the amount of SLS partitioning into the LTRs, the non-LTRs, and the passive
samples, the skin was pre-treated as described in the Section 2.2.4.1, but the coupling medium
also contained 0.5 pCi/mL C14-labeled SLS, in addition to the 1% (w/v) SLS, and 0.025% (w/v)
allura red in PBS. Skin samples were treated with 20 kHz ultrasound for a total ON time of 10
minutes (20 minutes at 50% duty cycle), resulting in skin samples with an average current of 330
gA (within the range of currents tested in the experiments used when calculating calcein
permeabilities). Following treatment, skin samples were rinsed with PBS, blotted dry with lab
tissue, and then LTRs (that were dyed red, see Figure 2-1) and non-LTRs (the undyed skin
regions, see Figure 2-1) were sampled using a circular cutting tool with an area of 7.9 mm 2 . On
each skin sample, it was typically possible to sample 2-3 LTR samples and 4-7 non-LTR samples
(since the non-LTRs occupy larger areas on the skin). The skin samples were then solubilized
using Soluene-350 (1.5 mL), and the amount of SLS was quantified using a Tri-Carb Liquid
Scintillation Counter (Perkin-Elmer), utilizing the scintillation cocktail Hionic-Fluor (5 mL).
This process was repeated for ten skin samples. Passive samples were contacted with the C14-
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labeled SLS-containing coupling medium for 20 minutes. For passive samples, the entire skin
sample that contacted the solution (with area of 1.77 cm2) was used to quantify the amount of
SLS in the skin. For the case of the larger passive samples, 5 mL of Soluene-350 and 15 mL of
Hionic-Fluor were utilized in the analysis of each sample. This process was repeated for 20 skin
samples. For all samples, the concentration of SLS in the skin was normalized by the surface
area of that sample.
In addition, to further test the mechanism of SLS penetration into non-LTRs, experiments were
conducted to quantify the penetration of SLS into the skin for two additional cases: i) with
increased temperature of the donor solution, and ii) with vigorous stirring in the donor
compartment of the diffusion cell. During ultrasound application, the temperature of the donor
solution increases linearly from room temperature (25 C) by no more than 10 'C during a two-
minute treatment (with 50% duty cycle, 5 s ON: 5 s OFF, and 1-minute ultrasound ON time).
Therefore, to quantify the effect of just the temperature increase on SLS penetration into the
skin, an identical donor solution to that described above was initially heated to 37 'C (body
temperature and approximately 10 'C higher than room temperature) and was contacted with the
skin in two-minute increments (the same time interval corresponding to the ultrasound
experiments). The solution was replaced 10 times, with the 37 'C donor solution, for a total
contact time of 20 minutes. To test the effect of decreasing the concentration boundary layer
above the skin, an experimental setup was designed to allow for rapid stirring of the donor
solution above the skin. Samples were prepared by: i) placing a 12.5 mm stir bar (VWR) in the
donor compartment (having a diameter of 15 mm), ii) filling the donor compartment with ~1.5
mL of C14-labeled SLS-containing coupling medium, and iii) capping the diffusion cell with a
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plastic stopper (Chemglass, Vineland, NJ, part# CG-3021-01). Once the samples were capped,
the distance between the skin surface and the bottom of the stopper was 5 mm. The diffusion
cells were placed underneath a /4" thick acrylic platform (fabricated in-house) with a magnetic
stir plate inverted on top of it (Coming, Lowell, MA, model PC-410). Once the samples were
placed under the magnetic stir plate, and the height of the platform was adjusted so that it was
resting on top of the diffusion cell, the magnetic stir bar was attracted to the stir plate and
therefore rested at the bottom of the plastic stopper (5 mm above the skin surface). It was
necessary that the stir bar not contact the skin during mixing, because if the stir bar had rested on
the skin surface, it could cause mechanical abrasion of the skin due to friction. The stir plate was
then set to its maximum speed, a setting of "10", and the experiment was allowed to proceed for
20 minutes. Although the LFS/SLS experiments have an LFS ON time of 10 minutes (50% duty
cycle), it was observed that fluid flow persisted in the donor compartment of the diffusion cell
during the LFS OFF time (that is, fluid flow did not cease immediately after LFS was turned
off). Accordingly, to better reproduce the environment above non-LTRs in the LFS/SLS
experiments, the vigorously-stirred experiments were conducted for 20 minutes (the full contact
time of the SLS donor solution with the skin during the LFS/SLS treatment). Both sets of
samples were prepared, and the amount of SLS quantified, in the same manner as described
earlier in this section for the passive samples contacted with C14-labeled SLS.
2.3 Theory
2.3.1 Calculating the Effective Aqueous Pore Radius of the Skin
In order to calculate the effective aqueous pore radius (r,,) of the skin samples tested, the
APPM was utilized.[22] The main assumption of this model is that aqueous permeants (in this
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case, calcein) traverse the skin along the same paths as the current carrying ions of the electrolyte
solution that the skin is immersed in (for PBS, the dominant ions are Na' and Cl~). This model
utilizes hindered transport theory[35] in order to quantify the steric hindrance exerted by the
finite-size skin pores on the flux of the aqueous permeant and the current carrying ions through
the skin. The hindrance factors corresponding to both species are related solely to the radius of
each permeant and rp,,,. Therefore, by equating the diffusion of the aqueous permeant, which is
related to P, and of the current carrying ions, which is related to R, one can determine rpore.
The relation between permeability, P, and skin electrical resistivity, R, in the context of the
APPM, is given by:[22]
log P = log C-log R (2.3)
where C is defined as follows:
kT D H(A)C = FC
22 Fioneo D,*,H (4At
(2.4)
where z is the electrolyte valence, F is Faraday's constant, c,, is the electrolyte molar
concentration, eo is the electronic charge, k is the Boltzmann constant, T is the absolute
temperature, D," is the infinite-dilution diffusion coefficient of solute i, H (A) is the hindrance
factor for solute i, and A, is defined as the ratio of the radius of solute i, r, to the radius of the
aqueous skin pores, rpo,.[14] Although previous work has utilized older expressions for the
hindrance factor, H(Ai) ,[14, 19, 22, 23, 26, 36, 37] the most advanced expression for H(A),
which has been used recently in the context of the APPM[38] and is valid for 1 < 0.95, is given
by:[35]
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H(A)=1+- 9Zln , -1.56034, +0.528155A' +1.91521A1' (2.5)
8
-2.81903A4 +0.270788Z, 5 +1.10115,6 -0.435933A,'
It is important to note that the only variable in Eq. (2.4) that depends on the intrinsic properties
of the skin is rp,,. All the other variables are either constants or are properties of the permeants
used. Therefore, once an experimental C value is determined using Eq. (2.3), rpr, can be
determined by iteratively solving Eq. (2.4) until C converges.
It is important to stress that, for any given aqueous permeant used (with given hydrodynamic
radius, which is 8 A for calcein[39]), only a certain range of r,,,, values can be probed in the
context of the APPM. In fact, for any permeant, there will be an upper bound on the rp,, values
that can be determined depending on the hydrodynamic radius of the permeant. This is due to the
fact that, as the pores become increasingly large, the extent of hindrance exerted by the pores on
the diffusing permeant becomes increasingly small as the hindrance factor approaches unity
(recall that hindrance factors range from 0 to 1, where a hindrance factor of 1 corresponds to no
hindrance and a hindrance factor of 0 corresponds to infinite hindrance). Beyond a certain rpore
value, the hindrance exerted by the pores on the permeant becomes statistically indistinguishable
from the diffusion of the permeant at infinite dilution, which corresponds to the upper bound of
r,, that can be probed with that permeant. This infinite-dilution limit (also known as an
infinite-pore limit) will be attained at lower rp,,, values for smaller permeants and will be higher
for larger permeants. This limit can be estimated in one of two ways: i) assuming that, beyond a
certain rp,,, value, the hindrance factor calculated for calcein cannot be differentiated from a
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hindrance factor of unity. In past publications, the level of uncertainty in the hindrance factor
was chosen to be 10%, and the pore radius corresponding to H (A)= 0.9 was chosen as the
upper bound for a given permeant,[22] or ii) assuming that the pores within the hydrophilic
dermis are infinite, and then using the pore radius calculated for the dermis in the context of the
APPM as the upper limit on roe. Both methods were tested, and they yielded a similar upper
limit of rpo,, for calcein, approximately 300 A.
In order to apply the APPM to the data, a linear regression was fit to each set of log P versus log
R values. For the model to be applicable, it was required that the 95% confidence interval of the
slope corresponding to every given data set include the theoretical value of -1 (see Eq. (2.3)).
Once this test was carried out, and it was confirmed that the data was described by the APPM, a
C value was determined using Eq. (2.3) for each data point tested. Subsequently, all of the
individual C values within each data set were averaged to yield the C value for that data set.
This C value was then used to calculate rore in the manner described above. Therefore: i) the
reported rpore value for a given data set was calculated from the mean value of C for that data set,
and ii) the 95% confidence interval reported for rpor, was calculated from the 95% confidence
interval for C for each data set. In general, all the statistical analyses reported in this study
involve two-sampled t-tests, at 95% confidence, unless noted otherwise.
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2.3.2 Calculating the Skin Porosity-to-Tortuosity Ratio
In order to gain deeper insight into the transdermal pathways present within each skin region, it
is possible to again implement the APPM to calculate the ratio between the skin porosity, r-, and
the skin tortuosity, T, using the following expression: [22]
= 1 (2.6)
soia,, H (.ZAo,i
where the subscript i denotes a given skin sample, 0-,s is the electrical conductivity of PBS
(0.012 Q-1cm'),[22] H(o1 ) is the hindrance factor for an ion calculated using Eq. (2.5), R
is the skin electrical resistivity, and Ax is the thickness of the skin layer that provides the
primary barrier to transport. For the non-LTRs and passive skin samples, Ax can adequately be
defined as the thickness of the stratum corneum, or 13.1 pim.[40] Selecting an appropriate Ax
value for LTRs will be further discussed in the Results section.
2.4 Results and Discussion
2.4.1 Dependence of LTR, non-LTR, and Total Calcein Permeabilities
on Electrical Current Treatment Threshold and Ultrasound Frequency
Figure 2-2 shows the calcein permeability data for each of the three groups of samples tested
(total, LTR, and non-LTR) at the three ultrasound frequencies considered (A - 20 kHz, B - 40
kHz, and C - 60 kHz). In addition, the passive group is included in these Figures for comparison
to the calcein permeability of native skin. As illustrated in Figure 2-2, at all three frequencies,
the permeability of calcein through the LTRs is much greater than those through all the other
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skin regions. Additionally, it is noted that the permeability within LTRs is of similar magnitude
to the permeability within dermis samples (P =1.8-10-2 cm/hr, calculated as described in
Section 2.2.4.5), suggesting that much of the barrier properties within the epidermis of these
regions has been overcome. These findings are consistent with previous results at 20 kHz.15
Moreover, at the three frequencies studied, the non-LTRs are also more permeable than the
native skin samples, which is consistent with earlier findings at 20 kHz.[14, 17, 21] As
expected, the calcein permeabilities of the total skin samples fall between those of the LTRs and
the non-LTRs at each of the three frequencies studied, because these samples contain both types
of skin regions.
Figure 2-2 also shows that for the total skin samples, at each of the three frequencies studied, the
calcein permeability increases linearly as a function of the skin electrical current threshold
(r 2 =0.94-0.98). In spite of the observed upward linear trend in calcein permeability for the total
skin samples, the permeabilities within the LTRs and the non-LTRs exhibit no dependence on
the electrical current threshold based on statistical analysis of the data at the three frequencies
studied. This indicates that, as the electrical current threshold increases, the permeability of the
skin increases due to an increase in the area of the LTRs present on the skin. This is clearly seen
in Table 2-1, where the LTR area increases with increasing skin electrical current threshold for
the three frequencies studied. Additionally, by comparing the calcein permeability of the total
skin samples, at each current threshold, as a function of ultrasound frequency, it is seen that the
total calcein permeabilities generally decrease with increasing ultrasound frequency (Figures 2-
2A-C). This suggests that the calcein permeation through the skin in the total skin samples is
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Figure 2-2. Calcein permeability for the total, LTR, non-LTR, and passive skin samples treated
to electrical current thresholds of 225 pA, 275 pA, and 335 pA at the three ultrasound
frequencies considered: 20 kHz (A), 40 kHz (B), and 60 kHz (C). Key: Total group (]); LTR
group (E ); Non-LTR group ( 0 ); Passive group (U ). Error bars = ±1 SD. Each bar in each
graph represents 8-12 samples, except for the passive group where the sample size is 20.
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Table 2-1. LTR area as a function of skin electrical current threshold and ultrasound frequency.
The total skin area of the samples is 1.77 cm 2.
20 kHz 40 kHz 60 kHz
( A) n LTR Area (cm 2) a n LTR Area (cm2 a n LTR Area (cm2 a
225 18 0.197± 0.070 16 0.282 ±0.079 15 0.154 ±0.034
275 17 0.265 ±0.055 19 0.399 ±0.080 19 0.327± 0.102
335 17 0.531 ±0.099 20 0.452 ±0.066 21 0.417± 0.117
a Range corresponds to a 95% confidence interval.
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Current
more hindered with increasing frequency. This result will be discussed more thoroughly in the
context of the APPM in the following sections.
Finally, by comparing the calcein permeability data in each skin region tested, one can quantify
the relative perturbation in these regions by calculating a permeability enhancement ratio
(P/Prassie ). In general, LTR samples are over four orders-of-magnitude more permeable than
native skin, and well over two orders-of-magnitude more permeable than non-LTR samples. In
addition, non-LTRs are over thirty-fold more permeable than native skin. This again confirms
the earlier finding that two levels of enhancement are observed when treating skin
simultaneously with LFS at 20 kHz and a chemical enhancer, such as SLS.[14, 17, 21] In the
following sections, possible causes leading to the observed two levels of enhancement will be
discussed in more detail in the context of the effective aqueous skin pore radii in the different
skin regions.
2.4.2 Determining Effective Aqueous Pore Radii in LTRs, non-LTRs,
and Total Skin Samples as a Function of Ultrasound Frequency
Figure 2-3 shows the log P vs. log R plot used to analyze the 40 kHz LTR data in the context of
the APPM. In order for the model to be applicable, it is first necessary to check whether each
data set's linear regression has a slope that is not statistically different (95% confidence) from
the theoretical value of -1 (see Section 2.3). The results of this analysis are reported in Table 2-
2, which shows that all the data sets have slopes that are within valid limits for the APPM to be
applicable. The r2 values for all the data sets, except for the passive skin samples, are also within
the expected range reported in previously published data.[22] Note that the low r2 value
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exhibited by the passive skin sample set can be rationalized as follows. The skin resistivity
values for the passive skin samples are grouped very closely to each other, given the resistivity
of native skin and the fact that it is required that the skin samples used possess sufficiently high
initial resistivity to ensure that they are not damaged. Therefore, any scatter in the permeability
data due to natural variations in the native skin has a very large effect on the r2 value for this data
set. Unlike in the LTR, non-LTR, and total skin samples, samples are not treated in a controlled
manner to a pre-determined current threshold. Therefore, the data is very susceptible to natural
variations in the skin barrier, which can be significant from sample-to-sample and especially
between animals. Nevertheless, the passive skin samples provide a good baseline for comparison
to the values obtained in the case of the LFS/SLS-treated skin samples and, therefore, have been
included in Table 2-2.
The r,,,r, values corresponding to the different skin regions studied, calculated in the context of
the APPM, are reported in Table 2-3. The total skin samples clearly exhibit a decrease in rore
with increasing ultrasound frequency. Utilizing a two-sample t-test at 95% confidence, it was
determined that, for the total skin samples, the difference between rr,, calculated at 20 kHz (105
A) and 40 kHz (73.9 A), and at 40 kHz and 60 kHz (50.7 A) are statistically significantly
different. It is also noted that a previous study by our group investigated the effect of different
permeants on skin pore radii with 20 kHz LFS/SLS under nearly identical treatment conditions
utilizing human skin.[23] In this study, the reported pore radii are very similar to the r,,,, value
reported here for calcein (molecular weight = 622.6 g/mol, r,,,,r = 105 A) at 20 kHz, for two other
hydrophilic permeants with molecular weights greater than 500 g/mol (for raffinose, rp,,,= 98 A
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Figure 2-3. Sample log P vs. log R plot. Data shown (EI) is for LTR samples treated at 40 kHz.
Units of P are cm/hr and units of R are kOhm-cm 2 . Key: solid black line - linear regression of
the data, gray line - linear regression with theoretical slope of -1.
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Table 2-2. Statistical analysis on the slopes of log P as a function of log R for all the data sets
tested. The 95% confidence interval for the slope must contain the value -1 for the APPM to be
applicable.
Total
Frequency n Slope a r2 n
20 kHz 35 -0.92 0.17 0.79 28 -1
40 kHz 30 -1.02 ±0.16 0.85 27 -1
60 kHz 36 -1.08 ±0.21 0.76 30 -0
Passive 20 -1.14 ±0.73 0.16
a Range corresponds to a 95% confidence interval.
LTRs
Slope a
.01± 0.26
.02 ± 0.26
.95 ± 0.32
r2
0.71
0.73
0.57
Non-LTRs
Slope a
-1.24± 0.38
-1.13 ±0.22
-1.07] 0.27
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2
r2r
0.68
0.79
0.70
r-
Table 2-3. Pore radii calculated for the total, LTR, non-LTR, and passive skin samples, as a
function of the ultrasound frequency. The lower and upper bounds correspond to the endpoints
of the 95% confidence interval of the pore radius.
Total LTRs Non-LTRs
Frequency Lower rPore (A) Upper Lower rpore (A) Upper Lower rpore (A) Upper
20 kHz 81.5 105 148 ----- ----- 17.0 18.5 20.4
40 kHz 61.6 73.9 92.9 165 276 ----- 17.2 18.2 19.4
60 kHz 43.6 50.7 61.1 97.2 161 ----- 17.3 18.4 19.8
Passive 12.9 13.6 14.4
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and for inulin, rpr,= 95 A). Another recent study also found that the average pore radius for
porcine skin treated with 20 kHz LFS/SLS, under identical treatment conditions to those utilized
in this manuscript, is 113 A, utilizing sucrose as a model hydrophilic permeant.[38] This
confirms that the data reported here at 20 kHz is consistent with the 20 kHz data reported
previously.
In order to explain the observed change in the rp,,, values with ultrasound frequency in the total
skin samples, it is revealing to examine the frequency dependence of the rp,, values in the LTRs
and non-LTRs. Table 2-3 clearly shows that within the non-LTRs, rp,,, is independent of the
applied ultrasound frequency. Specifically, the r, values in the non-LTRs remain nearly
constant, ranging from 18.2 - 18.5 A for the three ultrasound frequencies studied, with no
statistically significant difference between the three samples. However, these rpre values are
statistically significantly larger than the rore value observed in the passive skin samples (rp,,,=
13.6 A). It is noted that the rp,,, value for native skin that has been determined is consistent with
rpore values for native porcine skin reported in the literature (11 - 28 A).[41-43] Although the
calculated rp,,,, values for both the non-LTRs and native skin samples fall within the range of
rp,,,, values reported in the literature for native skin, it is important to stress that, with very high
statistical certainty (P<0.00001), the calculated rpo, values are in fact statistically significantly
different in the non-LTR and native skin samples. Accordingly, although there is a statistically
significant enhancement in ro,, within the non-LTRs relative to the native skin samples, the rpor
enhancement observed within the non-LTRs is not frequency dependent. On the other hand,
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within the LTRs, Table 2-3 clearly shows that there is a frequency dependence of rpore. Similar
to what is observed for the total skin samples, as the ultrasound frequency decreases, the rpore
values increase from 161 A at 60 kHz, to 276 A at 40 kHz, and then to co (>300 A, the upper-
bound for rpo,, values that can be probed with calcein) at 20 kHz. Because of the observed
frequency-independence of r,o, in the non-LTRs discussed above, the LTR findings suggests
that the observed increase in the rpo,, values with decreasing ultrasound frequency in the total
skin samples is due primarily to the increase in the rpore values within the LTRs. This result
reflects the fact that the total skin samples consist of both LTRs and non-LTRs, with the majority
of permeant transport occurring through the LTRs. As a result, the total skin samples exhibit a
similar trend in r,o, with ultrasound frequency as do the LTRs. However, because the LTRs
represent only a small fraction of the surface coverage of the total skin samples (see Table 2-1),
the average rpore values for the total skin samples are significantly lower than those for the LTRs
(see Table 2-3).
2.4.3 Mechanisms of Enhancement in the Non-LTRs of Skin Treated
with LFS/SLS
Many mechanisms have been proposed and tested to establish if they play a significant role in
skin permeability enhancement with LFS. These include: i) acoustic cavitation in the coupling
medium above the skin (stable and transient),[5, 6, 8, 9, 44] ii) thermal effects,[9, 44] and iii)
convection (acoustic streaming and resulting boundary-layer reduction).[9, 44] Of these, only
transient cavitation has been consistently identified as the primary mechanism of skin
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permeability enhancement in LFS, especially transient cavitation events near the surface of the
skin.[5, 8] These transient cavitation events near the skin surface can perturb the skin either by:
i) collapsing as a liquid microjet at the skin surface (either by impacting the skin or impinging
into the skin), or ii) spherical collapse near the skin surface (although it has been suggested that
spherical collapse close to a membrane may not be a physically achievable process because the
interaction between the membrane and the cavitation bubble will likely cause non-linear, or non-
spherical, oscillations).[5, 45] Note that cavitation within the skin has been conclusively shown
not to be a significant contributor to skin permeability enhancement when utilizing LFS, but can
contribute at higher frequencies.9 However, in nearly all the mechanistic LFS studies cited, SLS
was not utilized in the skin treatment regimen. The absence of SLS is significant, because it has
been shown at 20 kHz,[17] and confirmed in this paper at 20 kHz, 40 kHz, and 60 kHz, that two
levels of enhancement are present only when a chemical enhancer, such as SLS, is present in the
coupling medium during the LFS treatment. Furthermore, none of the mechanistic studies cited
above have independently considered LTRs and non-LTRs. In fact, many of these studies were
carried out before LTRs were discovered and were demonstrated to be regions of high
permeability. [14] For these reasons, it is possible that a mechanism that may contribute to non-
LTR permeabilization during the LFS/SLS treatment may have been overlooked in earlier
studies. With the above in mind, the previously proposed mechanisms are next examined, in the
context of the findings, to ascertain if they play a role in permeability and pore radius
enhancement within non-LTRs.
It is well established that acoustic cavitation is a frequency-dependent process.[9, 10]
Accordingly, it is unlikely that cavitation plays a major role in the observed enhancements within
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the non-LTRs, because it was found that the rp,,, values in the non-LTRs are frequency-
independent (see Table 2-3). This only leaves heating of the coupling medium and acoustic
streaming as potential mechanisms of enhancement in the non-LTRs. Because these experiments
involve a pre-treatment of the skin with LFS and SLS, the only role that heating or acoustic
streaming could play in permeability enhancement in the non-LTRs is to increase the flux of SLS
into the skin (note that calcein is not present during the LFS/SLS skin treatment). This is
because both heating of the coupling medium and acoustic streaming are not present in the donor
solution post-treatment, and there is no SLS present in the donor solution during the steady-state
calcein experiments. Furthermore, it has been shown that ultrasound-induced acoustic streaming
can produce significant agitation of aqueous systems, leading to a decrease in the boundary layer
above a membrane to an extent that the boundary layer is insignificant when compared to the
boundary layer under passive conditions.[44] In addition, heating is also known to increase
permeant diffusion coefficients, and it is therefore possible for this mechanism to increase the
flux of SLS into the skin. This leads us to propose that SLS is present in elevated amounts within
non-LTRs compared to native skin samples, but in far less amounts than in the highly-perturbed
LTRs, due to a mechanism such as acoustic streaming or heating that is not as significant as
cavitation. Note that acoustic streaming could operate as an enhancement mechanism by either
causing a decrease in the boundary layer above the skin or by inducing convective flux of SLS
into the skin. Each of these possibilities will be discussed in the following paragraph.
In order to test the hypothesis that there is increased uptake of SLS in the LTRs and non-LTRs
compared to the native skin samples, experiments were conducted (see Section 2.2.5) to quantify
the amount of SLS in LTRs, non-LTRs, and passive skin samples. Additionally, two groups of
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samples were tested to isolate the effects of vigorous stirring and heating in the donor solution
during treatment. Figure 2-4 shows a comparison of the penetration of SLS into the non-LTRs
with those of the vigorously stirred, the heated, and the passive samples (note that the amount of
SLS penetrating into the LTRs was not included in Figure 2-4, in order to more clearly compare
the mechanisms associated with SLS penetration into the non-LTRs). It was found that the
average amount of SLS in the non-LTRs, per unit area of skin, is 2.51-10-6 mmol/mm2, which is
nearly 2 times greater than that in the native skin samples (1.40 .10-6 mmol/mm2 ). In addition, the
average amount of SLS in the LTRs (1.52 -10-5 mmol/mm2), was found to be 11-fold greater than
that in the native skin samples. This strongly confirms the hypothesis that SLS is present in
increased levels in the non-LTRs compared to the native skin samples, but in far smaller amounts
than in the highly-perturbed LTRs. Furthermore, it was found that the SLS concentration in the
skin for the vigorously-stirred samples (2.49-10 -6mmol/mm 2) is statistically similar to that of
the non-LTR samples (see 95% confidence intervals in Figure 2-4). However, the samples
whose donor solutions were heated to 370 C showed no significant increase in SLS skin
concentration (1.62 .10-6 mmol/mm2) over the passive samples (see 95% confidence intervals in
Figure 2-4). Note that in the case of the vigorous stirring experiments, the direction of stirring is
parallel to the skin surface (utilizing a stir bar). With this in mind, it is unlikely that convection
into the skin is likely playing a role in increased SLS flux during these experiments and,
therefore, the uptake of SLS is only increased due to a decrease in the concentration boundary
layer above the skin. Therefore, these findings suggest that the dominant mechanism of SLS
penetration into the non-LTRs is, in fact, acoustic streaming-induced reduction of the boundary
layer above these skin regions.
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Additionally, it is well-established that the effect of SLS perturbation on skin can increase rp,,ore
values. Ghosh et al. demonstrated that native skin soaked in PBS has an average pore radius of
20±3 A, while skin contacted with an SLS solution for five hours has an average pore radius of
33±5 A.[41] This confirms that it is possible for r,,r, to increase solely due to the exposure of
the skin to SLS. Therefore, it was proposed that the observed increase in the rpor, values in the
non-LTRs, and the resulting increase in calcein permeabilities, compared to native skin, is due
mainly to the ultrasound-frequency independent process of SLS acting on these skin regions
(note that the variability in native skin pore radius distribution may also play a role), where
increased penetration of SLS in the non-LTRs is the result of a non-frequency-specific process
such as acoustic streaming (and resulting boundary-layer reduction).
Furthermore, it is important to explain the origin of the observed >30-fold increase in calcein
permeability within the non-LTRs, relative to the passive calcein permeability. For this purpose,
the permeability of calcein through skin is modeled as follows:4 0
PcaIcein, i = (Aacein)i c 
(2.7)
Ax r i
where Pcalcen, is the calcein permeability through skin sample i, c, is the skin porosity of sample
i, r, is the skin tortuosity of sample i, and all the other variables were defined previously.
Using Eq. (2.7) to calculate the permeability of calcein through the non-LTR samples, relative to
the passive permeability of calcein, and assuming that, in both the non-LTR and passive skin
samples, the stratum corneum is the primary barrier to transport (Ax is constant), one obtains:
163
3-1
E
E
E
C 60 2-10~6
C
0
0
Non-LTRs Vigorously Stirred Heated (37*C) Passive Control
Donor Solution Treatment
Figure 2-4. Concentration of SLS in skin treated under different experimental conditions in the
donor solution, compared to that of non-LTRs. In each case, the total concentration of SLS in
the donor solution was 1% (w/v), but stirring and heating (37' C) were varied in order to assess
the importance of these two processes on SLS penetration within non-LTRs. Error bars shown
are 95% confidence intervals.
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Ecalcein, non-LTR _H 'caicein )non-LTR (2.8)
Pcaicein, passive H {caein ) )non-LTR ) / passive j
Equation (2.8) clearly shows that the calcein permeability in the non-LTRs can increase relative
to the passive calcein permeability due to: i) a decrease in calcein hindrance (due to an increase
in the radii of the skin pores), and ii) an increase in e/r . Both of these quantities can be
calculated utilizing Eqs. (2.5) and (2.8). Note that one can also use Eq. (2.6), in place of Eq.
(2.8), to obtain very similar results when calculating the ratio of 6/r in the non-LTRs and
passive skin samples. However, Eq. (2.8) was used for simplicity. First, it was found that, over
all the non-LTR samples (recall that there is no frequency dependence within non-LTRs),
H ('clcein )non-LTR - 0.00 =4.1. This suggests that the -35% increase in pore radius observed
H({ Acalcein )pasv 0.020
within non-LTRs, compared to native skin, causes about a 4-fold decrease in calcein hindrance
through the skin pores. Next, using Eq. (2.8), it was found that
SPcalcein, non-LTR H (Acalcein )non-LTR 
_ 6. (4. l)1 = 8.8. It is important to
non-LT R| /)passive Pcalcein, passive H ( Acacein )passive )
note that the increase in pore radius that was calculated for the non-LTRs is embedded within
c/1, since c is defined as the area of pores on the skin divided by the total skin area. Therefore,
since an approximately 35% increase in pore radius between the non-LTR samples and native
skin (18.4 A and 13.6 A, respectively) was observed, the increase in pore radius can only account
for about a 2-fold (a,,r -,.e ) increase in S/i. However, it was just shown that E/i increases
nearly 9-fold between the non-LTRs and the native skin samples. It therefore follows that the
remaining ~4.5-fold increase in c/I must be due to either the creation of new pores or to a
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decrease in r. Furthermore, using the theoretical derivation found in Kushner et al.,[23] the
following equation can be used to calculate the ratio between rrnn-LTR passive
= (6tlag D H (Ap ))1/2 (2.9)
AX
where t,g is the lag time to reach steady-state diffusion and the remaining variables were defined
previously.
Using Eq. (2.9) for the non-LTR and passive skin samples, with Axnon-LTR =AXpassive, the
following results are obtained:
( >1/2
Tnon-LYR _ tiagnon-LTR H(Ap)non-LIR1 (2.10)
vpassivc tlassigaive H (.A, )passive 9
Then, substituting into Eq. (2.10), noting that t ag is simply the x-intercept on a plot of P vs. time,
1/2r H(A,) 3 1_hr_0_081/2one finds that Tnon-LTR - lagnon-LTR ilon-L7R '3.1 hr 0.081 = 0.94. This result
Tpassive 
t iag,passive H ( ,, 14.2 hr 0.020
implies that the tortuosity has decreased only slightly in the non-LTRs relative to the passive
skin samples. Therefore, the majority of the remaining 4.5-fold decrease in C/z must be due to
increases in porosity due to new pore creation. Nevertheless, it is important to recognize that it
is quite possible that SLS acting on the skin can, by itself, cause a change in /T. Indeed, it is
well established that surfactants are potent transport enhancers, due to their ability to
solubilize/extract lipids and denature corneocytes (keratin fibers).[46] In fact, in the same study
in which Ghosh et al. investigated the increase in pore radius of skin treated passively with
SLS,[41] compared to PBS controls, these authors found that the c/c ratio increased by nearly
166
an order-of-magnitude within samples treated with SLS compared to PBS controls, which is
consistent with the findings in this study. One can certainly justify the potential of SLS to create
new pores on the skin (an increase c) via the denaturation of comeocytes, which is the most
likely explanation for the observed increase in s/t based on the findings above. However, more
importantly, the analysis presented above confirms that the combined increases in H('Acacein)
and c/x can explain the observed >30-fold (4.1 x 8.8 = 36) increase in calcein permeability
within the non-LTRs relative to native skin.
2.4.4 Mechanisms of Enhancement in the LTRs of Skin Treated with
LFS/SLS
Next examining the observed trend in pore radii in the LTRs, as well as to the related observed
trend in the total skin samples, it was found that there is a strong dependence of r, on the
ultrasound frequency (see Table 2-3). This immediately suggests that cavitation is the primary
mechanism of enhancement in the LTRs.[10, 12, 47] It is also worth stressing that several
published papers have reported that transient cavitation events near the surface of the skin are the
primary mechanism of overall skin permeability enhancement with LFS.[5, 6, 8, 9, 44] One
study in particular concluded that cavitation, specifically in the vicinity of the skin, scales
directly with overall calcein permeability through rat skin.[48] Accordingly, since it was
concluded that cavitation is not a mechanism of enhancement in the non-LTRs, it follows that
this mechanism must be the primary enhancement mechanism in the LTRs.
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Further examination of the LTR data in Table 2-3 shows that the same inverse relationship
between the cavitation bubble resonant radius and ultrasound frequency applies to the variation
of ro,. with ultrasound frequency.[10-12] More specifically, it is well-established that the
relationship between the ultrasound frequency (f) and the resonant bubble radius (r.,) satisfies
the following relationship:[12]
r,", -f = Co (2.11)
where C, is a constant that depends on the properties of the solution in which cavitation is
taking place.
Then, by proposing that cavitation microjet collapse onto the surface of the skin is the primary
mechanism of skin perturbation and, therefore, that rp,,, and r,., are related directly, it can be
verified whether the rp,,, values determined within the LTRs are consistent with the expected
variation between the cavitation bubble radius and the ultrasound frequency. Using the same
expression given in Eq. (2.11) to relate rpo,, and f for the 40 kHz and 60 kHz LTR data, it is
verified that C,,,pore = rre,4okHz -40kHz = kr,s,6okz -60kHz (to less than 15% error), and an average
C,, pore value equal to 10.3-10' kHz -A is obtained. Using this Cvopo, value to calculate the
expected rpo, value at 20 kHz, a value of 520 A is obtained, which is greater than the infinite-
pore limit that was calculated for calcein ( rpo, >300 A) and consistent with the data.
Similar to the non-LTR case, it is necessary to explain the origin of the observed increase in
calcein permeability within the LTRs (greater than 4 orders-of-magnitude), relative to the
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passive calcein permeability. However, in the LTR case, because of the decreased barrier
properties of the stratum corneum, selecting a suitable value for Ax is more problematic.
Fortunately, however, Eq. (2.6) shows that c/T - Ax , while Eq. (2.7) shows that P- (Ax) 1'. As a
result, the dependence of permeability on Ax cancels out in Eq. (2.7). For simplicity, in the
following analysis it is assumed that, as is the case for non-LTRs and native skin, Ax is equal to
the thickness of the stratum comeum (as has been assumed in previous studies of LTRs[14]).
Using Eq. (2.7) for the LTRs and passive skin samples, it is found that:
Eca/cein, LTR - {\Acacein )LTR (2.12)
Pcalcein, passive -H( Acalcein ) pas L TR passive
Because the results of the analysis will change slightly based on the chosen frequency (recall the
frequency dependence of the pore radius within LTRs, see Table 2-3), only the 40 kHz LTR data
is considered, since this data lies between the data at 20 kHz and 60 kHz. Similar to the non-
LTR analysis presented above, for the LTRs it is found that: H( caein) 0-84 and
H ( Icacein ) passive 0.020
e > 1 07 -104
=0 . = 256. Using these results in Eq. (2.12), it is clearly seen that
KILTR ) passive 4.17.1 -0
these two effects account for the observed 4 orders-of-magnitude (42 x 256 = 1.1-104) increase in
calcein permeability. For completeness, it is important to stress that either: i) the Ax value used
for the LTRs has been underestimated, because the predicted increase in e/f (256) is less than
the increase expected solely from the 20-fold (276/13.6 = 20, see Table 2-3) increase in pore
radius calculated for the 40-kHz LTRs with respect to native skin (a ,,r,2,r = 400 ), or ii) the
number of pores within the LTRs has decreased compared to native skin (this is not
unreasonable, since the area of a single pore has increased by 400-fold, and therefore, multiple
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native skin pores may have merged into a single LTR pore). Note that, with respect to point (i),
if a larger Ax value was chosen for the LTR samples than for the passive skin samples, Eq.
(2.12) would need to be modified as follows:
Pealcein, LTR H (Acacein )LTR A passive E 1
vcalcein, passive H ( aicein )pjL T L r LTR| )passive
12 3
(2.13)
However, as stated previously, this will have no effect on 'calcein, L7R , but
Pcalcein, passive
simply will cause
term 2 in Eq. (2.13) to decrease linearly with increasing AxLTR , while term 3 in Eq. (2.13) will
increase linearly with increasing AxL7R (recall that c/r ~ Ax, see Eq. (2.6)). Therefore, in Eq.
(2.13), the contributions of AxLTR in terms 2 and 3 will cancel each other. Furthermore, as there
is no rigorous method to estimate Ax more accurately, Eq. (2.13) provides no additional useful
information compared to Eq. (2.12). Also, it is noted that a similar analysis to that done for the
non-LTRs using Eqs. (2.9) and (2.10), in order to determine the relative contributions of c and
r , cannot be carried out for the LTRs because of the uncertainty in the precise value of AxLTR '
In any case, regardless of the value of AxLTR assumed, the analysis presented here can explain
the overall increase in calcein permeability observed within LTRs relative to native skin, since
Pcalcein, LTR does not depend on the value of AxL TR chosen.
Pcalcein, passive
Finally, it is important to recognize that the r,, values corresponding to the ultrasound
frequencies considered here are on the order of tens of microns, while the rp,,e values calculated
in Table 2-3 are on the order of tens of nanometers. This, however, does not affect the
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conclusion that transient cavitation collapses near the skin surface are the primary cause for the
enlarged pores within LTRs. To reconcile the seemingly large difference between the determined
rp,, values and the expected r,.. values at each frequency, the following analysis will be
conducted. First, it is well-known that the r,..,values represent an upper bound on the average
cavitation bubble size in aqueous solution. [49, 50] For example, Burdin et al. and Tsochatzidis et
al. showed that at 20 kHz, although r,,,~ 150 ptm, the average bubble radius was calculated to be
between 3.15-5.25 ptm, depending on the measurement method and the applied ultrasound
amplitude, or approximately 25- to 50-fold smaller than the resonant radius.[49, 50] In fact, one
of the main conclusions of these studies is that the mean measured bubble radius is much smaller
than the resonant bubble radius. Second, it has been observed that when transient cavitation
bubbles collapse as microjets at an interface, the radius of the impinging microjet is about one
order-of-magnitude smaller than the radius of the collapsing cavitation bubble.[45, 51] Third,
because the skin is an elastic membrane, it is likely to rebound to some extent after a microjet
collapses on it. Although there has been no direct research into the actual physical size or shape
of the pores left in the skin by collapsing acoustic cavitation microjets, an interesting analogy
may be drawn to sharp punctures of the skin by needles and liquid jet injectors. Significant
research has been conducted on the penetration of soft solids, such as skin and silicone rubbers,
by sharp microscopic objects.[52, 53] For example, Shergold et al. found, utilizing pig skin and
silicone rubbers, that the ratio between the persistent defect left in the skin and the diameter of a
sharp tipped object was, in all cases, less than unity (tested for diameters of 300 pm - 2.0 mm),
with this ratio ranging between ~0.25-0.6 at the surface of the samples.[53] In addition, Roxhed
et al. found that a microneedle, with a diameter of 108 jim, left a persistent hole in human skin of
only 50 pim, leading these authors to conclude that the persistent damage left in the skin was only
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about half of the microneedle's shaft diameter.[54] This is relevant to the current analogy
because it has recently been shown that liquid jet injectors also penetrate, and damage, the skin
in the same manner as sharp-tipped objects puncturing soft materials, such as the skin.[55]
Liquid jet injectors transport fluid into the skin by delivering a high-velocity liquid jet (100-200
m/s), having a radius as small as 15 tm, directed at the skin surface,[56] much like an acoustic
microjet delivers a liquid jet at the surface of the skin (where the acoustic microjet is expected to
have a diameter of ~1 pm or less and have a maximum jet velocity of 153 m/s directed towards
the skin[45]). Therefore, the pore radius measured within LTRs are not necessarily equal to the
actual radius of the collapsing acoustic microjet itself, but instead, may be equal to the persistent
radius of the resulting pore left by the collapsing acoustic microjet. These three mechanisms
combined can account for the approximately three orders-of-magnitude difference observed
between the expected resonant bubble radii and the calculated rp,, values.
Additional research is needed to show definitively that cavitation microjets directed at the skin
surface are the primary cause for the formation of pores within LTRs, which would require
imaging of the cavitation field above the skin and the pores left within the skin. However, these
findings, coupled with the mechanistic analysis described above, provide compelling evidence
that this enhancement mechanism is the most likely cause for the observed trend in r,,, values
seen in the LTRs.
2.5 Conclusions
In this study, it was shown that the pore radii in the non-LTRs are independent of ultrasound
frequency, ranging from 18.2 - 18.5 A. In addition, it was determined that the pore radii in the
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non-LTRs are statistically significantly larger than the rp,e values for the native skin samples
(13.6 A), suggesting that a frequency-independent enhancement process is at play in these skin
regions. Additional experiments were carried out to quantify the amount of SLS penetrating into
LTRs and non-LTRs relative to native skin, and it was found that nearly twice as much SLS
penetrates into the non-LTRs per unit area than into native skin. Furthermore, by studying
different mechanisms of SLS penetration into skin, it was shown that boundary-layer reduction
caused by acoustic streaming is the most likely cause for the increased SLS uptake within non-
LTRs. Therefore, recognizing that SLS itself can increase pore radii in the skin,[41] it was
concluded that a frequency-independent process, such as acoustic streaming, causes increased
penetration of SLS into the skin, with SLS acting on the skin being the main contributor to the
observed increase in pore radius. In the LTRs, it was observed that the pore radii increase
dramatically with decreasing frequency (161 A, 276 A, and oo for 60 kHz, 40 kHz, and 20 kHz
LFS, respectively). Accordingly, strong support was provided to the proposal that transient
cavitation events near the skin surface, which are known to be frequency dependent,[10] are the
primary mechanism of skin permeability enhancement in LTRs, which is consistent with
previous literature findings.[5, 6, 8, 15, 21] The variation of the rpore values with ultrasound
frequency in the LTRs also suggests that transient cavitation microjets impinging on the skin
surface can explain the observed values of the pore radii.
In Chapter 3, I build upon the knowledge of the role of surfactants in LFS treatment. Recall that,
in this chapter, it was found that surfactants play a significant role in skin permeability
enhancement within non-LTRs. Therefore, in Chapter 3, the focus is shifted to more deeply
understand the effect of non-traditional surfactants in causing skin perturbation when combined
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with LFS. Specifically, the fluorescent dye sulforhodamine B (SRB), which has been utilized in
the past with LFS treatments as a colorimetric dye, is studied to understand if SRB, by itself, can
have an effect on LFS treatment. Furthermore, in Chapter 3, the effect of combining the non-
traditional surfactant SRB and a traditional surfactant, SLS, with LFS is investigated.
Subsequently, in Chapter 4, the physical model presented in the present study is utilized to
provide insight on the synergism between LFS and chemical penetration enhancers, such as
surfactants.
2.A Correcting Sample Absorption Values to Account for Lipid
Absorption
A series of twenty negative controls were carried out, identical to the experimental protocol
described in Section 2.2.4.4, except that PBS was used in the donor chamber instead of 0.2%
(w/v) calcein in PBS. This was done in order to test if background species, such as skin lipids,
could absorb in the receiver solution at the maximum absorbance wavelength for calcein (X =
494 nm). It was found that there is time-dependent absorbance at a wavelength of 494 nm for
the negative controls. However, the level of absorbance was such that it only affected calcein
permeability values significantly (>5%) when the total absorbance in the samples containing
calcein was below 0.4. Therefore, only the non-LTR samples and the passive control samples
were found to be affected significantly by background lipid absorption at 494 nm.
In order to properly account for background lipid absorption in the affected samples, the
absorbance intensity as a function of wavelength was measured, in the range 420 nm - 550 nm,
for the negative control samples and for samples containing known concentrations of pure
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calcein. Figure 2-5 shows the variation of the absorbance with wavelength in: negative control
samples containing skin lipids (Figure 2-5A), samples containing solely calcein (Figure 2-5B),
and non-LTR samples containing a mixture of skin lipids and calcein (Figure 2-5C). One can
clearly see that the curve in Figure 2-5C is a simple combination of the curves in Figures 2-5A
and 2-5B.
Unfortunately, the variation in the absorption between samples for the negative controls was too
large to simply average the lipid absorption at each sampling time point and then subtract it from
the non-LTR and the passive sample data. Fortunately, however, the background absorption for
all the negative control samples were found to have similar shapes, indicating that the absorption
curve for any of these samples could be reproduced by multiplying a standard background curve
(which was generated by averaging the lipid absorption at each wavelength over all the negative
control samples) by a constant parameter associated with that given sample. Specifically,
A, (A) = c,Asc (2) (2.A 1)
where Ai (2) is the absorption of sample i at a given wavelength (2) between 420 - 550 nm, c,
is the constant background parameter associated with that sample, and Ac (2) is the absorption
at a given wavelength for the standard curve.
Therefore, the entire background curve for any sample can simply be defined by a single
parameter. In addition, in the negative control samples, this parameter is essentially wavelength
independent in the relevant range of 420 nm - 550 nm. This indicates that one can extract the
background absorbance parameter at any wavelength, or range of wavelengths, and still
reconstruct the entire background absorbance curve for the range of wavelengths between 420
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Figure 2-5. Absorption as a function of wavelength, in the range 420 - 550 nm, for: a
background sample containing skin lipids (A), a pure calcein sample (B), and a non-LTR sample
containing both calcein and skin lipids (C).
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nm and 550 nm. An examination of the plots in Figure 2-5 shows that in the range 420-430 nm
and 540-550 nm there is much larger absorption in the background curve (Figure 2-5A) than in
the pure calcein curve (Figure 2-5B). As a result, the curve in Figure 2-5C closely resembles
Figure 2-5A in these two regions. Therefore, in order to decompose a curve like that in Figure 2-
5C into its corresponding background curve (Figure 2-5A) and pure calcein curve (Figure 2-5B),
the background absorbance parameter was calculated in the range 420-430 nm and 540-550 nm
by dividing the absorbance in these regions by the absorbance for that wavelength in the standard
background curve. Subsequently, the simple arithmetic mean of these twenty-two values was
calculated to obtain the background absorbance parameter for that sample, and the background
curve was reconstructed by multiplying the calculated parameter by the standard background
curve. The calculated background curve (such as Figure 2-5A) was then subtracted from the
total curve (such as Figure 2-5C) in order to construct a pure calcein curve (such as Figure 2-5B)
for that sample. The resulting curve was then used to calculate the concentration of calcein in the
receiver chamber.
In order to validate that the decomposition method described above yields reproducible and
reliable calcein concentrations, a series of 10 samples with predetermined absorption profiles of
background lipids and predetermined absorption profiles of pure calcein were mixed. The actual
concentration of calcein was compared to the value obtained using this decomposition method,
and the difference between the calcein concentration calculated by the decomposition method
and the actual calcein concentration in each case was found to be less than -5%, thereby
validating this method.
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Chapter 3
The Effect of Non-Traditional Surfactants on Low-
Frequency Ultrasound-Mediated Skin Permeability
Enhancement: The Case of Sulforhodamine B
3.1 Introduction
As shown in Chapter 2.4.3, the addition of surfactants to the coupling solution during a low-
frequency sonophoresis (LFS) treatment can have pronounced effects on the permeability and
structural parameters of the skin. In this chapter, I will investigate how non-traditional
surfactants, such as the dye sulforhodamine B (SRB), can also have a significant impact on skin
permeability enhancement with LFS. Often, the amphiphilicity of non-traditional surfactants is
not recognized, and therefore, these effects can be overlooked, leading to unintended effects,
especially when combined with other surfactants. This chapter will investigate the effects of a
non-traditional surfactant, SRB, and the combination of a non-traditional surfactant and a
traditional surfactant, sodium lauryl sulfate (SLS), on skin permeability enhancement by LFS.
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Rhodamine dyes are a class of xanthene-derived molecules that are commonly used as laser dyes
and fluorescent probes. Although most rhodamine dyes are cationic or have a net neutral charge
(zwitterionic), there are forms of these dyes that have been imparted with added water solubility,
and a net negative charge, by aromatic sulfonation of the phenyl pendant group. One such
molecule, sulforhodamine B (SRB, see Figure 3-1), has been used extensively during the last few
decades as: (i) a fluid-phase tracer,[1-3] (ii) a principal component in an assay for
cytotoxocity,[4-5] and (iii) a model hydrophilic probe,[6-19] among others.
In spite of the widespread use of SRB, investigations into its chemical nature, especially with
respect to its surface activity and interactions with surfactants, have been limited in scope in
comparison to research done on other dyes, including several other rhodamines. For example,
dyes such as rhodamine B[20-24] and rhodamine 6G[22, 25-27] have been studied extensively
with regards to: (i) their adsorption at oil/water or air/water interfaces, (ii) their aggregation in
aqueous solution as either dimers or higher-order aggregates, and (iii) their interactions with
surfactant monomers and micelles. Many other fluorescent dyes, such as rose Bengal[28, 29] and
various porphyrins,[30, 31] have also been studied with regards to their interactions with
surfactants and their solubilization within, or association with, micelles. This is because dye-
surfactant interactions can lead to the break-up of dye dimers or to the solubilization of dyes in
the palisade layer or non-polar core of micelles, both of which can have dramatic consequences
on the dye absorption and fluorescence wavelength and intensity.[32, 33] For example, an
amplification of fluorescence has even been observed for certain fluorophores when they
associate with surfactants.[34-36]
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Figure 3-1. Chemical structures of sulforhodamine B (top) and sodium lauryl sulfate (bottom),
where the sodium counterion corresponding to both molecules is not shown for clarity.
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Like many dyes, SRB is known to dimerize in solution,[20] and belongs to a family of dyes that
have been shown to include amphiphiles (such as the aforementioned rhodamine B[24] and
rhodamine 6G[25]). However, in contrast to other rhodamine dyes, SRB adsorption has only
been studied with respect to charged surfaces (such as cationic octadecylamine Langmuir-
Blodgett films and anionic silica glass[37-39]), with minimal investigation into its activity at
polar/non-polar interfaces or its potential interaction with surfactants in aqueous solutions. The
likely reason for this lack of investigation is due to the relatively high water solubility of SRB
compared to other rhodamine dyes, which has led some to designate SRB as a "model
hydrophilic" fluorescent probe.[6-19] However, as will be demonstrated experimentally in this
paper, SRB does not behave as a simple salt, and has the ability to: (i) adsorb at an air-water
interface, causing a decrease in surface tension, and (ii) interact strongly with surfactants in
aqueous media, inducing significant changes in the driving force for micellization, as evidenced
by a significant decrease in the critical micelle concentration (cmc) of SLS upon mixing with
SRB.
In the present study, the amphiphilic nature of SRB is investigated both experimentally and using
molecular dynamics simulations. Experimentally, surface tension measurements are used to
study SRB adsorption at air/water interfaces, including its ability to affect the cmc of the
commonly-used anionic surfactant, SLS. The extent of SRB incorporation into SLS micelles is
also investigated experimentally. To elucidate the experimental findings, bulk and interfacial
molecular dynamics (MD) simulations of SRB in aqueous solution were conducted, both in the
absence and in the presence of SLS. Such simulations provide a useful means for elucidating
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dye-surfactant interactions, and may be applied more broadly to other dyes, thus minimizing the
need for rigorous spectroscopic experimental measurements.
Finally, to illustrate the implications of the amphiphilic nature of SRB, an interesting case study
on the effect of SRB on transdermal drug delivery using low-frequency ultrasound is presented.
Amphiphilic molecules are known to act synergistically with low-frequency ultrasound in
inducing skin permeability enhancement, which motivated the case study to further test the
amphiphilicity of SRB.[40, 41] The results obtained with SRB are compared to those obtained
with the non-amphiphilic dye allura red (red food coloring).
3.2 Experimental
3.2.1 Materials
SRB, SLS, and phosphate buffered saline (PBS) were obtained from Sigma-Aldrich Company
(St. Louis, MO). Allura red was obtained from TCI America (Portland, OR). All chemicals were
used as received. Milli-Q (Millipore Corporation, Billerica, MA) water was used for the
preparation of all aqueous solutions.
3.2.2 Surface Tension Measurements
The surface tensions of aqueous solutions of SLS, SRB, and SLS in 9 mM SRB were measured
as a function of concentration using a KrUss K 11 tensiometer (Hamburg, Germany). The plate
method was utilized with a titanium Wilhelmy plate (Krtss, wetting length of 42 mm). For each
measurement, twenty surface tension readings were obtained, three seconds apart, and the final
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ten readings were averaged to yield the surface tension for that measurement (with the first ten
measurements serving as an equilibration period). Surface tension measurements of each
solution considered were repeated until consistent values were obtained for three consecutive
measurements (<0.1 mN/m variation at 25±1 C). These three measurements were then averaged
to yield the surface tension of the solution reported here.
3.2.3 Determination of the Amount of SRB Unbound to SLS Micelles
In order to determine the amount of SRB incorporated into SLS micelles, aqueous solutions of 9
mM SRB were prepared, with varying concentrations of SLS (0 - 64 mM). 5 mL of each
solution was then added to 10,000 molecular weight (MW) filter centrifugation tubes (Sartorius
Stedim Biotech, Goettingen, Germany) and subsequently centrifuged at 900 g for 2 minutes.
Since the aggregation number of an SLS micelle is ~50 and SLS has a MW of 288.4 g/mol,[42-
44] the MW of an SLS micelle is greater than the MW threshold for the selected filter
membrane. Assuming that any formed SRB/SLS micelles have an aggregation number
comparable to, or larger than, that of an SLS micelle, SRB is expected to be present in the filtrate
in only its unbound form (i.e., in monomeric or dimeric form). Note that the rotational speed and
duration of centrifugation were chosen such that less than 10% of the solution would pass
through the filter (0.2 - 0.4 mL). This limits the extent of micelle disassociation in the retentate,
which is similar to previously reported protocols used to separate monomers from self-assembled
aggregates.[45] 20 gL of the permeate was then diluted to 20 mL (1000-fold dilution), to ensure
that the SRB molecules being assayed were in monomeric form. The concentration of SRB was
then quantified using a UV/VIS spectrophotometer (DU800, Beckman Coulter Inc., Brea, CA) at
a wavelength of 560 nm (the observed peak absorbance of SRB). For each SLS concentration
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considered, the amount of unbound SRB was then reported as the ratio of the concentration of
SRB in the filtrate divided by the initial amount of SRB in solution (9 mM).
3.2.4 Testing the Ability of SRB to Enhance Skin Permeability
Previously published protocols[46, 47] were utilized for the storage and preparation of skin
samples. Skin samples utilized in the study were harvested from the back and flank of Yorkshire
pigs in accordance with the MIT Committee on Animal Care. Skin electrical resistivity, R, is
known to scale directly with skin permeability, and provides an accurate, instantaneous measure
of the structural state of the skin.[48] Previously published method[46-49] were followed to
measure R of each skin sample. Pre-treatment of skin samples by low-frequency ultrasound was
also carried out according to previously published methods,[46, 47] at an intensity of 7.5 W/cm 2
duty cycle of 50% (5 s on, 5 s off), and tip displacement of 3 mm for 10 minutes of ON time
(replacing the coupling medium every two minutes to minimize thermal effects). The coupling
media utilized in the experiments are reported in Section 3.3.3. Interested readers should refer to
Refs. [46-49] for complete experimental details.
3.2.5 Molecular Dynamics Simulations
To simulate the adsorption of a single SRB molecule at the air/water interface, an SRB molecule
was initially positioned at the center of a water box. The size of the water box was chosen to be
sufficiently large (4 x 4 x 10 nm3) such that the concentration of SRB in water (10.4 mM)
corresponds to less than one-half of its experimental solubility. The water box was sandwiched
between two large layers of vacuum (4 x 4 x 5 nm 3 each) in order to mimic the air/water
interfaces. Note that in all the simulations reported here, sodium counterions were added by
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replacing the corresponding number of water molecules to maintain electroneutrality of the
simulated systems. As the simulation proceeded, the SRB molecule gradually diffused and
eventually adsorbed at the air/water interface after 25 ns. The simulation was run for an
additional 15 ns for data collection. For simulations testing the adsorption of SRB dimers at the
air/water interface, SRB molecules were initially placed randomly at the interface. Simulations
were then run in an identical fashion to the single SRB monomer case described above. After
equilibration, both SRB monomers and dimers were observed in the bulk solution and adsorbed
at the interface. To determine the dimer hydration data, the longest adsorbed stable SRB dimer
was selected and tracked for 4 ns for the data analysis.
Following the procedure introduced by Stephenson et al., the relative hydration of each atomic
group in SRB was defined as the ratio between the number of water contacts around each atomic
group computed in the SRB adsorption simulation, relative to the number of water contacts
computed in the SRB monomer simulation.[50] Note that the SRB monomer simulation was
carried out by solvating and equilibrating a single SRB molecule in a water box for 5 ns.
To simulate the aggregation of SRB molecules in the bulk water phase, the SRB molecules were
positioned randomly in the simulation box, followed by solvating them with randomized water
molecules. Five different SRB concentrations were considered, corresponding to 6 to 49 SRB
molecules in the simulation box. Each simulation was equilibrated for 30 ns with the last 10 ns
used for data analysis. During the bulk simulations, the formation of SRB dimers was observed
and dominated the population of SRB aggregates (with few monomers and trimers observed). In
order to better understand the orientation between SRB molecules that form dimers, the angular
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distribution function of the angle between the pendant groups of SRB molecules in the dimeric
state were computed for the lowest SRB concentration case.
To simulate the interactions between the SRB and SLS molecules, 10 SRB and 40 SLS
molecules were positioned randomly in the simulation box, followed by solvating them with
randomized water molecules. Note that the total number of SRB and SLS molecules was
selected to be similar to the aggregation number of an SLS micelle (~50). A second simulation
was also conducted, keeping the concentration of SLS and SRB constant, but with 30 SRB and
120 SLS molecules in the simulation box. The larger simulation was conducted to check the
hydration calculations, because it is known that the amount of free monomer present can effect
the micelle aggregation number due to the long times scales associated with micellar fission. [51]
The simulations were equilibrated for 60 ns, with the last 30 ns used for data analysis. Two
SRB-SLS micelles were formed during the 50 molecule simulation and eventually stabilized,
with -6 micelles forming in the larger simulation. Relative hydration calculations for both
simulations were carried out and the values obtained were found to be nearly identical. The
relative hydration diagram reported in the text corresponds to that of the larger micelle in the 50
molecule simulation. Note that the relative hydrations of the SRB and SLS molecules in this case
were defined as the number of water contacts around each atomic group in the micellar state
relative to the hydration of that atomic group in a bulk aqueous monomer simulation.[50] The
SLS monomer simulation was conducted as discussed earlier for the SRB case.
Water molecules were modeled using the standard SPC/E model,[52] with bond lengths
constrained using the SETTLE algorithm.[53] SRB and SLS molecules were modeled using the
193
OPLS-AA force field.[54] Previously published force-field parameters were utilized for SLS
and rhodamine dyes.[55, 56] The +1 charge on the xanthene structure was delocalized
symmetrically over the xanthene rings, as in previously published studies[55] (note that the
depiction of a localized +1 charge in Figure 3-1 is for illustrative purposes only). Bond lengths in
the SRB and SLS molecules were constrained using the parallel version of the LINCS
algorithm.[57, 58] van der Waals (vdW) attractions and hard-core steric repulsions were treated
with a cutoff distance of 0.9 nm, which falls within the typical range of cutoff values used in
other studies.[59, 60] The vdW attractions and the hard-core steric repulsions between different
atoms were calculated from the Lennard-Jones potential using the standard geometric averaging
rule which is implemented in the OPLS-AA force field.[54] Long-range electrostatic
interactions were treated using the particle mesh Ewald (PME) summation method.[61, 62] The
equations of motion were integrated with a time step of 2 fs using the Verlet (Leap-Frog)
algorithm.[63, 64] SRB adsorption at the air/water interface was simulated under the NVT
ensemble (constant number of atoms, constant volume, and constant temperature of 298.15 K),
while all the other simulations were conducted under the NPT ensemble (constant pressure of 1
bar instead of constant volume) in order to best mimic the experimental conditions. The
velocity-rescaled Berendsen thermostat was implemented to maintain a constant temperature in
the simulated system.[65] The pressure was coupled to an isotropic Berendsen barostat.[66]
Periodic boundary conditions were applied in all three directions. The trajectories corresponding
to all the atoms in the system were saved every 10,000 steps (20 ps) to satisfy the ergodicity
criterion for data analysis.[67] All the simulations presented here were carried out using the
GROMACS 4.0 software package.[68]
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3.3 Results and Discussion
3.3.1 Adsorption of SRB at the Air/Water Interface
The surface tension measurements revealed that SRB adsorbs at the air/water interface, as
reflected in the observed concentration-dependent reduction in the surface tension of aqueous
SRB solutions (see Figure 3-2, open circles). This behavior is in stark contrast with the effect of
allura red (red food coloring), where no decrease in surface tension is observed as a function of
concentration with this non-amphiphilic dye (see Figure 3-2, black diamonds). At the highest
SRB concentration considered (22 mM), the surface tension reduction was found to be ~23
mN/m, which is quite significant considering that SLS was found to decrease the surface tension
of water by ~33 mN/m above its cmc. The surface excess of SRB was calculated from the Gibbs
Adsorption Equation,[69] assuming complete dissociation of sodium ions from the sulfonate
groups, in the linear region of the data (2-22 mM) and found to be 1.18-10~6 mol/m2, which
corresponds to 140 A2/molecule. As a point of comparison, the surface excess of SLS was found
to be 3.56- 10-6 mol/m 2, in the linear region below the cmc (3-7 mM, Figure 3-2, open squares),
which corresponds to 46.6 A2/molecule, a value that is consistent with previously reported values
(for example, 46 A2/molecule at 4 mM[70]). The higher surface excess of SLS, relative to that
of SRB, reflects the fact that more SLS molecules can adsorb at the interface, per unit area, than
SRB molecules. In view of the chemical structures of SRB and SLS shown in Figure 3-1, this
result is expected because SRB is generally bulkier than SLS.
MD simulations of SRB molecules near the air/water interface were carried out to elucidate the
adsorption behavior of SRB. The final state of the simulation, with a single SRB molecule
adsorbed at a clean air/water interface, is shown in Figure 3-3B. Figure 3-3A shows the relative
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Figure 3-2. Surface tension versus concentration data for aqueous solutions of allura red (*),
SRB (0), SLS(M), and SLS with 9 mM SRB (A). The vertical dashed lines denote the cmc's of
the specified solutions. The horizontal gray line represents the measured surface tension of pure
water.
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hydration of different atomic groups in the SRB molecule when adsorbed at the air/water
interface, relative to the fully-hydrated state in bulk aqueous solution (note that the atomic
groups in Figure 3-3A correspond to the SRB structure shown in Figure 3-1). In addition, note
that in the simulations, the pendant group and the three-ringed xanthene structure actually lie out
of plane from each other, contrary to the two-dimensional representation used in the figures for
clarity. As expected, the simulation revealed that the pendant group of SRB, which contains the
two charged sulfonate atomic groups, resides within the bulk aqueous phase. Conversely, a clear
division is observed in the xanthene structure, with the carbon groups located closest to the
pendant group remaining significantly hydrated (as reflected in the relative hydration of these
groups being greater than 0.6), with the rest of the SRB molecule in various states of dehydration
(relative hydrations less than 0.6), indicating that these groups are located, on average, in the air
phase. It has been previously shown, in similar investigations regarding the relative hydration of
amphiphilic molecules in micelles, that relative hydration values greater than 0.6 correspond to
the hydrophilic domain of the surfactant molecule (the "head"), while hydration values below 0.6
correspond to the hydrophobic region of the surfactant molecule (the "tail").[71] Therefore,
extending this criterion to a molecule adsorbed at an interface, a clear division between head and
tail regions of SRB can be made by laterally bisecting the xanthene structure, with the section of
SRB containing the pendant group comprising the head of the surfactant. The combined
experimental and simulation data conclusively demonstrates that SRB is indeed an amphiphile
and preferentially adsorbs at the air/water interface.
Note that no cmc is observed for SRB in aqueous solution (the open circles in Figure 3-2),
because a solubility limit is reached before reaching a plateau in the surface tension versus
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Figure 3-3. A: Relative hydration of an SRB molecule adsorbed at the air/water interface. The
blue color corresponds to a group with hydration similar to that in bulk aqueous solution, while
the transition to yellow corresponds to groups in less hydrated states. The number adjacent to
each atomic group denotes the relative hydration. B: Equilibrium MD simulation snapshot
showing an SRB molecule adsorbed at the air/water interface. Color legend: yellow - sulfur, red
- oxygen, white - hydrogen, blue/green - carbon, and dark blue - nitrogen.
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concentration curve. This should be contrasted with the behavior of SLS in aqueous solution,
which exhibits a clear plateau in surface tension at its cmc (7.67 mM, see the open squares in
Figure 3-2). MD simulations were carried out at various SRB concentrations in bulk aqueous
solution to elucidate this finding. The simulations revealed primarily dimer formation at all SRB
concentrations tested, with very few trimers, and no higher-order SRB aggregates observed, thus
confirming the inability of SRB to form conventional micelles by itself. The ability of SRB to
form dimers in aqueous solution has previously been shown experimentally.[20] At the higher
SRB concentrations simulated, most of the SRB molecules formed dimers, with few SRB
monomers observed. The dimers (see Figure 3-4A) were found to lie approximately parallel to
each other in the plane of the xanthene rings, where the most likely angle between the plane of
the pendant groups of each SRB molecule was found to be 750 (for a definition of a, see Figure
3-4A). The angular distribution function of the angle between the pendant groups, a, of the two
SRB molecules forming the dimer is shown in Figure 3-4B.
In MD simulations carried out at higher SRB surface concentrations, dimers were observed to
form at the air/water interface, as shown in Figure 3-5B, along with adsorbed SRB monomers.
SRB molecules were found to interchange between monomeric and dimeric states in the time
scales of the simulation, although some stable adsorbed dimers were observed to exist for large
durations of the simulation (> 4 ns). The relative hydration of SRB in a stable adsorbed dimer
(see Figure 3-5A) was distinctly different than that in the adsorbed monomer state (see Figure 3-
3A). Specifically, it was observed that one of the SRB molecules in the adsorbed dimer was
oriented approximately parallel to the air/water interface (see Figure 3-5B), as in the case of an
adsorbed monomer, while the other molecule was offset by approximately 75', as expected from
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Figure 3-4. A: MD simulation snapshot of the orientation of an SRB dimer in bulk aqueous
solution, where a is the angle between the planes of the pendant groups of each SRB molecule in
the dimer (each SRB molecule is shown in a different color for clarity). B: Angular distribution
function of a.
200
>0.75
0 48 0.55 0 47 40.7
0.65
0.55
0 0 64 0 057 0 .8 01 0,61
0.50
0 59 0.87 o 30.45
0.40
089 087 - 035
0.30
0 9
40.25
A B
Figure 3-5. A: Relative hydration of an SRB molecule adsorbed at the air/water interface in the
dimer state. The blue color corresponds to groups with hydration similar to that in bulk aqueous
solution, while the transition to yellow color corresponds to groups in less hydrated states. The
number adjacent to each atomic group denotes the relative hydration. B: Equilibrium MD
simulation snapshot of SRB adsorbed at the air/water interface in the dimer state. The two SRB
molecules of the adsorbed dimer are shown in different colors for clarity.
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the angular distribution function in Figure 3-4B. However, due to the fact that the offset SRB
molecule in the dimer extends upward into the air phase, the SRB molecule parallel to the
surface of the air/water interface was forced slightly deeper into the water phase than in the case
of an adsorbed SRB monomer. When averaged over both SRB molecules in the dimer (each
SRB molecule may alternatively be found parallel to the air/water interface during the
simulation, as the dimer rotates), greater hydration of the SRB molecule was observed in the
adsorbed dimer state than in the adsorbed monomer state, which is clearly seen by comparing
Figure 3-5A and Figure 3-3A. In spite of the difference in hydration states, the same qualitative
relative hydration profile trends are seen between adsorbed SRB monomers and dimers, with
much greater hydration of the sulfonate-containing pendant group and decreased hydration in
groups further away from the pendant group. However, because the adsorbed SRB monomer can
extend further into the air phase, compared to the average configuration of an SRB molecule
adsorbed at the interface as a dimer, there is greater dehydration of the groups furthest from the
pendant group for the monomer case relative to the dimer case.
3.3.2 Interaction of SRB with SLS in Aqueous Solution
The absorption and emission of fluorescent dyes can be strongly affected by their interactions
with surfactants. Figure 3-6A clearly shows how the visible color and opacity of a 9 mM SRB
aqueous solution changes when the concentration of SLS is varied between 0 - 64 mM.
Furthermore, the addition of SRB to aqueous solutions containing SLS was found to decrease the
cmc of SLS from a value of 7.67 mM (without SRB), to a value of 2.00 mM (with 9 mM SRB,
see Figure 3-2). As a point of comparison, the emc of SLS in allura red (which has been shown
to be non-amphiphilic, see black diamonds in Figure 3-2), was tested and found to remain
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Figure 3-6. A: Color change in 9 mM aqueous solutions of SRB with increasing SLS
concentration. B: Fraction of SRB molecules that are not incorporated into SLS micelles, relative
to the total concentration of SRB in solution, as a function of SLS concentration. The vertical
dashed line corresponds to the cmc of SLS in a 9 mM SRB solution (2.0 mM), and the error bars
correspond to a 95% confidence interval on the data.
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equal to the eme of SLS (cme = 7.62 mM) at low allura red concentrations (0.5 mM). Note that
at higher concentrations of allura red, or any salt, there will be a decrease in the cmc due to
electrostatic screening and counter-ion binding effects. At 9 mM allura red, the cmc of SLS was
found to be 4.50 mM, which is still higher than that found for SLS in 9 mM SRB, despite allura
red being a 1:2 electrolyte (2 additional sodium ions per mole of allura red) and SRB being a 1:1
electrolyte (1 additional sodium ion per mole of SRB). Clearly, this shows that the inclusion of
the amphiphilic SRB increases the thermodynamic driving force for micellization compared to
the non-amphiphilic allura red, as ionic effects alone cannot explain the observed decrease in the
cmc. In addition, Figure 3-6B shows that SRB is incorporated within SLS micelles, as reflected
by a decrease in the fraction of unbound SRB monomers with increasing SLS concentration (the
total SRB concentration in each solution is constant at 9 mM). At an SLS concentration which is
twice the cmc of SLS in the presence of 9 mM SRB (4 mM SLS), approximately 10% of the
SRB molecules are incorporated into SLS micelles. Furthermore, at 16 times the cmc of SLS in
the presence of 9 mM SRB (32 mM), nearly 90% of the SRB molecules are incorporated into
SLS micelles (see the fraction of unbound SRB in Figure 3-6B at the specified SLS
concentrations). At intermediate SLS concentrations (between 4-16 mM SLS), the molar ratio
between SLS and SRB in the micelles is about 3:1, with the molar ratio increasing as the
concentration of SLS increases thereafter (5:1 at 32 mM and 10:1 at 64 mM). Note that the term
"incorporated into SLS micelles" is used rather than "co-micellized", because the solubility limit
of SRB precludes single-component SRB micelle formation in aqueous solution, in spite of the
clear amphiphilicity exhibited by SRB.
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In order to gain a molecular-level understanding of the experimental observations made,
including the incorporation of SRB molecules into SLS micelles, MD simulations were carried
out on systems comprising SLS and SRB. In the initial configuration of these simulations, the
SRB and SLS molecules were randomly placed and oriented in the simulation box. Self-
assembly was observed to occur as the simulation proceeded. An equilibrium snapshot of the
final configuration of one of the micelles that formed is shown in Figure 3-7B. The molar ratio
of SLS to SRB in the simulated micelles is approximately 6:1, which is in general agreement
with the experimental data at high concentrations of SLS, reported in the previous paragraph.
The SRB molecules were found to be incorporated in the palisade layer (head region) of the
SRB/SLS micelles. An examination of the average relative hydration of SRB molecules
incorporated in SLS micelles (see Figure 3-7A), reveals that the majority of the atomic groups of
the SRB molecule are incorporated in the micelle, with only the sulfonate groups, and adjacent
atomic groups, remaining hydrated to a significant extent (relative hydrations of 0.74 - 0.95).
This is in contrast with the adsorption of SRB at the air/water interface (see Figure 3-3A), where
the entire pendant group and a portion of the xanthene structure exhibit high levels of hydration
(0.60 - 0.97). Comparing the hydration levels of SLS and SRB in the micelle state (Figure 3-7A,
where the atomic groups correspond to the structure shown in Figure 3-1), it is clear that the
sulfonate groups of SRB (relative hydration equal to 0.80 - 0.95) and the sulfate group of SLS
(relative hydration equal to 0.80) are located within approximately the same radial shell of the
micelle (forming the outer shell of the micelle). Meanwhile, the remainder of the SRB molecule
extends into the micelle core (relative hydrations equal to 0.36 - 0.57), in the same radial shell
where carbons 1 - 3 of the SLS molecules reside (relative hydrations equal to 0.33 - 0.55, see
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Figure 3-7. A: Relative hydration of an SRB molecule solubilized in an SLS micelle. The blue
color corresponds to groups with hydration similar to that in bulk aqueous solution, while the
transition to yellow color corresponds to groups in less hydrated states. The number adjacent to
each atomic group denotes the relative hydration. B: Equilibrium MD simulation snapshot of
SRB incorporated into an SLS micelle. Blue corresponds to SLS molecules, while purple
corresponds to SRB molecules.
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Figure 3-1 for the carbon labeling of SLS). In the simulations, the xanthene structure of the SRB
molecule was not found to extend deeply into the micelle core. This is due to: (i) packing
considerations, which include the large, rigid planar configuration of the xanthene structure
relative to the more flexible configuration of the SLS tail, and (ii) electrostatic considerations,
which involves the net +1 charge partially distributed across the xanthene structure. Moreover,
no SRB dimers were observed in the simulations when SLS micelles were present. SRB
absorbance is known to red-shift in the monomeric state, compared to the dimer state (spectral
data for SRB in the monomer and dimer states can be found in Chambers et al.).[20] Therefore,
this finding can explain the observed color shift in the aqueous SRB solutions with increasing
SLS concentration (see Figure 3-6A).
3.3.3 Case Study: Implications of the Amphiphilic Nature of SRB on
Ultrasound-Mediated Transdermal Drug Delivery
Many chemical skin penetration enhancers, particularly amphiphiles, are known to induce
synergistic enhancement in skin permeability when combined with low-frequency
ultrasound.[40, 41] Since SRB exhibits amphiphilic character, as demonstrated above, and has
been used extensively in transdermal research under the assumption that it behaves as an inert
fluorescent probe,[6, 8, 12,14, 16-19, 41, 49, 72-76] the possibility that SRB could act alone as a
skin penetration enhancer was investigated. An SRB concentration of 9 mM was utilized, which
is a commonly used concentration of SRB in transdermal research.[8, 41, 49, 73-75] To quantify
skin permeability enhancement, an enhancement ratio (ER) was calculated, where ER is defined
as the ratio of the post-treatment skin resistivity at steady state (18 hours post-ultrasound
treatment), and the initial skin resistivity of that sample (prior to ultrasound treatment). Skin
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Table 3-1. Steady-state enhancement ratio of skin samples treated with the specified coupling
medium and low-frequency ultrasound (20 kHz, 7.5 W/cm 2, 10 minutes).
Coupling Medium b n EnhancementRatioa
Water 10 1.71 ± 0.67
9 mM Allura Red 10 1.87± 0.62
9 mM SRB 11 54.0± 19.6
9 mM SLS 11 79.6 ±27.1
a Error bars correspond to a 95% confidence interval on the data.
b All solutions are aqueous, containing only the specified components.
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resistivity is known to scale directly with skin permeability.[48, 77] The results of these
experiments are summarized in Table 3-1.
Table 3-1 shows that skin samples treated with water/ultrasound (control) had a statistically
similar enhancement ratio (ER=1.71±0.67) as those treated with an aqueous solution of 9 mM
allura red/ultrasound (ER=1.87±0.62, two-sample t-test at 95% confidence). However, the ER
corresponding to skin samples treated with an aqueous solution of 9 mM SRB/ultrasound was
found to be 30-fold greater than the controls (54.0±19.6), which is a statistically significant
difference (p-value = 0.004, p-value must be below 0.05 for there to be a statistically significant
difference at 95% confidence). This clearly shows the ability of SRB to act as a skin
permeability enhancer when combined with low-frequency ultrasound, thus further
demonstrating its amphiphilic nature. For comparison, the ER for 9 mM SLS (a known
surfactant and skin penetration enhancer) is also shown in Table 3-1 (79.6±27.1). Interestingly,
the ERs of SRB and SLS are not statistically significantly different, owing to the generally large
variance associated with each sample (p-value = 0.15), but also confirming that SRB is a
statistically significant skin penetration enhancer.
Note, however, that SRB alone (in the absence of LFS) does not act as a skin permeability
enhancer. Specifically, in Figure 3-8 (gray bars) shows that both allura red and SRB at high (9
mM) and low (0.45 mM) concentrations have no significant impact on the enhancement ratio of
skin after 18 hours of passive contact. The inability of SRB to act as a passive skin permeability
enhancer is likely due to its high molecular weight (559 g/mol), and therefore, is limited in
perturbing the skin appreciably due to its failure to penetrate the skin in significant amounts.
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Figure 3-8. Enhancement ratios of skin samples treated passively for 18 hours with various
coupling solutions. Gray bars correspond to solutions containing only those specified, while red
bars contain specified solutions and 35 mM sodium lauryl sulfate.
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Figure 3-9. Steady-state (18 hour) enhancement ratios of skin samples treated with LFS for 10
minutes with various coupling solutions. Gray bars correspond to solutions containing only
those specified, while red bars contain specified solutions and 35 mM sodium lauryl sulfate.
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However, when 35 mM SLS is added to the solutions, it is observed that, while the non-
amphiphilic allura red has no affect on the enhancement ratio of SLS, the addition of SRB to the
solution has an antagonistic effect (Figure 3-8, red bars). This finding is not surprising
considering that it was shown that SRB is also amphiphilic and has the ability to incorporate into
SLS micelles. Therefore, as Figure 3-8 shows, the antagonistic effect increases with increasing
SRB concentration, where the observed decrease in enhancement ratio is likely due to an
increase in the size of the micelles as more SRB is incorporated into them. Therefore, the larger
SLS/SRB micelles encounter greater steric hindrance when trying to enter the aqueous skin
pores. As a result, their diffusion into the skin is decreased, causing less perturbation to the skin.
A similar antagonistic effect is seen when SRB is added to SLS coupling solutions for
simultaneous treatment with LFS (see Figure 3-9). In this case, again, the presence of the non-
amphiphilic allura red has no impact on the steady-state enhancement ratio of SLS. On the other
hand, the addition of SRB to the SLS coupling solution has a clearly negative impact on the
enhancement ratio observed. Therefore, it is evident that the use of SRB with other surfactants
for LFS treatments can have pronounced, unintended effects on bulk and interfacial properties of
the solution that manifest as changes in the level of skin perturbation induced.
3.4 Conclusions
We have demonstrated that SRB is an amphiphilic molecule that preferentially adsorbs at an
air/water interface, bringing about a considerable decrease in the surface tension of pure water
(23 mN/m reduction). MD simulations revealed that SRB is thermodynamically stable in its
adsorbed state, both as monomers and dimers, with clearly defined head and tail regions as
quantified by the hydration of its atomic groups, similar to conventional surfactants.
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Furthermore, SRB was shown to be able to incorporate into SLS micelles, which results in a
dramatic decrease in the cmc of SLS. Because of its incorporation into SLS micelles, SRB was
observed to have a significant shift in color and opacity in aqueous solution with increasing SLS
concentration. MD simulations revealed that the SRB molecules reside mainly in the palisade
layer of the SLS micelles. A case study on skin permeability enhancement by ultrasound and
SRB showed that SRB acts as a synergistic skin penetration enhancer, much like many
traditional surfactants.
The study presented here shows that even highly water soluble fluorescent dyes can behave as
amphiphiles. In many previous studies, SRB has been assumed to be an inert dye and, therefore,
was utilized as a simple colorimetric dye or model hydrophilic permeant. However, the present
study shows that one must pay careful attention when selecting an appropriate dye, or fluorescent
probe, in a given system. SRB can interact strongly with other surfactants, inducing significant
changes in bulk and interfacial properties of aqueous solutions. It is therefore recommended that
if a fluorescent probe is not needed, it is best to choose the simplest possible dye, such as allura
red (red food coloring). If, however, a fluorescent dye is required, special care should be taken to
ensure that the dye does not interact with other components of the system. The present study
also demonstrates that molecular dynamics simulations can be utilized effectively to study the
organization and hydration of dyes in bulk solution, at interfaces, and in micellar environments.
These types of studies have previously been carried out using more tedious, experimentally-
intensive spectroscopic methods. However, using the approach presented here, it may be
possible to more easily investigate multiple fluorescent dyes in order to aid in the selection of an
appropriate dye for a given system.
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The synergism observed between LFS and amphiphiles, such as SRB and SLS, which was
demonstrated in the study presented in this chapter, will be investigated further in Chapter 4.
Prior to the work conducted in Chapter 4, the mechanism that leads to the synergism between
LFS and chemical enhancers, such as SRB and SLS, was previously not well understood from a
quantitative perspective. In the next chapter, insight gained from the preceding chapters,
especially regarding the physical mechanistic picture proposed in Chapter 2, will be utilized to
solve for flux equations that will provide insight into the direct mechanism of increased skin
penetration of chemical enhancers when treated simultaneously with LFS.
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Chapter 4
A Physical Mechanism to Explain the Synergism in
Transdermal Enhancement between Low-Frequency
Ultrasound and Chemical Penetration Enhancers
4.1 Introduction
In Chapter 3, I demonstrated the extremely large synergistic effect that combining low-frequency
sonophoresis treatment with a chemical penetration enhancer (CPE), such as sodium lauryl
sulfate (SLS) or sulforhodamine B, can have on the extent of skin perturbation induced. In this
chapter, I will study directly the physical mechanisms that lead to this synergistic effect,
including how it varies with the nature of the CPE considered. This will allow us to gain a deeper
understanding of how ultrasound-induced cavitation bubbles interact with various CPEs.
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The use of low-frequency sonophoresis (LFS) for the transdermal delivery of drugs has been
shown to be a feasible and emerging method of local, regional, and systemic drug delivery,
which allows for the minimization of side effects, associated with oral and intravenous
delivery.[1, 2] When combined with CPEs, such as SLS, LFS treatment has been shown to result
in a synergistic effect in skin permeability enhancement.[3, 4] This synergism has been studied
to a large extent experimentally, demonstrating that combined treatment with LFS and CPEs
(primarily surfactants) allows for decreased treatment times, decreased energy-input
requirements, increased skin permeability, higher-connectivity of lacunar regions in the stratum
corneum, and less physical skin perturbation compared to the LFS treatment alone.[3-6] The
origin of this synergism is the ability of LFS to not only increase the penetration of CPEs into the
skin, but also to deliver CPEs deeply into the skin, including increasing their dispersion in the
skin.[3] In the absence of LFS, CPEs are generally limited in their passive diffusion into the
skin, owing to the innate barrier properties of the outermost layer of the skin, the stratum
corneum. On the other hand, when LFS assists the delivery of CPEs directly into the stratum
corneum, these molecules are no longer limited by passive diffusion, thereby allowing them to
induce increased chemical perturbation to the skin, in addition to the physical perturbation
induced by the LFS treatment.
In spite of establishing that increased penetration and dispersion of CPEs in the skin by LFS is
the origin of their synergism, to date, no direct mechanism has been proposed to explain how
LFS increases the penetration of CPEs into the skin. Other studies have investigated the
synergism between LFS and specific CPEs, such as SLS, more closely, and found that their
simultaneous use causes subtle changes in the skin, such as altered pH profiles.[7] However, to
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my knowledge, no previous investigations have explained or proposed a model as to why there is
a general increase in the penetration of CPEs into the skin when treated simultaneously with
LFS, which would explain this commonly observed synergism.
In this study, I propose a physical mechanism that explains why all CPEs exhibit synergism with
LFS, as well as why surfactants, specifically, exhibit greater synergism with LFS than non-
amphiphilic CPEs. In addition to proposing a physical mechanism, a kinetic-transport model is
presented to explain the synergism quantitatively, by solving explicitly for the expected CPE flux
into LFS-treated skin, with supporting data from experiments conducted with both amphiphilic
and non-amphiphilic CPEs.
4.2. Experimental
4.2.1 Materials
SLS, octyl glucoside (OG), and propylene glycol (PG), were obtained from Sigma-Aldrich
Company (St. Louis, MO). C14-labeled SLS, OG, and PG were obtained from American
Radiolabeled Chemicals (St. Louis, MO). Hionic-Fluor, a scintillation cocktail, and Soluene, a
tissue solubilizer, were obtained from Perkin-Elmer (Waltham, MA). Allura red (red food
coloring) was obtained from TCI America (Portland, OR). All chemicals were used as received.
Milli-Q water (Millipore Corporation, Billerica, MA) was used for the preparation of all aqueous
solutions.
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4.2.2 Surface Tension Measurements
The surface tensions of aqueous solutions of the two amphiphiles, SLS and OG, were measured
as a function of concentration using a Krtiss K 11 tensiometer (Hamburg, Germany). The
Wilhelmy-plate method was utilized with a titanium plate (Kriss, wetting length of 42 mm). For
each measurement, twenty surface tension readings were obtained, three seconds apart, and the
final ten readings were averaged to yield the surface tension for that measurement (with the first
ten measurements serving as an equilibration period). Surface tension measurements of each
solution considered were repeated until consistent values were obtained for three consecutive
measurements (<0.1 mN/m variation). These three measurements were then averaged to yield the
surface tension of the solution. The surface tension measurements were utilized to deduce the
critical micelle concentration (cmc) of the surfactants, SLS and OG. This was accomplished by
determining the intersection of the linear region below and above the cmc in a plot of surface
tension vs. log surfactant concentration. [8]
4.2.3 Preparation and Treatment of Skin Samples by LFS and CPEs
Previously published protocols were utilized for the storage and preparation of skin samples.[9-
15] These protocols have been approved by the MIT Committee on Animal Care. Briefly, skin
was harvested from the back and flank of Female Yorkshire pigs, sectioned into 25-mm strips,
and stored at -85 'C for up to 6 months. Before use in experiments, the skin was thawed for 1
hour in PBS and all excess hair and subcutaneous fat were removed. Full-thickness skin samples
were utilized without further preparation. The skin was then cut into 25 mm by 25 mm samples,
for use in the 15-mm inner diameter diffusion cells (PermeGear, Hellertown, PA).
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Treatment of skin samples was carried out according to previously published methods. [9-15]
Skin treatment was carried out with a 20 kHz ultrasound horn (VCX 500, Sonics and Materials,
Inc., Newtown, CT), under the following experimental conditions: intensity - 7.5 W/cm 2, duty
cycle - 100%, and tip displacement - 3 mm. The coupling solution between the skin and the
ultrasound horn contained aqueous solutions of SLS (1- 100 mM), OG (4 - 100 mM), and PG
(100 - 700 mM) with 0.5 mM allura red (used for visualization of LTRs only, see Figure 4-1).
The concentration of CPEs was selected so that they produced consistently large enough LTRs to
allow sampling utilizing the techniques discussed in Section 4.2.4. Note that dilute allura red
solutions have previously been shown not to interact strongly with other surfactants, or affect
bulk or interfacial properties of aqueous surfactant solutions.[14] The concentration of radio-
labeled permeant in the solutions was chosen to be between 0.3 - 0.5 ptCi/mL, in order to ensure
that the fluxes of the radio-labeled materials into the skin were at a level which is significantly
higher than the background values. After every 40 s of LFS treatment, the coupling medium
(volume = 1.5 mL) was changed in order to minimize thermal effects (i.e., to maintain the
temperature within 10 'C of room temperature), and samples were treated for a total of 10
minutes. Note that for these studies, LFS treatment was applied continuously, rather than in a
pulsed manner as was conducted in the other chapters of this thesis, so that there was no
additional passive flux associated with application of permeants during the LFS treatment.
Untreated skin samples were prepared in the same manner as other samples, but were contacted
with the coupling solutions for 10 minutes without ultrasound treatment. Following treatment,
samples were rinsed thoroughly in order to remove all excess material from the skin surface prior
to sampling of the tissue.
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Figure 4-1. Skin sample treated with 4 mM octyl glucoside and 20 kHz LFS for 10 minutes.
Regions stained by allura red are LTRs and unstained regions are non-LTRs.
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4.2.4 Quantifying the Flux of CPEs into LTRs, non-LTRs, and
Untreated Skin Samples
In order to quantify the amount of radio-labeled SLS, OG, and PG penetrating into the localized
transport regions (LTRs, see Figure 4-1), the non-LTRs, and the untreated skin samples, samples
were first blotted dry with lab tissue to remove all excess fluid on the surface of the skin. In
samples treated with LFS, LTRs were identified visually because they were stained a deep red by
the allura red dye, while non-LTRs were not stained to a noticeable extent (see Figure 4-1). In
the timeframe of the experiments (10 minutes), permeants were not found to pass through the
skin samples into the receiver compartment of the Franz diffusion cell. Therefore, the flux of
permeant in each of the LTR and non-LTR regions was sampled by simply removing that portion
of the skin using a spherical cutting tool (similar to a hole-puncher).[16] Two diameters were
utilized, 1 mm and 2.5 mm, depending on the area of the LTR being sampled. Non-LTRs were
only sampled utilizing the 2.5 mm - diameter cutting tool, because these regions comprised
larger areas of the skin surface. Note that this sampling method has been successfully utilized in
previous studies for the quantification of radio-labeled permeants within LTRs and non-
LTRs.[16] On each skin sample, it was typically possible to sample 2-5 LTR samples and 5-8
non-LTR samples (since the non-LTRs occupy larger areas on the skin), with a total of 8-10
samples typically taken from each piece of treated skin. The skin samples were then solubilized
using Soluene-350 (1.5 mL), and the amount of radio-labeled permeant was quantified using a
Tri-Carb Liquid Scintillation Counter (Perkin-Elmer), utilizing the scintillation cocktail Hionic-
Fluor (5 mL). This process was repeated for 4-5 skin samples for each chemical penetration
enhancer at each concentration tested. Untreated skin samples were contacted for 10 minutes
with a coupling solution which was identical to that used in the previous treatments, but in the
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absence of LFS. For untreated samples, the entire skin sample that contacted the solution (with
area of 1.77 cm 2) was used to quantify the amount of radio-labeled permeant in the skin. For the
larger samples, 5 mL of Soluene-350 and 15 mL of Hionic-Fluor were utilized in the analysis of
each sample. This process was repeated for 4-5 skin samples for each CPE considered at each
concentration tested. For all samples, the concentration of the CPE was normalized by the
surface area of that sample and by the application time (10 minutes = 600 s) in order to calculate
the average flux into the skin in that area for the duration of the experiment. Note that in all the
plots shown here, error bars correspond to 95% confidence intervals.
4.3. Theory
4.3.1 The Physical Picture
The basis of the physical mechanism underlying the synergism between LFS and CPEs is the
physical picture proposed in Chapter 2.[16] In this study, it was found that acoustic cavitation
microjets impinge on the skin primarily within LTRs, while acoustic streaming is the main
mechanism of increased permeant uptake within non-LTRs (see Figure 4-2). The presence of
acoustic cavitation microjets has a pronounced impact on the flux of permeants into the skin
within LTRs, as discussed next in Section 4.3.2.
4.3.2 Modeling the Flux of CPEs into the Skin
The synergism between LFS and CPEs, specifically surfactants, was previously shown to occur
due to increased penetration and dispersion of these molecules in the skin.[3] However, no
physical mechanism was proposed to explain how LFS induces greater penetration of surfactants
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pSkin
Figure 4-2. Illustration of the physical mechanisms occurring during LFS treatment of skin. The
top chamber of a Franz diffusion cell is shown in the illustration. Arrows represent an
enhancement in stirring induced by acoustic streaming, with microjet collapse occurring above
the LTR.
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and other CPEs into the skin. In this section, the physical picture presented in Figure 4-2 will be
utilized to model the fluxes of different types of CPEs into untreated skin samples and into the
non-LTRs and LTRs of LFS-treated skin samples. Through this analysis, the origin of the
synergism between LFS and CPEs will become apparent, including why amphiphilic CPEs (such
as OG or SLS) exhibit even greater synergism with LFS than non-amphiphilic CPEs (such as
PG).
4.3.2.1 The Flux of Permeants into Untreated Skin
Modeling the flux of CPEs into untreated skin is straightforward. In this case, permeant flux into
the skin, Jp,,,,,,,, is related directly to the bulk concentration of that species, Ch , by a diffusional
mass-transfer coefficient, k,. Note that it is assumed, throughout this report, that the aqueous
concentration just above the skin is much less than Cb , and therefore, the driving force for
diffusion is written as Ch rather than a concentration difference. Specifically,
ipassive= kmCb (4.1)
If the permeant is amphiphilic (e.g., SLS or OG), and able to self-assemble into micelles, Eq.
(4.1) needs to be modified to account for both monomeric and micellar species present in the
coupling medium solution, because monomers and micelles will have different mass-transfer
coefficients relating their fluxes into the skin to the corresponding bulk concentrations. Taking
both monomers (mon) and micelles (mic) into account results in the following expression for
Jpassve , for the case of amphiphilic permeants above their cmc (the surfactant concentration
beyond which micelles form):
ipassive = k,,non Ccc + k, ,mwnaggCni, (4.2)
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where kmon is the mass-transfer coefficient of the amphiphilic monomers, C,,,, is the critical
micelle concentration (cmc) of the surfactant, km,ic is the mass-transfer coefficient of a
monomer incorporated into a micelle, ngg is the aggregation number of the micelles, and Cmic
is the bulk concentration of micelles in solution.
We can then relate Cb,c to the experimentally controllable variable Cb through the following
relation:
Cbmc - cb Ccmc (4.3)
agg
Substituting Eq. (4.3) into Eq. (4.2) yields the following relation for the simultaneous flux of
monomeric and micellar species into the skin:
Jpassive =kmmi Cb + (km, mon - kmmic ) C,, (4.4)
4.3.2.2 The Flux of Permeants into the Non-LTRs of LFS-Treated Skin
As stated in Section 4.3.1, the flux of permeants into non-LTRs is enhanced solely by a decrease
in the bulk solution resistance due to an increase in stirring induced by acoustic streaming.
Therefore, the expressions for the fluxes of monomers and micelles into non-LTRs of LFS-
treated skin are similar to those in the untreated case, albeit with enhanced mass-transfer
coefficients. In particular, for both non-amphiphilic and amphiphilic permeants below their cmc
(where only monomers are present), the flux into the skin can be modeled as follows:
Anon-LTR nkACb (4.5)
where the prime indicates an enhanced mass-transfer coefficient.
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Similarly to the untreated case, above the cmc, when both monomers and micelles are present in
solution, the resulting equation relating the overall non-LTR flux to the bulk concentration is
given by:
kmri (4.6)Anon-LTR n'tich b (kn,tnon nk,tnic ) cnc '6
where the primes indicate enhanced mass-transfer coefficients.
4.3.2.3 The Flux of Permeants into the LTRs of LFS-Treated Skin
Modeling the flux of permeants into the LTRs of LFS-treated skin is not as straightforward as in
the untreated or non-LTR cases, because the impingement of acoustic cavitation microjets within
these regions must be accounted for, in addition to the convection-enhanced diffusional
contribution to the flux. First, let us consider the case of a non-amphiphilic (NA) permeant,
where adsorption of molecules onto the cavitation bubbles is not possible since they are not
surface active. In this case, the flux of permeant into the skin is dependent on two contributions:
(i) a convection-enhanced diffusional contribution, similar to that in the non-LTR case, and (ii) a
contribution related to the amount of bulk fluid "injected" into the skin as a result of each
acoustic cavitation microjet collapse at the skin surface. Specifically, the amount of permeant
delivered per microjet collapse is equivalent to the volume of bulk fluid transported into the skin
per cavitation microjet collapse on the skin surface (Vcav) multiplied by the bulk concentration of
that species (C,). Incorporating this contribution results in the following expression:
JLTR,NA bkC ±a cav Cb (7)
Diffusive Flux Convective Flux
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where the double-prime indicates that the diffusive mass-transfer coefficient (k,) may be
different from the diffusive mass-transfer coefficient (k' ) in the non-LTR case (see Eq. (4.5))
and hcav is the number of acoustic cavitation microjet collapses per LTR area per unit time.
Collecting terms, Eq. (4.7) can be simplified as follows:
JLTR,NA e ( k+cavVcav ) C, (8)
Equation (4.8) shows that the flux of non-amphiphilic species into the skin should be directly
proportional to the bulk concentration, C, , but to a much greater extent than in the untreated or
non-LTR cases (see Eqs. (4.1) and (4.5)).
4.3.2.4 The Flux of Amphiphilic Permeants into the LTRs of LFS-
Treated Skin below their CMC
In the case of the surface-active amphiphilic permeants, an additional contribution to the flux
must be accounted for-the amount of permeant that is adsorbed at the gas/water interface of the
cavitation bubbles (see Figure 4-3). Note that previous sonochemical studies have established
that there is an accumulation of surfactants at the gas/water interface of acoustic cavitation
bubbles. [17]
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Below CMC
Monomer
Above CMC
Micelle
Figure 4-3. Schematic illustration of amphiphilic monomers adsorbing to an acoustic cavitation
bubble. Note that only the monomers can adsorb to cavitation bubbles and, therefore, the
adsorbed monomer concentration is constant above the cmc.
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Cavitation Bubble
For the case of amphiphilic (A) permeants below their cmc, their flux within LTRs is modeled
by modifying Eq. (4.8) as follows:
JLTR,A b cav cav b+ ha aF (4.9)
Diffusive Flux (onvectve Flux Adsorptive Flux
where Acv is the average surface area of an acoustic cavitation bubble, and F is the equilibrium
concentration of surfactant species adsorbed at the cavitation bubble interface. The justification
for the assumption that F is reaching equilibrium will be discussed in Section 4.4.3.1.
To find an expression for F, it is assumed that only monomers can adsorb to, and desorb from,
the gas/water interface (see Figure 4-4). In addition, because the quantity of permeant
transported onto the cavitation bubbles and into the skin is small relative to the total permeant
concentration in solution, the concentration of monomers and micelles in solution may be
assumed to be constant. As a result, the equilibrium between monomers and micelles will be
assumed to remain unperturbed at concentrations above the cmc (see Section 4.4.3.1). For
simplicity, the dependence of F on Cb will be modeled by utilizing Henry's adsorption
isotherm, which is valid for dilute surface concentrations and has been previously used to model
SLS adsorption at an air/water interface.[18, 19] This gives us the expression:
F = KHCb (4.10)
where KH is the Henry equilibrium adsorption constant for a given amphiphilic permeant, and is
defined as KH = KLFo , where KL is the equilibrium adsorption coefficient of the amphiphile
(defined as the ratio of the rate of amphiphile adsorption to the rate of amphiphile desorption,
ka /kd , see Figure 4-4), and F. is the maximum surface concentration of the amphiphile. The
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k ka d
C
Cb ,mic
b,mon
Figure 4-4. Surfactant adsorption model utilized. Only monomers can adsorb to, and desorb
from, the gas/water cavitation bubble interface. Monomers and micelles are assumed to be at
equilibrium.
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specific values of KL and F. are not important in the context of this discussion and, therefore,
the lumped K, parameter will be utilized throughout the paper.
Substituting Eq. (4.10) into Eq. (4.9), the flux of the amphiphilic permeant into LTRs, below the
cmc, is modeled as follows:
u, ,A = kC + n7cayveCb + n ,ca AcaK H b
Diffusive Flux Convective Flux Adsorptive Flux
(4.11)
Collecting terms, Eq. (4.11)) can be simplified as follows:
JLR,A = [km + ca (Vcav +AcavKH)]Cb (4.12)
Equation (4.12) indicates that the flux of amphiphilic permeants into LTRs, below their cmc,
should be even greater than that of non-amphiphilic permeants (see Eq. (4.8)).
4.3.2.5 The Flux of Amphiphilic Permeants into the LTRs of LFS-
Treated Skin Above their CMC
Because micelles cannot directly adsorb to the gas/water interface of cavitation bubbles, the
model must be modified above the cmc to account for the presence of both monomers and
micelles. Using Eq. (4.6) to model the diffusive flux above the cmc and now holding the
concentration of monomers constant at the cmc, one obtains:
(4.13)Smmic b +( kN + hlcaVcav Cb + haAc KH CcLTR,A ,mnic b m,non rn,ic cmc cavca cayH ,cm
Diffusive Flux Convective Flux Adsorptive Flux
where the double-prime indicates that kri and kmnon may be different from k'mic and km
for the flux into the non-LTRs.
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Collecting terms, Eq. (4.13) can be simplified as follows:
ILTR,A n,mon kiic )+ hcav AKH] Ccmc + (k mtc cav cav)Cb
Note that the slope of the JLTRA vS. Cb curve is equal to that corresponding to a non-amphiphilic
species in Eq. (4.8). This result will be analyzed further in Section 4.4.3.2.
4.3.2.6 Summary of Expected Trends in the Flux Data
As shown in Sections 4.3.2.1 - 4.3.2.2, the flux of both amphiphilic and non-amphiphilic species
into untreated skin and the non-LTRs of LFS-treated skin should follow similar trends (see
Section 4.4.1). However, due to the enhanced stirring induced by acoustic streaming, the flux
into the non-LTRs should be increased relative to that into untreated skin (compare Eqs. (4.1)
and (4.4) to Eqs. (4.5) and (4.6)). This suggests that the slope observed for the flux vs. bulk
concentration curve should be greater in the non-LTR case than in the case of untreated skin.
Within LTRs, the expected flux of non-amphiphilic permeants should be dominated by a
convective term associated with the collapse of acoustic cavitation microjets (see Section 4.4.2).
Furthermore, for amphiphilic permeants below their cmc (amphiphilic monomers), the flux into
the LTRs is expected to be further enhanced due to the adsorption of the amphiphiles onto the
surface of cavitation bubbles (see Section 4.4.3). However, above the cmc of amphiphilic
permeants, the slope of the flux vs. bulk concentration curve should revert to a value which is
similar to that of a non-amphiphilic molecule because micelles are not able to adsorb at the
surface of cavitation bubbles (see Eqs. (4.8) and (4.14)).
It is therefore hypothesized that the origin of the increase in the penetration of CPEs into the skin
induced by LFS, and consequently their synergism, results from the cavitation-related convective
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and adsorptive contributions to the flux. Specifically, the flux into the LTRs of any permeant
that acts as a CPE will be enhanced by the convective flux contribution. In addition, the flux of
amphiphilic permeants (e.g., surfactants) will be enhanced even further due to their ability to
adsorb at the surface of acoustic cavitation bubbles, thereby generating an even greater flux into
the skin. The concepts of convective and adsorptive fluxes will be tested in Section 4.4 by
utilizing a non-amphiphilic CPE, propylene glycol (PG), and two amphiphilic CPEs, sodium
lauryl sulfate (SLS, an anionic surfactant) and octyl glucoside (OG, a nonionic surfactant). The
simplifications and assumptions made in the derivation of the flux model presented in Section
4.3 will be analyzed and justified in Section 4.4.3.1.
4.4 Results and Discussion
To test the flux model presented in Section 4.3, the fluxes of three CPEs into the skin were
investigated, in both LFS-treated and untreated skin. LFS-treated skin samples consisted of both
LTRs and non-LTRs (see Figure 4-1), and each of the regions were sampled as discussed in
Section 4.2.4. The first CPE tested was PG, a non-amphiphilic, low-molecular weight (MW =
76 Da) molecule that is completely miscible in water. The other two CPEs, SLS and OG, are
both amphiphilic molecules. Specifically, SLS is an anionic surfactant (MW = 288 Da), whose
micelles have an aggregation number of ~60,[20] indicating that SLS micelles have a molecular
weight of about 17 kDa. OG is a nonionic surfactant (MW = 292 Da), whose micelles have an
aggregation number of -90,[21] indicating that OG micelles have a molecular weight of about 26
kDa.
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4.4.1 Flux of Permeants into Untreated Skin and the Non-LTRs of LFS-
Treated Skin
As discussed in Section 4.3.2.1, the flux of any given monomeric permeant into untreated skin is
expected to be directly proportional to the bulk permeant concentration in solution, as related by
a mass-transfer coefficient, k,, , which is specific to that permeant (see Eq. (4.1)). If micelles are
present in solution, both amphiphiles in monomeric and micellar states are expected to have
different mass-transfer coefficients (k,,,,n and km,,, respectively), with the amphiphilic
molecules present within micelles expected to have decreased mobility relative to the monomers
(that is, kmmon > km,c ). The fluxes of monomeric and micellar permeants into the non-LTRs of
LFS-treated skin samples are expected to follow the same trend as in untreated skin, but with
enhanced mass-transfer coefficients (k'mo, and k',,,c, respectively), as a result of the decreased
bulk resistance due to enhanced stirring caused by acoustic streaming (see Section 4.3.1). The
flux of PG, OG, and SLS into untreated skin and the non-LTRs of LFS-treated skin are shown in
Figures 4-5, 4-6, and 4-7, with the corresponding mass-transfer coefficients calculated from
these plots summarized in Table 4-1. Recall that for the amphiphilic permeants (OG and SLS),
the slope below the cmc is equivalent to k,,11  for the untreated skin samples and to k'mo, for
the non-LTR samples. Similarly, the slope above the cmc is equivalent to kmmic for the untreated
skin samples and to k'mic for the non-LTR samples. In the analysis of the data, the y-intercept
of the linear regressions for the non-amphiphilic permeant (PG), as well as for the amphiphilic
permeants (OG and SLS) below their cmc, were forced to zero, because a non-zero y-intercept
has no physical meaning in the context of the flux model. The cmc's of OG and SLS were found
experimentally to be 18 mM and 7.7 mM, respectively, utilizing surface tension
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Figure 4-5. Flux of PG into untreated skin and the non-LTRs of LFS-treated skin as a function
of PG concentration in bulk solution. The corresponding mass-transfer coefficients derived from
the slopes of this data are reported in Table 4-1.
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Figure 4-6. Flux of OG into untreated skin and the non-LTRs of LFS-treated skin as a function
of OG concentration in bulk solution. The corresponding mass-transfer coefficients derived from
the slopes of this data are reported in Table 4-1.
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Figure 4-7. Flux of SLS into untreated skin and the non-LTRs of LFS-treated skin as a function
of SLS concentration in bulk solution. The corresponding mass-transfer coefficients derived
from the slopes of this data are reported in Table 4-1.
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Table 4-1. Mass-transfer coefficients of PG, OG, and SLS into untreated skin and the non-LTRs
of LFS-treated skin. Values were calculated from the slopes of the linear regressions shown in
Figure 4-7, with the corresponding r2 values calculated based on the mean flux value at each
concentration reported.
Untreated Skin Non-LTRs
CPE kmmon r 2 k,, ny r 2 k',non r 2 k'nMin r 2
PG 2.7-10-9 m/s 0.95 no cmc 4.6.10-8 m/s 0.93 no cmc
OG 6.5 -10-9 m/s 0.93 2.8-10-9 m/s 0.80 6.0.10-8 m/s 0.87 3.2-10-" m/s 0.96
SLS 6.3-10-8 m/s 0.90 1.7. 10-8 m/s 0.93 2.2-10- 7 m/s 0.97 6.0 -10-8 m/s 0.82
248
measurements (see Section 4.2.2). Note that there is good agreement between the break in the
flux curves shown in Figures 4-6 and 4-7 and the experimentally deduced cmc values, as is
expected within the formulated flux model.
Figures 4-5 to 4-7, as well as Table 4-1, show that the untreated skin and non-LTR data follow
the trends predicted in Sections 4.3.2.1 and 4.3.2.2, respectively. In other words, for each
permeant considered, the flux vs. bulk concentration curves follow similar trends in both the
untreated and non-LTR skin samples, with an enhancement observed in the non-LTR samples
relative to the untreated samples. In the case of the nonionic permeants, the mass transfer
coefficients increase by approximately one order-of-magnitude for both PG and OG monomers,
as well as for the OG micelles, in the non-LTR samples relative to the untreated skin samples
(see Table 4-1). For SLS monomers and micelles, the increase in the mass-transfer coefficients
between the non-LTR samples and the untreated skin samples is about 4-fold in each case (see
Table 4-1). The increase in the flux of SLS in the non-LTRs relative to the untreated skin
samples is less than in the case of the nonionic species because: (i) both the skin and SLS are
negatively charged, and therefore, partitioning of the ionic molecules into the skin may be a
limiting factor, and (ii) kmon and kmn, are larger for SLS than for PG and OG (see Table 4-1),
and, as a result, there may be less inherent bulk resistance to SLS flux into the skin, which would
result in acoustic streaming having a less significant role in increasing the mass-transfer
coefficients of SLS into the non-LTRs of LFS-treated skin.
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4.4.2 Flux of Non-Amphiphilic Permeants into the LTRs of LFS-Treated
Skin
As shown in Section 4.3.2.3, the flux into the LTRs of LFS-treated skin depends on the amount
of material delivered into the skin due to the impingement of microjets in these regions (as
reflected in hcav - v,), in addition to a less significant diffusive flux term (k. ). This cavitation-
related contribution is effectively a convective flux, and therefore may be expressed as follows:
JV -Cb (4.15)
where V is an effective convective velocity associated with the impingement of microjets and is
equivalent to ncv -Vcav in terms of the variables defined previously. Therefore, regardless of the
size of the permeant being delivered, this convective flux contribution should be constant as long
as the cavitation field remains constant (i.e., hcav and Vcav do not change) and there is no
additional flux associated with the adsorption of molecules to the cavitation bubbles (as is the
case for amphiphilic permeants).
The flux of PG into the LTRs of LFS-treated skin as a function of PG bulk concentration is
presented in Figure 4-8. Figure 4-8 shows that as predicted by the flux model for this non-
amphiphilic molecule, the data is linear (see Eq. (4.12)), but with a much larger flux than in the
case of the non-LTRs (see Eq. (4.5)). Because the LTRs and the non-LTRs were sampled from
the same pieces of skin (both LTRs and non-LTRs are present on LFS-treated skin samples, see
Figure 4-1), the importance of the convective contribution relative to that of the diffusive
contribution can be gauged by assuming k,, ~ k ,PG. Making this assumption, it follows that
the slope in Figure 4-8, 5.1 -10- m/s (see Table 4-2), is over an order-of-magnitude greater than
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Figure 4-8. Flux of PG into the LTRs of LFS-treated skin as a function of PG concentration in
the LFS coupling solution.
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kmp( (4.6'10-8 rn/s, see Table 4-1). Accordingly, to leading order, the flux of PG into the LTRs
of LFS-treated skin is proportional to the convective contribution. Therefore, to a good
approximation, it can be assumed that the diffusive contribution to the flux is negligible in the
LTRs (see Eq. (4.7)), and that the flux of non-amphiphilic permeants into the LTRs is given by:
JLTR,NA cay cav b - b (4.16)
Furthermore, in the context of the flux model, it is important to recognize that the flux of
amphiphilic permeants into the LTRs of LFS-treated skin, above their cmc, exhibits the same
dependence on the permeant bulk concentration as do non-amphiphilic permeants Accordingly,
Eq. (4.16) will become useful in analyzing the OG and SLS data at concentrations above the cmc
for each permeant, and in supporting the flux model (see Section 4.4.3.2).
4.4.3 Flux of Amphiphilic Permeants into the LTRs of LFS-Treated Skin
As discussed in Section 4.3, in addition to the convective contribution to the flux, which is
significant within the LTRs of LFS-treated skin, an adsorptive contribution to the flux must also
be included to model the flux of amphiphilic species within LTRs. This is due to the fact that
amphiphiles can adsorb to the surface of cavitation bubbles and be transported into the skin, in
addition to being delivered into the skin due to convection induced by the impingement of
acoustic cavitation microjets.
4.4.3.1 Assumptions of the Model
In order to estimate the concentration of adsorbed amphiphiles in the context of the flux model,
the following simplifying assumptions are implemented.
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1. The concentrations of bulk monomers, Cbmon, and bulk micelles, C,,,,,, are constant in
the LFS coupling solution, and therefore, equilibrium between these two species is
maintained throughout the LFS treatment.
- In order to test this assumption, the amount of permeant transported into the skin
was compared to the total amount of permeant in the LFS coupling solution. Typically,
the total surface coverage of LTRs is 5-20% and that of non-LTRs is 80-95%. Because
more permeant enters LTRs than non-LTRs, assuming that 20% of the skin samples
contain LTRs should provide an high-end estimate. Multiplying the LTR fluxes found in
Figures 4-8 to 4-10 and the non-LTR fluxes found in Figures 4-5 to 4-7 by the treatment
time (600 s) and the skin surface area of each region (with a total area of 177 mm 2), it is
found that for both OG and SLS, the upper threshold for the amount of permeant
transported into the skin is <1% of that in bulk solution, thereby validating assumption 1.
2. The cavitation bubbles are at adsorption equilibrium when collapsing at the skin surface.
- In order to test this assumption, one must compare the lifetime of an average
cavitation bubble with the time scale associated with monomer adsorption onto a
cavitation bubble. The average velocity of cavitation bubbles at 20 kHz, generated using
equipment which is similar to the one utilized in the present study, was reported to be
1.007 m/s.[22] In these experiments, the ultrasound horn is positioned 3 mm from the
skin surface. Therefore, taking the characteristic length scale to be of order 1 mm, it is
found that the average bubble lifetime is on the order of 1 ms. In the context of Henry's
adsorption isotherm used in this analysis, the relevant adsorption parameters could only
be found for SLS. Specifically, taking into account the characteristic length scale of SLS
adsorption (the distance an SLS molecule must travel in the bulk solution to adsorb to the
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gas/water interface) , which is reported to be of the order 1.10-'m,[18] and the rate of
SLS adsorption (ka), which was reported to range between 5.5- 10- -3 m/s below the
cmc,[19] the timescale for adsorption of SLS onto the cavitation bubbles is estimated to
be ~0.03-180 pts, which is significantly faster than 1 ms. It then follows that the
equilibrium assumption (assumption 2) is valid, since the timescale for adsorption is
much faster than the average lifetime of a bubble.
3. As stated in Section 4.3, the derivation of the flux model assumes that the cavitation field
parameters, nca v , and Ac, do not vary significantly during these experiments. In
this respect, sonochemical research has shown that there is not much dependence of
sonoluminescense and other indicators of the cavitation field on CPE concentration at
low frequencies (e.g., 20 kHz).[23] For example, the presence of methacrylic acid (a
small organic compound that is soluble in both water and organic solvents), at
concentrations up to 65 mM, was shown to only decrease sonoluminescense on the order
of 10% at 20 kHz. Moreover, surface tension effects have also been shown to not greatly
affect indicators of the cavitation field, such as sonoluminescence.[24] It is also noted
that above the cmc of each amphiphile, the surface tension should not change greatly and,
therefore, only electrostatic effects may cause changes in the cavitation field parameters
for the majority of concentrations tested in this study (see Section 1.4.2.1). Therefore, at
the operating frequency used in the present study (20 kHz), assumption 3 is assumed to
be reasonable, and is required for the direct analysis of the data presented in the following
sections. Potential violations of this assumption that lead to deviations from the described
flux model will be analyzed in Section 4.4.3.4.
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4.4.3.2 Fluxes of OG and SLS into the LTRs of LFS-Treated Skin
As discussed in Section 4.3.2.3, the flux of amphiphilic permeants into LTRs, below their cmc,
should be larger than that of non-amphiphilic permeants, because of the additional contribution
of the surface adsorptive flux (see Eq. (4.11)). As the amphiphilic permeant concentration
increases beyond its cmc, the slope of the flux vs. bulk concentration curve should revert to that
expected for a non-amphiphilic permeant, as shown in Eq. (4.16), because micelles cannot
adsorb onto the surface of cavitation bubbles.
Figures 4-9 and 4-10 show that the fluxes of both OG and SLS, below their cmc's, are greater
than the flux of PG (compare the data points to the dashed lines in Figures 4-9 and 4-10). This
follows from the flux model (compare Eqs. (4.9) and (4.7)) because the flux of amphiphilic
permeants into the skin over this concentration range depends on both the adsorptive flux and the
convective flux. By comparing the slopes of the OG and SLS data to the slope of the PG data
(see Table 4-2), it follows that the adsorptive flux accounts for 30% of the OG flux into the skin
and 73% of the SLS flux into the skin below the cme for each amphiphile. In the context of the
flux model, the difference in the slopes of the OG and SLS data below the cmc of each
amphiphile reflects the different KH values associated with each amphiphile (see Eq. (4.12)).
Further discussion about the kinetic adsorption parameters of OG and SLS is presented in
Section 4.4.3.3.
However, as predicted by the flux model (see Eq. (4.16)), the slopes above the cmc's of both OG
and SLS are nearly identical to that of the PG data (within 10% error, see Table 4-2). This
indicates that both small molecules, such as OG (MW = 76 Da), and large micellar aggregates
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Figure 4-9. Flux of OG into the LTRs of LFS-treated skin as a function of OG concentration in
the LFS coupling solution. The dashed line corresponds to the flux of PG, and is included for
comparison purposes.
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Figure 4-10. Flux of SLS into the LTRs of LFS-treated skin as a function of SLS concentration
in the LFS coupling solution. The dashed line corresponds to the flux of PG, and is included for
comparison purposes.
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Table 4-2. Slopes of the permeant flux vs. bulk coupling medium concentration curves, both
below and above the cmc of the tested CPEs. The corresponding r 2 values were calculated based
on the mean flux value at each concentration.
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ha (Vca + AaKvH C) fcav *Cav
Species (slope below cmc) (slope above cme)
value r2 value r2
PG no cmc 5.1.10-7 m/s 0.94
OG 7.3 10-7 m/s 0.95 4.7 -10-7 m/s 0.97
SLS 1.9.10~6 m/s 0.95 4.6. 10-7 m/s 0.99
(from 8-50 mM)
(MW = 17-26 kDa) are transported into the skin at nearly the same rate! This result is indicative
of convective transport (see Eq. (4.15)), which in this case results from the collapse of acoustic
cavitation microjets, and fits the expected trends of the flux model. It is important to stress that,
for the SLS data presented in Figure 4-10, the flux model no longer fits the data at and above a
threshold SLS concentration of 65 mM, since the data falls below the predicted trend line.
Because the flux model still holds at similar concentrations of the nonionic amphiphile OG (see
Figure 4-9), it is likely that electrostatic effects may be the cause of the observed deviation from
the flux model above a threshold concentration for the charged, anionic SLS amphiphile. Further
analysis and discussion of this deviation is presented in Section 4.4.3.4.
4.4.3.3 Analysis of Kinetic and Cavitation-Related Variables Deduced
from the Flux Model
Equation (4.13) derived in Section 4.3.2.3 to model the flux of permeants into the LTRs of LFS-
treated skin contains four variables, ncav, Vcav, Aav , and K., of which the species-specific KH
variable is only relevant for amphiphilic permeants. Therefore, given that there are a total offive
unknown variables (including KH for OG and SLS) and there are a total of three equations
relating them (those corresponding to PG, OG, and SLS), two variables must be accurately
estimated in order to be able to fully define the system. This analysis is critical in determining
whether the quantitative values derived from the flux model are realistic, and therefore in further
substantiating the flux model.
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A logical starting point in this analysis involves estimating the two variables that depend on the
size of the cavitation bubbles, Vca and A,.. Specifically, v,av is the volume of bulk fluid
delivered into the skin by each collapsing cavitation bubble, and Av is the average surface area
of a cavitation bubble. Therefore, Vcav and A,, will first be related to the average cavitation
bubble radius to eliminate one unknown. First, the dependence of Vcav on the average size of a
cavitation bubble before it collapses onto the skin will be analyzed. To leading order, the
simplest scenario assumes that the amount of volume that a cavitation bubble delivers into the
skin is directly proportional to the volume of fluid that it displaces in solution. In other words,
for a spherical cavitation bubble Vcav and Rcav are simply related as follows:
4
va = -;Ra (4.17)
3
where Rcav is the average radius of a cavitation bubble prior to its collapse on the skin surface.
Similarly, the average surface area of a cavitation bubble is related to Rcav as follows:
Ac = 4rR (4.18)
av cay
Equations (4.17) and (4.18) allow us to express Vcav and Aav in terms of the single variable,
Rcav. Therefore, if Rcav can be estimated, the three equations corresponding to the fluxes of PG,
OG, and SLS into LTRs can be solved explicitly. Interestingly, a previous study conducted using
similar equipment to the one used here, at 20 kHz, found that the number average diameter of
cavitation bubbles is 6.3 tm, corresponding to a number average radius of 3.15 tm.[22] Using
this Rcav value in Eq. (4.17), it is found that:
4 43
Vcav =-747R 3 , = -r(3.15.10~ 6m) = 1.3110 -16 m 3  (4.19)3 3
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Utilizing the PG data, vca from Eq. (4.19) can be substituted in Eq. (4.16), utilizing the slope of
the PG curve reported in Table 4-2, to solve for hcav as follows:
JLTR,NA
Cb PG slope hcav *Vav 5.1 -10- m/ s 9  microjets
cay v cav cav -163 mcrojets= 3.910 2 s
(20)
Our group has previously reported that typical LTR areas formed at 20 kHz during a 10 minute
treatment at an US intensity of 7.5 W/cm2 are 10 - 40 mm 2 (for a sample having a total area of
177 mm 2 , such as the one considered here).[9] Accordingly, the data suggests there are on the
order of 107 cavitation bubble collapses into LTRs during a typical 10-minute ultrasound
treatment at the conditions examined here.
Next, the remaining two unknown variables are considered, KH,OG and KH,SLS, the equilibrium
adsorption coefficients for OG and SLS, respectively. Substituting the slopes of the OG and SLS
curves below their cmc (see Table 4-2), in addition to Ac,, from Eq. (4.18) and the values of Vcav
and hcav calculated in Eqs. (4.19) and (4.20), respectively, in the expression for the expected
slope for amphiphilic permeants below the cmc, hcav (Vcav+ Acv K,), yields:
For OG:
For SLS:
7.3.10-7 M/s =3.9 109 microjets [1.3.10-1m 3 +4r(3.15-10-6) 2 -KHG
1.9.10-6rm/s =3.9-10, microjets 1.3 10 16M3 4c (3 .1 0-6M)2K
(4.21)
(4.22)
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Solving Eqs. (4.21) and (4.22) results in values of KHOG = 4.6 -10-7 m and KH,SLS = 2.9 .10 6m.
Because OG has not been studied as widely as SLS, typical KHOG values for the adsorption of
OG onto a static, planar air/water interface could not be found in the literature. Therefore, to
verify that this data is reasonable, the KHSLS values deduced from the experiments will be
compared to reported literature values of the equilibrium SLS adsorption rate to a static, planar
air/water interface, K xpLS. Typical values for KPL are reported to be between
1.1-1.5-10- 6m .[18] Therefore, it is found that the KHSLS value deduced from the experimental
data is slightly larger than the previously reported values corresponding to adsorption to a
stagnant, planar interface. Recognizing that the calculation of KHSLS made use of several
assumptions, the estimated value of KHSLS= 2.9 .1-6 m is generally consistent with the reported
literature values. For example, if the average cavitation bubble radius was one half of the values
assumed here (3.15 ptm), that is if Rcav =1.6 gm, then the estimated KH,SLS value would be
1.5 .10-6 m and fully consistent with the range of K eSL values reported in the literature. In fact,
it is reasonable that the cavitation bubbles present in the system may be smaller than those
previously reported in [22] because the distance from the ultrasound transducer at which the
reported bubble diameters were measured was 30 mm. On the other hand, in these experiments,
the distance between the ultrasound transducer and the skin surface is only 3 mm. Accordingly,
cavitation bubbles in the system have less time to grow by rectified diffusion and should possess
smaller radii. Moreover, the fact that the KH,SLS value found here is in general agreement with
the K7'xS literature values is also consistent with the reported observation that the kinetics of
SLS adsorption onto an air/water interface is adsorption-rate limited and not diffusion-rate
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limited.[19] Therefore, the convective processes associated with the applied ultrasound field
should not have a significant effect on the adsorption of SLS monomers onto the cavitation
bubble surface.
4.4.3.4 Deviation of the Experimental Data from the Flux Model beyond
a Threshold Concentration in the Case of Charged Amphiphiles (SLS)
As discussed in Section 4.4.3.2, for the charged, anionic amphiphile SLS, the expected LTR flux
data deviates from that predicted by the flux model (at concentrations at and above 65 mM, see
Figure 4-10). Because the observed deviation from the expected flux model prediction is only
observed for the case of the ionic SLS, electrostatic effects are the probable cause for this
deviation. In order to further rationalize the observed deviation, the assumptions in the flux
model that may change due to electrostatic effects must be identified. Examination of Eq. (4.14)
reveals that hcav and Vcav are the only variables related to the cavitation field that appears in the
slope of the flux equation for amphiphilic permeants above their cmc. It is important to stress,
before proceeding any further, that in nearly all ultrasound experimental treatment protocols,
including clinical uses of this technology,[25] the concentration of SLS used is 1 wt% (35 mM)
or lower. Therefore, operating in the SLS concentration region where deviation from the
expected flux model prediction is observed (>65 mM) is not typical.
Previous sonochemical studies have investigated the effect of amphiphiles, including SLS, on the
activity and properties of acoustic cavitation bubbles.[23, 24, 26, 27] Some of these studies have
even compared the effect of ionic and nonionic amphiphiles, revealing the importance of
electrostatic effects.[26] Specifically, at low ionic concentrations (1-2 mM), without added salt,
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charging the surface of a cavitation bubble with ionic amphiphiles can produce stabilization and
repulsive effects between bubbles. This phenomenon was likely not observed in the experiments
because experiments were only conducted at one data point in this range (1 mM). However, the
presence of an electrolyte (either in the form of an added ionic amphiphile or through the
addition of other salts) can result in electrostatic screening which can have the inverse effect.
This phenomenon has been studied with SLS at 1 mM.[24] Specifically, it was found that with 1
mM SLS in water (Debye screening length ~ 10 nm, see Figure 4-11), electrostatic repulsions
between negatively-charged cavitation bubbles were able to inhibit bubble coalescence.
However, when 100 mM sodium chloride was added to the SLS solution, decreasing the Debye
screening length to ~1 nm, the secondary Bjerknes (attractive) force was found to dominate.
Therefore, the authors concluded that at high ionic concentrations, Bjerknes (attractive) forces
dominate, which may allow for bubble coalescence to take place.[24] In this system, no salt is
added. Therefore, the only mechanism leading to a decrease in the Debye screening length, and
an associated shift in bubble coalescence, is the addition of more negatively-charged SLS to the
coupling solution. The Debye screening length, r- 1 , is defined as follows: [8]
[2 12
zn (4.24)
where eo is the electronic charge (1.6-10- 19C), s=cos, is the dielectric permittivity of the
medium (eo=8.85-10-12 C for water, Er=78.54), kB is the Boltzmann constant
J-m
(1.38 .10-23 J/K), T is the absolute temperature, z, is the valence of species i, n,( is the bulk
concentration of species i, and i indicates that the summation is over all ionic species. Note that
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Figure 4-11. Debye screening length as a function of SLS concentration, assuming complete
dissociation. The dashed, horizontal line corresponds to a value of 1 nm.
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K iS a property of the solution and is independent of the properties of the cavitation bubbles
present in the solution.
Assuming complete dissociation of SLS, Figure 4-11 shows the dependence of K-1 on bulk SLS
concentration. Figure 4-11 shows that a value of K 1 =1 nm is only approached at bulk SLS
concentrations which are equal to or exceed 65 mM, corresponding to the threshold SLS
concentration beyond which the flux model prediction begins to deviate from the experimental
flux data (see Figure 4-10). Therefore, it is plausible that the cavitation-related parameters, ncav
and VcaI which were assumed to be constant in the flux model may begin to change at SLS
concentrations above this threshold due to increased bubble coalescence. One possible
explanation could be that increased coalescence of cavitation bubbles in the bulk solution may
lead to instability and collapse of the cavitation bubbles prior to reaching the skin surface. In
that case, the efficiency of bubble transfer to the skin surface may be decreased, thereby
decreasing the number of cavitation bubbles collapsing at the skin surface. Such a process would
result in a decrease in the flux of SLS into the skin (lower hcav), as reflected in the flux data
beyond concentrations of 65 mM (see Figure 4-10).
4.5 Conclusions
In this study, a physical mechanism that explains how LFS increases the transdermal uptake of
CPEs is presented. Specifically, the findings suggest that the origin of the observed synergism
between LFS and CPEs is the ability of LFS to increase the penetration and dispersion of CPEs
by direct deposition of permeants into the LTRs of LFS-treated skin through the collapse of
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acoustic cavitation microjets. Moreover, amphiphilic permeants exhibit even greater synergism
with LFS than non-amphiphilic permeants because their flux into the skin is further enhanced by
the adsorption of amphiphilic monomers to the surface of the cavitation bubbles. Therefore, in
addition to a convective flux induced by the collapse of acoustic cavitation microjets that drives
all CPEs, amphiphilic CPEs adsorbed to cavitation bubbles are also directly deposited into the
skin. More modest increases in the uptake of CPEs into the non-LTRs of LFS-treated skin,
relative to untreated skin, were also observed (as predicted recently[16]) and are consistent with
the prediction of the flux model.
The elucidation of the mechanism of deposition of amphiphilic CPEs into LFS-treated skin may
help to explain other interesting phenomena reported in the literature. For example, in some
cases, extreme synergism or antagonism in skin permeability enhancement has been reported
between LFS and binary mixtures of surfactants.[4] In the context of the findings here,
synergism in these cases may be due to more efficient adsorption or packing of multiple
surfactants on the surface of cavitation bubbles, while antagonism may be a result of decreased
adsorption onto cavitation bubbles. Moreover, these trends may depend on the monomer
concentration of each amphiphile in solution, since it was shown that only monomers can adsorb
to the surface of cavitation bubbles. Therefore, a dramatic decrease in the cmc of binary
surfactant mixtures may lead to antagonism between the surfactants comprising the mixtures,
while an increase in the cmc may explain an even stronger synergism with LFS. Accordingly, an
exciting area of future research may involve testing the flux of binary surfactant mixtures into
the LTRs of LFS-treated skin. Additional areas of experimentation that may also be of interest
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include further testing of charged surfactants, including cationic or zwitterionic surfactants, to
further confirm the trends observed here with SLS (anionic) and OG (nonionic).
In Chapter 5, the mechanistic investigation into the synergism between LFS and CPEs presented
in this chapter will be utilized to study this synergism from a different perspective. Specifically,
the next chapter will discuss the effect of LFS/CPE synergism in terms of its effect on skin
structural perturbation, including how the addition of a CPE to the LFS coupling medium
induces changes in structural parameters associated with the skin.
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Chapter 5
Application of the Aqueous Porous Pathway Model
to Quantify the Effect of Sodium Lauryl Sulfate on
Ultrasound-Induced Skin Structural Perturbation
5.1 Introduction
The study presented in Chapter 4 provides a better understanding of the mechanisms by which
low-frequency ultrasound exhibits synergism with both amphiphilic and non-amphiphilic
chemical penetration enhancers. Specifically, it was demonstrated that transient cavitation
microjets collapsing on the skin surface are responsible for the observed large synergistic effect.
However, the effect of these collapsing microjets on the skin structure is not fully understood. In
this chapter, I expand upon the mechanistic insight gained in the previous chapter by studying
the synergistic effect between low-frequency ultrasound and sodium lauryl sulfate (SLS) from
the perspective of its effect on the skin structure.
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Enhancement of skin permeability by the application of ultrasound is referred to as sonophoresis.
Although the use of ultrasound for transdermal delivery of therapeutics dates back to the 1950s,
extensive research in this area has only taken place in the past two decades.[1, 2] In the early
years of sonophoresis research, therapeutic frequencies, ranging from 1-3 MHz, were most
common.[3-5] However, a significant shift in the methodology and understanding of
sonophoresis took place once the switch was made to low-frequency sonophoresis (LFS,
utilizing frequencies in the range of 20 - 100 kHz), because it was possible to achieve even
greater skin permeability enhancements compared to therapeutic frequencies.[6] Following this
shift, research on the mechanisms of LFS showed conclusively that cavitation above the skin, in
the aqueous coupling medium, is the primary mechanism of enhancement.[7, 8] Much of this
initial mechanistic research involving LFS was done utilizing pure aqueous media, containing no
chemical enhancers in the coupling solution.[6-9] However, another breakthrough in the field
occurred when it was shown that combining LFS with a chemical enhancer, specifically a
surfactant such as SLS, caused a synergistic effect, resulting in orders-of-magnitude
improvements in skin permeability enhancement over the application of LFS alone.[10-14]
Since that time, the synergistic effect between chemical enhancers (mainly SLS) and LFS has
been well documented,[2, 10-12, 15] although the precise physical mechanisms responsible for
the observed synergism are still not well understood. Nearly all previous studies on LFS/SLS
synergism have focused primarily on the effect of a simultaneous SLS and LFS treatment in
order to increase skin permeability to different solutes. Although the extent to which LFS/SLS
enhances skin permeability, relative to LFS alone, is generally well understood, very little is
known about how these synergistic enhancers affect the skin structure itself. To date, only a
small number of publications have commented on the structural changes in skin treated with
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LFS/SLS and LFS.[16-18] These studies provided useful microscopy-based insight into the
structural changes that occur when LFS/SLS and LFS are applied to skin. In the present study,
the aqueous porous pathway model (APPM) is implemented to probe changes in skin structural
parameters and to draw quantitative conclusions about the role of SLS in inducing skin
perturbation.
With the above in mind, it is clear that a quantitative study investigating the effect of LFS/SLS
on skin structural parameters, compared to that of LFS alone, would provide significant insight
on how adding SLS to the LFS coupling medium affects skin perturbation. Furthermore,
because LFS/SLS combines both physical and chemical enhancement mechanisms, while LFS
acts solely in a physical manner, it is likely that the mechanical properties of the skin model used
may also play an important role in determining the extent of skin perturbation. [9, 19, 20]
Specifically, pig full-thickness skin (FTS), which possesses a full dermal backing, may impart
increased mechanical support to the skin in response to the physical perturbation induced by
LFS, relative to pig split-thickness skin (STS, dermatomed to 700 gm thickness). In fact, Seto et
al. have recently shown that when treating skin with LFS/SLS at 20 kHz, the thickness of the
skin plays a significant role in determining the extent of skin perturbation in human skin models
(250 pm STS, 700 ptm STS, and FTS), while in pig skin models, skin thickness does not play a
significant role (700 tm STS and FTS).[19] Moreover, the difference in LFS/SLS treatment
times for pig and human 700 pm STS reported by Seto et al. led the authors to propose that
intrinsic skin differences (e.g., dermal elastic fiber content) may explain the observed
differences. In this study, I utilize an approach similar to the one used by Seto et al. to gauge
overall skin perturbation. Specifically, APPM is utilized to calculate two skin structural
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parameters: (i) log C, which is related to the average radius of the aqueous skin pores, and (ii) the
porosity-to-tortuosity ratio (c/r). The structural parameters of skin treated with LFS/SLS and
LFS are compared to that of untreated skin (for both FTS and STS), to better understand the
effect of SLS on skin structural perturbation and transdermal pathways when utilized in
combination with LFS. Furthermore, the reproducibility and predictability of the LFS/SLS and
LFS treatments is explored by comparing: (i) the width of the 95% confidence intervals for the
structural parameters calculated, (ii) the correlation coefficient observed between the
permeability and the resistivity of skin samples (see Theory section), and (iii) the trends
observed in treatment times for skin samples treated to different extents of skin electrical
resistivity. Clearly, the reproducibility and predictability of skin permeability enhancement are
essential for the successful clinical implementation of this technology. [21, 22]
With the above motivation and background in mind, it is important to stress that the study
presented here is the first one to investigate the synergism between LFS and SLS in the context
of quantifying skin structural perturbation, while utilizing a fixed skin electrical resistivity
protocol. It is noteworthy that previous studies have focused primarily on fixed treatment time
protocols (typically treating skin samples with LFS for 10 minutes in the presence and in the
absence of SLS). [11, 12, 15] The present study differs from previous ones in that skin samples
were treated with both LFS/SLS and LFS to attain a wide range of skin electrical resistivity
levels, allowing treatment times to vary in order to reach those levels. This modification in the
treatment protocol is significant, because treating skin samples with LFS for a fixed period of
time does not ensure that the skin samples are perturbed to any significant extent. Indeed, skin
permeability enhancement is usually modest under this type of treatment protocol, since LFS
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application for 10 minutes results in just a 1.5-fold enhancement in skin electrical resistivity. [12]
Note that this is a very small extent of skin electrical resistivity enhancement, considering that
skin hydration itself can cause similar extents of enhancement during a 24-hour period.[12]
Accordingly, in the present study, it was required that LFS be applied to attain greater
enhancements in skin electrical resistivity, which allows us to better understand the effect of the
purely physical enhancement mechanism associated with LFS, relative to the combined physical
and chemical enhancement mechanisms associated with LFS/SLS.
Along the lines discussed above, the objectives of the present study are to explain: i) how the
extent of skin perturbation differs between skin samples treated with LFS/SLS and LFS, in the
context of the APPM, ii) hows/r ratios differ between skin samples treated with LFS/SLS and
LFS, iii) how the amount of mechanical support (i.e., the thickness of the dermis in the skin
model considered) affects the extent of skin perturbation in samples treated with LFS/SLS and
LFS , and iv) how the reproducibility and predictability of skin permeability enhancement and
treatment times of skin samples treated with LFS/SLS compares to those of skin samples treated
solely with LFS. Addressing (i) - (iv) will help explain the role of SLS in inducing skin
structural perturbation, including the role of SLS in enhancing transdermal transport.
5.2 Materials and Methods
5.2.1 Materials
Phosphate buffered saline tablets (PBS; 0.01 M phosphate, 0.137 M NaCl) and SLS were
obtained from Sigma Chemical Company (St. Louis, MO). C14-labeled sucrose (specific activity
of 600 mCi/mmol) was obtained from American Radiolabeled Chemicals (St. Louis, MO).
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Hionic-Fluor, a scintillation cocktail, was obtained from Perkin-Elmer (Waltham, MA). All
chemicals were used as received. Deionized water from a Milli-Q water purification system
(Millipore, Bedford, MA) was used for the preparation of all solutions.
5.2.2 Preparation and Pre-Treatment of Skin Samples by LFS/SLS
Previously published protocols were utilized for the storage and preparation of skin samples. [19,
20] This procedure has been approved by the MIT Committee on Animal Care. Briefly, skin was
harvested from the back and flank of Female Yorkshire pigs, sectioned into 25-mm strips, and
stored at -85 'C for up to 6 months. Before use in experiments, the skin was thawed for 1 hour
in PBS and all excess hair and subcutaneous fat were removed. Full-thickness skin (FTS)
samples were utilized without further preparation, while split-thickness skin (STS) samples were
dermatomed to 700 pm thickness using an electric reciprocating dermatome (Zimmer Orthopedic
Surgical Products, Dover, OH). The skin was then cut into 25 mm by 25 mm samples, for use in
the 15-mm inner diameter diffusion cells (PermeGear, Hellertown, PA).
LFS/SLS and LFS pre-treatment of skin samples was carried out according to previously
published methods.[12, 13, 17, 19, 20, 23] Skin treatment was carried out with a 20 kHz
ultrasound hom (VCX 500, Sonics and Materials, Inc., Newtown, CT), under the following
experimental conditions: intensity - 7.5 W/cm 2, duty cycle - 50% (5 s on, 5 s off), and tip
displacement - 3 mm. Two different coupling media were utilized to treat the skin samples: i)
1% SLS in PBS solution (LFS/SLS treatment), and ii) PBS solution alone (LFS treatment).
Samples were treated with LFS until they reached currents ranging from 5 pA (low level of LFS
treatment) to 200 pA (high level of LFS treatment), in order to test a wide range of LFS-induced
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skin perturbation (higher currents suggest higher levels of skin perturbation). Note that the range
of skin currents used here is similar to previously reported ranges used with LFS.[19, 24] After
each minute of LFS treatment, the coupling medium was changed in order to minimize thermal
effects (maintain the temperature within 10 'C of room temperature), and the electrical current of
the skin samples was measured to determine if a desirable skin current had been attained.
Following LFS treatment, samples were rinsed thoroughly with PBS in order to remove all
excess SLS from the skin surface, and the coupling medium was replaced with PBS prior to the
sucrose permeability experiments.
5.2.3 Skin Electrical Resistivity Measurements
Skin electrical resistivity, R, has been shown to be an accurate and instantaneous indicator of the
structural state of the skin.[9, 19, 25] Previously published methods[9, 23, 24] were followed to
measure R and are summarized next. A signal generator (Hewlett-Packard, model HP 33120A)
was used to generate an AC voltage at 100 mV and 10 Hz. The voltage was applied across the
skin using two Ag/AgCl electrodes (In Vivo Metrics, Healdsburgh, CA). The skin electrical
current was measured using a multimeter (Fluke Corporation, Model 189) and the skin electrical
resistance was calculated using Ohm's Law. R was then calculated by subtracting the
background resistance and then multiplying the resulting skin electrical resistance by the area of
the skin sample. In order to ensure that the skin was intact prior to experimentation, the initial R
value of a skin sample was required to be above 50 kOhm-cm 2 .[26-28]
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5.2.4 Calculating the Steady-State Sucrose Skin Permeability
Following the LFS/SLS or LFS treatments, the steady-state sucrose skin permeability was
determined. Sucrose was chosen as a model hydrophilic permeant because it has previously
been utilized in the context of the APPM to accurately describe skin perturbation with LFS/SLS
through the measurement of aqueous pore radii and the calculation of /r values.[ 19, 20] Before
commencing the permeability experiments, skin samples were remounted into clean, dry
diffusion cells, and filled with 12 mL of PBS in the receiver chamber. For both the LFS/SLS-
treated and the LFS-treated skin samples, 2 mL of donor solution containing 0.3-5 pCi/mL of
C14-labeled sucrose was utilized. For the passive skin samples, 0.75-1.0 mL of donor solution
containing 25-50 pCi/mL of C14-labeled sucrose was utilized (note that a higher concentration is
necessary because of the low permeability of the untreated skin samples, and therefore, a smaller
donor volume is utilized to minimize the amount of radiolabeled chemicals used). The
radiolabeled sucrose concentrations were chosen such that the level of radioactivity in the
receiver chamber aliquots was significantly greater than the background radioactivity levels
(approximately 10-fold greater). The receiver chambers were stirred magnetically at 400 rpm.
The diffusion cells were sampled every two hours, between 18 and 26 hours, in order to measure
the steady-state sucrose permeability of the skin samples. Note that this time frame has
previously been established as being appropriate for measuring the steady-state permeability of
sucrose through porcine skin.[19, 20] For skin samples treated with LFS/SLS or LFS, 200-pL
aliquots of the donor solutions and 400-pL aliquots of the receiver solutions were withdrawn at
each time point, in addition to measuring R. For passive skin samples, 20-pL aliquots of the
donor solutions and 500-gL aliquots of the receiver solutions were withdrawn at each time point.
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Upon withdrawal of solution from the receiver chamber, an identical volume of PBS was added
in order to keep the solution level constant. The concentration of sucrose in each sample was
measured by adding 5 - 15 mL of scintillation cocktail to each sample and then analyzing the
samples on a Tri-Carb 281 OTR liquid scintillation counter (PerkinElmer, Waltham, MA).
The permeability of sucrose through the skin, P, was calculated at steady-state, infinite sink
conditions using the following equation:[20]
P V(AC) (5.1)
ACd At)
where A is the area of skin available for permeation, V is the volume of PBS in the receiver
chamber, Cd is the average sucrose concentration in the donor chamber over the sampling
period, and (AC/At) is the rate of change of sucrose concentration in the receiver chamber
(where replacement of the sampled aliquots by PBS is taken into account).
5.3 Theory
5.3.1 The Aqueous Porous Pathway Model
By assuming that a hydrophilic permeant, such as sucrose, follows a similar path through the
skin as the current carrying ions (for PBS, the dominant ions are Na+ and Cl), one can utilize the
APPM to calculate meaningful structural parameters of the skin.[20] This model utilizes
hindered-transport theory[29] in order to quantify the steric hindrance exerted by the finite radius
of the skin pores on the fluxes of the aqueous permeant and the current carrying ions through the
skin. The hindrance factors corresponding to both species are related solely to the radius of each
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permeant and to the average radius of the aqueous skin pores, rpo,. Then, by equating the
diffusion of the aqueous permeant, which is related to the skin permeability, P, and the diffusion
of the current carrying ions, which is related to the skin electrical resistivity, R, one can
determine a log C value (see Eq. (5.2) below), which is related to rp,,e and the extent of skin
structural perturbation.
The relation between skin permeability, P, and skin electrical resistivity, R, in the context of the
APPM, is given by:[20]
log P = log C -log R (5.2)
where C is defined as follows:
kT D,"HOW 
_C 2 - D (
22 Fcioneo D;",H ( Zon
(5.3)
where z is the electrolyte valence, F is Faraday's constant, e, is the electrolyte molar
concentration, e0 is the electronic charge, k is the Boltzmann constant, T is the absolute
temperature, D," is the infinite-dilution diffusion coefficient of solute i, H (A,) is the hindrance
factor for solute i, and A, is defined as the ratio of the radius of solute i, r, to the radius of the
aqueous skin pores, rpore.[13] The most up-to-date expression for H(A), which is valid for
A, 0.95, is given by:[14, 19, 29]
9
H (A) =1+- 9l, n A, -1.56034A, + 0.528155A,2+1.91521A,38
-2.819034 +0.270788A' +1.10115/,6 -0.435933Z7
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(5.4)
It is important to note that the only variable in (5.3) that depends on the intrinsic properties of the
skin is r,,,, (which appears through A, and A). All the other variables are either constants or
are properties of the permeants used. Therefore, once an experimental C value is determined
using Eq. (5.2), r,,,r, can be determined by iteratively solving Eq. (5.3) until it converges.
Before applying the APPM to an experimental data set, it is first necessary to determine whether
the model is applicable. To this end, a linear regression is fit to each set of log P versus log R
data sets, and only if a 95% confidence interval on the slope of the regression includes the
theoretical value of -1 (see Eq. (5.2)) and the linear regression is found to be statistically
significant, is the model assumed to be valid. For a more detailed discussion on the applicability
of the APPM, see Seto et. al.[19] After confirming that the data set can be described by the
APPM, a log C value is determined using Eq. (5.2) for each data point contained within the data
set. Subsequently, all the individual log C values are averaged to yield the log C value
corresponding to that data set. The average log C value can then be utilized to calculate roe and
to assess the structural perturbation of the skin.
It is important to stress that, for any aqueous permeant utilized (with given hydrodynamic
radius), only a certain range of r,,,re values can be determined. In fact, for any permeant, there
will be an upper bound on the value of rr,,, that can be probed depending on the hydrodynamic
radius of the permeant (the hydrodynamic radius of sucrose is estimated to be 5.5 A[20]). This
follows, because as the pores become increasingly large, the amount of hindrance exerted by the
pores on the diffusing permeants becomes increasingly small as the hindrance factor approaches
unity. Recall that hindrance factors range from 0 to 1, where a hindrance factor of 1 corresponds
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to no hindrance, and a hindrance factor of 0 corresponds to infinite hindrance. Beyond a certain
rore value, the hindrance exerted by the pores on the permeant becomes statistically
indistinguishable from the diffusion of the permeant at infinite dilution, which corresponds to the
upper bound of rpo, (calculated from the corresponding upper bound on log C) that can be
probed with that permeant. This infinite-dilution limit (or infinite-pore limit) will be attained at
lower rpo,, values for smaller permeants and will be higher for larger permeants. The infinite-
pore limit for sucrose has been previously established to be ~120 A (based on Eq. (5.4)).[19, 20]
Therefore, for pore radii which are larger than the upper bound for sucrose, log C values can still
be used to compare relative skin perturbations of different skin samples.
In addition to calculating log C and rpo,, values in the context of the APPM, this model can also
be used to compute the porosity-to-tortuosity ratio (e/r ) of the skin samples. This allows us to
gain deeper insight into the transdermal pathways present within the skin, by understanding the
importance of the area of skin pores present on the skin surface (reflected in C) relative to the
length of the aqueous pathways present in the skin (reflected in r ). Specifically, 6/r is given
by the following expression: [20]
1 (5.5)R A 0  H (Ao
where o-,, is the electrical conductivity of PBS (0.012 Q-rcm-1),[20] H (Aon) is the hindrance
factor for an ion calculated using Eq. (5.4), and Ax is the thickness of the skin layer that
provides the primary barrier to transport, which is assumed to be the thickness of the stratum
corneum (13.1 tm).[13, 30]
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5.4 Results
5.4.1 Analysis of the Experimental Data in the Context of the Aqueous
Porous Pathway Model
In order to verify that the APPM is valid over the range of R values attained using the LFS/SLS
and LFS skin treatments, it was determined if the regressed slopes are not significantly different
from the theoretical value of -1 (see Eq. (5.2)). The log P-log R plots generated for this analysis
are reported in Figure 5-1, with the resulting linear regression parameters listed in Table 5-1.
Note that a subset of the LFS/SLS data has been published in [19]. Table 5-1 shows that the
95% confidence intervals on the slopes of all 6 sample sets tested include the theoretical value of
-1, thus validating use of the model.' After establishing the applicability of the APPM, the skin
structural parameters are calculated to assess the effect of SLS on skin perturbation, when
utilized simultaneously with LFS.
5.4.2 Evaluation of Skin Perturbation through a Comparison of Log C
Values
To assess the overall skin perturbation of the two LFS/SLS-treated and two LFS-treated skin
models, an analysis-of-variance (ANOVA) test was performed on all the log C values
corresponding to the four sample groups tested (see Table 5-2). The ANOVA test yielded
Note that for the passive skin samples (samples with no LFS/SLS or LFS treatments), there is greater uncertainty
in the slope of the data, as reflected in the large range for the 95% confidence intervals for these two data sets (1.48
and 0.87, respectively). This is expected, because the passive skin samples have very similar electrical resistivities
due to the inherent barrier properties of the skin, and because it is required that the skin samples have a certain initial
electrical resistivity to ensure their integrity. Therefore, any natural variation in skin permeability, or in skin pore
radius distribution, will result in relatively large deviations from expected values and cause greater uncertainty in the
regressed values.
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Figure 5-1. Log P-log R plots for LFS/SLS-treated and LFS-treated skin samples. The solid line
on each plot corresponds to the linear regression fitted to each data set. The regression
parameters are listed in Table 5-1.
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Table 5-1. Model validation for the skin treatments and skin thicknesses tested.
Linear Regression Parameters
Treatment Thickness n Slopea rz
LFS/SLS FTS 58 -1.08 0.09 0.92
LFS/SLS STS 37 -1.07 0.22 0.73
LFS FTS 30 -0.98 0.33 0.57
LFS STS 30 -1.02 0.37 0.53
None FTS 8 -1.01 1.48 0.32
None STS 11 -1.80 0.87 0.71
a Range corresponds to a 95% confidence interval.
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P<0.0001 (note that, at 95% confidence, P must be below 0.05 to reject the null hypothesis that
all the sample groups tested have the same population mean), indicating that one or more of the
four sample groups do not contain the same population mean. Additional analysis showed that
there is no statistical difference in the log C values of the two LFS/SLS-treated skin models (FTS
and STS), while there is significant statistical difference between FTS and STS treated solely
with LFS (P<0.0001). Next, an ANOVA test was performed on the LFS/SLS-treated FTS and
STS models, along with the LFS-treated FTS model, and no statistical difference in the log C
values of these three skin models was observed. Pairwise t-tests assuming unequal variances
between the log C values of all the four skin models confirmed that the LFS-treated STS model
exhibits a significantly different extent of skin perturbation compared to the other three skin
models tested, while none of the other three skin models tested are statistically different from
each other.
As a reference point, log C values for untreated FTS and STS were also determined, and the two
LFS/SLS-treated and two LFS-treated skin models were found to have significantly different log
C values than the untreated skin samples (pairwise t-tests at 95% confidence). Furthermore, a
comparison of untreated FTS and untreated STS showed no statistical difference in their log C
values. Utilizing Eqs. (5.3) and (5.4), the average aqueous pore radius of untreated FTS was
found to be 16.4 A (95% confidence interval of [13.6 A, 21.8 A]), and that of STS was found to
be 16.6 A (95% confidence interval of [14.2 A, 20.5 A]). Note that because the log C values for
the LFS/SLS-treated and LFS-treated skin samples were above the infinite-pore limit, suggesting
that the skin is exerting no hindrance or negative hindrance on the diffusing permeants, it is
therefore not valid to utilize the APPM to calculate average pore radius values. Therefore, only
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Structural parameter values for FTS and STS samples treated with LFS/SLS
Treatment Thickness n log C a,b 8/* - 106 a
LFS/SLS FTS 58 -2.96 ± 0.05 45.6 ± 12.7
LFS/SLS STS 37 -2.90 ± 0.09 45.6 ± 13.3
LFS FTS 30 -2.96 ± 0.10 42.0 ± 9.06
LFS STS 30 -2.68 ± 0.13 36.1 ± 10.9
None FTS 8 -3.35 ± 0.15 2.07 ± 0.50
None STS 11 -3.34 ± 0.11 2.81 ± 0.40
a Range corresponds to a 95% confidence interval.
b log C is equivalent to the y-intercept of a linear regression of log P vs.
log R with a slope equal to -1.
289
Table 5-2 and LFS.
log C values were used to compare the extent of skin structural perturbation of these skin
models, as the validity of the APPM is in question for these data sets. However, it is still valid
utilize log C values to compare the extent of skin perturbation with different skin treatments, as
previously reported in the literature.[19]
5.4.3 Evaluation of the Skin Structural Parameter, e/
s/r values were calculated using Eq. (5.5) for the two LFS/SLS-treated and two LFS-treated
skin samples, as well as for untreated FTS and STS. These results are reported in Table 5-2.
The s/r values of both LFS/SLS-treated FTS and STS are identical, while the s/r values of the
LFS-treated FTS and STS groups are lower, and generally decrease with decreasing skin
thickness. There is no statistical difference between the E/r values of untreated FTS and STS.
On average, s/r was found to increase approximately 20-fold between untreated skin samples
and samples that were treated with LFS/SLS or LFS, suggesting an increase in the number of
pores on the skin (reflected in a larger e value) or the creation of more direct (less tortuous)
paths through the skin (reflected in a smaller r value) following treatment of the skin.
5.4.4 Treatment Time Required to Reach Specific Skin Electrical
Resistivity Levels
In order to assess reproducibility and predictability of the LFS/SLS and LFS treatment regimens,
in addition to the regression analyses (r2 values and 95% confidence intervals) reported in Tables
5-1 and 5-2, treatment times were compared for each of the two treatment conditions (with and
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Table 5-3. Skin treatment times associated with three levels of skin electrical resistivitya for FTS
and STS models treated with LFS/SLS and LFS.
1.5 ± 0.6 k-cm2  4.0 1.6 k-cm2  10.0 ± 4.0 k-cm2
Treatment Thickness n time (min) n time (min)b n time (mm)
LFS/SLS FTS 15 2.4 ± 0.4 11 2.0 ± 0.9 12 1.4 ± 0.6
LFS/SLS STS 11 2.8 ± 1.2 10 1.8 ± 0.8 9 1.2 ± 0.4
LFS FTS 10 14.0 ± 3.9 14 22.1 ± 5.3 4 16.5 ± 5.7
LFS STS 8 13.1 ± 4.1 14 12.2 ± 4.7 6 6.4 ± 3.3
a These three ranges of R values were chosen in order to make useful statistical comparisons
between the treatment times.
b Range corresponds to a 95% confidence interval.
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without SLS) at three separate skin perturbation levels (as quantified by R values of 1.5, 4.0, and
10.0 kQ-cm2 ±40%). Note that a smaller skin electrical resistivity value corresponds to a greater
extent of skin perturbation (less resistance of the skin membrane). This data is reported in Table
5-3. For LFS/SLS-treated skin samples, treatment times increased monotonically with
decreasing skin electrical resistivity. In addition, treatment times were not significantly different
between FTS and STS samples at each of the skin electrical resistivities considered. On the
other hand, the treatment times for skin samples treated solely with LFS did not behave in a
straightforward manner, and took 5-fold to 12-fold longer to reach skin electrical resistivity
levels similar to those of skin samples treated with LFS/SLS. In addition, no statistically
significant difference was found between the treatment times required to reach any of the three
skin electrical resistivities considered in the case of LFS-treated FTS.
5.5 Discussion
5.5.1 Effect of SLS on the Structural Perturbation of LFS-Treated Skin
The primary criterion that was used to quantify skin perturbation utilizes the effective radii of the
hydrophilic diffusive pathways in the skin models tested, which scale directly with log C in the
context of the APPM (see Eqs. (5.2) - (5.4)). A less negative log C value indicates an increase
in the pore radius, suggesting increased perturbation of the skin samples by the treatment
administered. The main objective was to compare the results for skin samples treated with
LFS/SLS with those for skin samples treated only with LFS, in order to understand the effect of
SLS on skin perturbation when used simultaneously with LFS. In addition, in order to test the
effect of the skin mechanical support on skin perturbation, for the two skin treatments used
(LFS/SLS and LFS), both FTS (typical thickness of 1.5-1.8 mm) and STS (thickness of 0.70
292
mm) models were tested. It is important to recognize that both the FTS and STS models are
equivalent, in the context of the APPM, prior to treatment, as clearly reflected in their: (i) nearly
identical log C values (see Table 5-2, corresponding to pore radii of 16.4 A and 16.6 A,
respectively), and (ii) their statistically similar values of c/r (see Table 5-2). Therefore, any
observed increases in log C or /r in the treated skin samples can be attributed solely to the
LFS/SLS or LFS treatments applied to those skin samples.
5.5.1.1 Comparison of the LFS/SLS-Treated FTS and STS Models
A comparison of the skin structural parameters of LFS/SLS-treated FTS and STS shows that: (i)
their log C values are statistically similar (see Table 5-2), and (ii) their e/r values are essentially
identical (see Table 5-2). Furthermore, Table 5-3 shows that the treatment times associated with
the three levels of skin electrical resistivity for FTS and STS are statistically similar for the three
skin electrical resistivities analyzed. This confirms that, irrespective of the skin thicknesses
studied, skin perturbation induced by LFS/SLS is generated in a consistent and similar manner.
In other words, the FTS and STS models are identical in terms of their response to the LFS/SLS
treatment. This important conclusion is consistent with the recent findings by Seto et al. [19]
5.5.1.2 Comparison of log C Values for LFS/SLS-Treated and LFS-
Treated Samples
For LFS-treated FTS, the extent of skin perturbation, as quantified by the log C values, is
statistically similar to both LFS/SLS-treated FTS and LFS/SLS-treated STS. However, as Table
5-2 shows, the log C value corresponding to LFS-treated STS is significantly less negative than
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those corresponding to the other three skin sample groups tested (pair-wise t-tests comparing
LFS-treated STS to the other three sample groups yields P<0.006). This interesting finding
follows because: i) in the absence of SLS, skin samples must be treated for much longer time
periods to reach similar skin electrical resistivity values (see Table 5-3), and ii) the thinner STS
model does not respond to the physical enhancement mechanism (cavitation) associated with
LFS in the same manner as the thicker FTS model. Simply stated, the stresses put on the thinner,
less mechanically robust STS during the long LFS treatment induce significantly greater skin
perturbation than that observed in: (i) the more mechanically robust FTS model, and (ii) the
combined chemical/physical enhancement induced by the shorter LFS/SLS treatment. This
finding also shows that, although the skin electrical resistivity is a good quantitative measure of
skin perturbation, the extent to which it scales with skin permeability depends on both the skin
model and skin treatment regimen used.
5.5.1.3 Comparison of s/ Values for LFS/SLS-Treated and LFS-Treated
Samples
Table 5-2 shows that the s/r values for the LFS-treated samples decrease with decreasing skin
thickness, and are generally lower than those corresponding to the LFS/SLS-treated samples.
Although the observed differences are not statistically significant to 95% confidence, they are
nevertheless interesting because they provide some insight into the role that SLS plays in
perturbing the skin, when combined with LFS. More specifically, although the LFS/SLS-treated
samples are subjected to 5- to 12-fold shorter treatments (see Table 5-3), these samples still have
higher 6/r values, suggesting that they are either more porous (larger e value) and/or less
tortuous (smaller r value) than those treated only with LFS. It is not likely that an increase in c
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can explain the difference in s/r values for LFS/SLS-treated and LFS-treated skin samples.
This is because previous studies have shown that the radius of impinging cavitation microjets
and the overall number of cavitation events observed near the skin surface decreases in
LFS/SLS-treated samples, with respect to samples treated solely with LFS.[11, 12] Since
cavitation bubble collapse near the skin surface is the primary mechanism of new pore formation
and permeability enhancement for skin treated with LFS/SLS and LFS, this would in fact suggest
that the porosity of LFS-treated samples should be greater than the porosity of LFS/SLS-treated
samples (which is further enhanced because LFS treatments are an order-of-magnitude longer
than LFS/SLS treatments). Therefore, the most likely explanation for the observed increase in
./r in LFS/SLS-treated samples, with respect to LFS-treated samples, is the ability of SLS to
fluidize/disorder lipid bilayers and expand lacunar regions, thereby creating less tortuous and
more direct permeation pathways through the skin membrane. Note that this explanation is
consistent with the findings of Paliwal et al., who showed that, in LFS-treated skin, the number
density of lacunar regions increases significantly with respect to those in untreated and
LFS/SLS-treated skin (which suggests greater porosity).[18] In addition, Paliwal et al. showed
that in LFS/SLS-treated skin, the number density of lacunar regions did not increase with respect
to that in untreated skin, although the total area of the lacunar regions did increase. This suggests
increased length and connectivity of the lacunar regions, which could be explained by an inter-
connected three-dimensional network of pores (which suggests decreased tortuosity).[18]
Accordingly, the ability of LFS and SLS to work in concert, in order to permeabilize skin in both
a physical and chemical manner, leads to the observed higher /r values for the LFS/SLS-
treated samples, compared to the samples treated only with LFS.
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5.5.2 Reproducibility and Predictability of Skin Perturbation in Samples
Treated with LFS/SLS and LFS
Reproducibility and predictability of skin perturbation are important characteristics of any skin
treatment regimen. Clinically, not all patients have skin with similar thickness, elasticity, or other
biomechanical properties.[31, 32] Therefore, a robust skin treatment protocol is ideal.
Consequently, examining the data presented in this study, it is not surprising that a combination
of LFS/SLS is presently used in clinical applications of LFS (the company commercializing this
technology is Echo Therapeutics, Franklin, MA).[21, 22]
An examination of the log P-log R plots shown in Figure 5-1 reveals much greater variability in
the regression lines shown for samples treated solely with LFS (Figures 5-1(c) and 5-1(d)),
compared to those treated with LFS/SLS (Figures 5-1(a) and 5-1(b)). This is also shown
quantitatively in Tables 5-1 and 5-2, where the 95% confidence intervals for both the slope of the
linear regression and the log C values are broader for the LFS-treated samples (0.33-0.37 and
0.10-0.13, respectively) compared to those for the LFS/SLS-treated samples (0.09-0.22 and 0.05-
0.09, respectively). Similarly, the r2 values for the linear regressions of the LFS-treated data
(0.53-0.57) are smaller than those of the LFS/SLS-treated data (0.73-0.92), thus demonstrating
that skin perturbation, and the resulting skin permeability enhancement, are less predictable for
skin treated solely with LFS.
Another significant difference between the LFS/SLS-treated and LFS-treated samples is in the
observed trends in treatment times (see Table 5-3). Specifically, samples treated with LFS/SLS
take nearly an order-of-magnitude less time to reach similar skin electrical resistivities than LFS-
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treated samples do. Note that the observed decrease in treatment time is consistent with the
previous finding that the energy density threshold required to observe skin permeability
enhancement in LFS/SLS-treated skin is an order-of-magnitude smaller than that for LFS-treated
skin (note that energy density scales with treatment time).[11] In addition, LFS/SLS-treated
samples behave in a more predictable manner, where: (i) treatment times decrease with
increasing skin electrical resistivity, and (ii) the treatment times necessary to reach the various
skin electrical resistivity levels considered are not significantly different for the FTS and STS
samples. On the other hand, for FTS samples treated solely with LFS, treatment times show no
statistically significant difference to reach the three skin electrical resistivity levels reported in
Table 5-3 (an ANOVA analysis yielded a p-value of 0.172, which was confirmed by pairwise t-
tests at 95% confidence), while the treatment times for LFS-treated STS samples decrease in a
non-linear manner with increasing skin electrical resistivity levels. In addition, a comparison of
treatment times for the LFS-treated FTS and STS samples reveals that, at the 1.5 k-cm2 skin
electrical resistivity level, the treatment times are statistically similar, while they are statistically
significantly different (95% confidence) at both the 4 and 10 kM-cm 2 levels. This again points to
the lack of predictability and reproducibility of skin samples treated only with LFS, where some
skin samples respond much more favorably to the LFS treatment than others. With all of the
above in mind, it is quite clear that it is extremely advantageous to treat skin with a combination
of LFS/SLS. Not only are the required treatments much shorter using LFS/SLS, but also the
combined chemical and physical enhancement mechanisms involved in skin perturbation using
LFS/SLS induce much more predictable trends in skin perturbation than those induced by the
purely physical mechanism associated with LFS.
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The most significant implications of these findings involve an improved mechanistic
understanding of the combined effect of LFS and SLS on skin perturbation. Specifically, it was
shown that, although not intuitive, the combination of both a chemical and physical skin
penetration enhancer can, in fact, be less perturbing to the skin (based on log C values) than a
physical skin penetration enhancer alone. Furthermore, the results show that the addition of SLS
to the LFS coupling medium not only allows the delivery of permeants in an equivalent manner
to LFS alone, but also induces less perturbation to the skin membrane in a much shorter,
reproducible, and predictable manner. Clearly, the reduction in treatment time in the presence of
SLS is a great advantage clinically, because it would require health personnel an order of
magnitude more time to treat patients with LFS alone. Furthermore, the importance of decreased
skin perturbation and shorter application time is very significant with respect to patient safety
and compliance. Future research in this area should be aimed at identifying surfactants that can
provide similar, or greater, levels of skin permeability enhancement when combined with LFS,
than LFS/SLS, while inducing even less skin perturbation and irritation. To this end, in vivo
studies on the irritancy potential of the LFS/surfactant treatment of skin should be considered.
5.6 Conclusions
In this study, the effect of SLS on skin perturbation was investigated, when utilized
simultaneously with LFS, by treating two skin models, pig FTS and pig STS, with two treatment
regimens, LFS/SLS and LFS, to reach a range of skin electrical resistivity levels. The LFS/SLS
treatment was found to provide consistent extents of skin perturbation, as quantified using the
log C and s/r values obtained. Skin samples treated solely with LFS yielded less consistent
results, where the log C values of the FTS and STS skin models were statistically significantly
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different. Additionally, the E/r values for LFS-treated skin samples were generally less than
those for LFS/SLS-treated samples, suggesting that SLS acting on the skin creates more direct
paths through the skin membrane by the disordering/fluidization of lipid bilayers, denaturation of
keratin fibers, and expansion of lacunar regions. An analysis of the variability in the log P-log R
linear regression parameters and log C values revealed greater variation in samples treated solely
with LFS, resulting in lower r2 values and broader confidence intervals for the regression
parameters and log C values, with respect to LFS/SLS-treated samples. Additionally, the LFS-
treated samples required 5-fold to 12-fold longer treatment times than the LFS/SLS-treated
samples to reach similar skin electrical resistivity levels. Treatment times for the LFS/SLS-
treated samples behaved predictably, decreasing monotonically with increasing skin electrical
resistivity level, showing no significant difference in treatment times between FTS and STS
samples at each of the skin electrical resistivity levels analyzed. On the other hand, LFS-treated
samples were perturbed in a less predictable manner, with large variations and no statistical
significance in treatment times between the skin electrical resistivity levels considered.
In summary, SLS has a generally positive impact on skin structural perturbation when utilized in
combination with LFS, compared to LFS treatment alone, by: (i) requiring equal, or less, skin
perturbation to reach similar skin electrical resistivity values (as reflected in the log C values),
(ii) reaching similar skin electrical resistivity levels in much shorter treatment times (about an
order-of-magnitude decrease in treatment times), and (iii) inducing skin perturbation in a
significantly more reproducible and predictable manner.
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Chapter 6
Thesis Summary, Evaluation of Low-Frequency
Ultrasound-Mediated Transdermal Delivery, and
Future Research Directions
6.1 Thesis Summary
The primary focus of this thesis has been to extend current knowledge on the role of cavitational
and surfactant effects in skin permeability enhancement by low-frequency sonophoresis (LFS),
especially with regards to elucidating previously unexplained phenomena such as heterogeneous
transport and synergism between LFS and chemical penetration enhancers (CPEs). In Chapter 2,
the permeation pathways within highly-perturbed regions of LFS-treated skin, localized transport
regions (LTRs), and non-LTRs were investigated. This allowed me to identify the mechanisms
of skin permeability enhancement in each skin region, and to demonstrate that cavitation
microjet collapses within LTRs play a significant role in skin perturbation. Chapter 3 focused on
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the effect of non-traditional surfactants when combined with LFS treatment. Specifically, it was
found that even common dyes, which are typically assumed to be inert constituents of LFS
coupling solutions, can have dramatic effects on bulk and interfacial solution properties due to
their amphiphilic nature. These effects can also significantly affect skin perturbation caused by
LFS treatment. Chapter 4 began the study into the synergism between LFS and CPEs. In this
chapter, I presented a flux model that explains the synergism between both amphiphilic and non-
amphiphilic CPEs by explaining how in each of these cases there is increased CPE penetration
into the LTRs and non-LTRs of LFS-treated skin. This flux model was also able to explain why
amphiphilic CPEs are expected to have a greater flux into the skin relative to non-amphiphilic
CPEs, which in turn explains why amphiphilic CPEs are generally observed to have greater
synergism with LFS treatment. Finally, in Chapter 5 I further studied the synergism between
LFS and an amphiphilic CPE, sodium lauryl sulfate (SLS), albeit from the unique perspective of
the effect of SLS on the skin structure when combined with LFS treatment. The findings show
that, in spite of utilizing two types of skin permeability enhancers (chemical and physical), the
inclusion of SLS in the coupling medium results in milder treatment with more reproducible and
predictable enhancements in skin permeability. In the rest of this section, the major conclusions
of this thesis will be discussed in more detail.
6.2 Major Thesis Conclusions
In Chapter 2, the aqueous porous pathway model was utilized to study the frequency dependence
in pore size within LTRs and non-LTRs of LFS-treated skin. It was shown that the pore radii in
the non-LTRs are independent of ultrasound frequency, ranging from 18.2 - 18.5 A. In addition,
it was determined that the pore radii in the non-LTRs are statistically significantly larger than the
306
values for the native skin samples (13.6 A), suggesting that a frequency-independent
enhancement process is at play in these skin regions. Additional experiments were carried out to
quantify the amount of SLS penetrating into LTRs and non-LTRs relative to native skin, and it
was found that nearly twice as much SLS penetrates into the non-LTRs per unit area than into
untreated skin. Furthermore, by studying different mechanisms of SLS penetration into skin, it
was shown that boundary-layer reduction caused by acoustic streaming is the most likely cause
for the increased SLS uptake within non-LTRs. Therefore, recognizing that SLS itself can
increase pore radii in the skin, it was concluded that a frequency-independent process, such as
acoustic streaming, causes increased penetration of SLS into the skin, with SLS acting on the
skin being the main contributor to the observed increase in pore radius. In the LTRs, it was
observed that the pore radii increase dramatically with decreasing frequency (161 A, 276 A, and
oo for 60 kHz, 40 kHz, and 20 kHz LFS, respectively). Accordingly, strong support was provided
to the proposal that transient cavitation events near the skin surface, which are known to be
frequency dependent, are the primary mechanism of skin permeability enhancement in LTRs.
The variation of the skin radii with ultrasound frequency in the LTRs also suggests that transient
cavitation microjets impinging on the skin surface can explain the observed changes in pore
radii.
In Chapter 3, a fluorescent dye, sulforhodamine B (SRB), commonly used in LFS treatments,
was studied first with regards to characterizing its amphiphilicity and then to quantify its effect
on skin permeability enhancement with LFS. It was demonstrated that SRB is an amphiphilic
molecule that preferentially adsorbs at an air/water interface, bringing about a considerable
decrease in the surface tension of pure water (23 mN/m reduction). MD simulations revealed that
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SRB is thermodynamically stable in its adsorbed state, both as monomers and dimers, with
clearly defined head and tail regions as quantified by the hydration of its atomic groups, similar
to conventional surfactants. Furthermore, SRB was shown to be able to incorporate into SLS
micelles, which results in a dramatic decrease in the cmc of SLS. Because of its incorporation
into SLS micelles, SRB was observed to have a significant shift in color and opacity in aqueous
solution with increasing SLS concentration. MD simulations revealed that the SRB molecules
reside mainly in the palisade layer of the SLS micelles. With respect to skin permeability
enhancement with LFS treatment, SRB was shown to increase skin permeability significantly
when combined with LFS treatment, acting as a CPE itself. However, when combined with SLS,
SRB had an antagonistic effect. This was attributed to a decrease in the cmc of SLS and the
growth of SLS micelles with the incorporation of SRB, leading to lower amounts of SLS
delivered into the skin.
In Chapter 4, a physical mechanism that explains how LFS increases the transdermal uptake of
CPEs was presented. Specifically, it was found that the origin of the observed synergism
between LFS and CPEs is the ability of LFS to increase the penetration and dispersion of CPEs
by direct deposition of CPEs into the LTRs of LFS-treated skin through the collapse of acoustic
cavitation microjets. Moreover, amphiphilic CPEs were found to exhibit even greater synergism
with LFS than non-amphiphilic CPEs because their flux into the skin is further enhanced by the
adsorption of amphiphilic monomers to the surface of the cavitation bubbles. Therefore, in
addition to a convective flux induced by the collapse of acoustic cavitation microjets that drives
all CPEs, amphiphilic CPEs adsorbed to cavitation bubbles are also directly deposited into the
skin. More modest increases in the uptake of CPEs into the non-LTRs of LFS-treated skin,
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relative to untreated skin, were also observed and found to be consistent with the prediction of
the flux model proposed.
In Chapter 5, the effect of SLS on skin perturbation, when utilized simultaneously with LFS, was
investigated by treating two skin models, pig FTS and pig STS, with two treatment regimens,
LFS/SLS and LFS, to reach a range of skin electrical resistivity levels. The LFS/SLS treatment
was found to provide consistent extents of skin perturbation, as quantified using the log C and
porosity-to-tortuosity (e/r) values obtained. Skin samples treated solely with LFS yielded less
consistent results, where the log C values of the FTS and STS skin models were statistically
significantly different. Additionally, the 9/r values for LFS-treated skin samples were generally
less than those for LFS/SLS-treated samples, suggesting that SLS acting on the skin creates more
direct paths through the skin membrane by the disordering/fluidization of lipid bilayers,
denaturation of keratin fibers, and expansion of lacunar regions. An analysis of the variability in
the log P-log R linear regression parameters and log C values revealed greater variation in
samples treated solely with LFS, resulting in lower r2 values and broader confidence intervals for
the regression parameters and log C values, with respect to LFS/SLS-treated samples.
Additionally, the LFS-treated samples required 5-fold to 12-fold longer treatment times than the
LFS/SLS-treated samples to reach similar skin electrical resistivity levels. Treatment times for
the LFS/SLS-treated samples behaved predictably, decreasing monotonically with increasing
skin electrical resistivity level, showing no significant difference in treatment times between FTS
and STS samples at each of the skin electrical resistivity levels analyzed. On the other hand,
LFS-treated samples were perturbed in a less predictable manner, with large variations and no
statistical significance in treatment times between the skin electrical resistivity levels considered.
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Therefore, it was concluded that SLS has a generally positive impact on skin structural
perturbation when utilized in combination with LFS, compared to LFS treatment alone, by: (i)
requiring equal, or less, skin perturbation (based on log C values) to reach similar skin electrical
resistivity values (as reflected in the log C values), (ii) reaching similar skin electrical resistivity
levels in much shorter treatment times (about an order-of-magnitude decrease in treatment
times), and (iii) inducing skin perturbation in a significantly more reproducible and predictable
manner.
6.3 Evaluation of the Current Prospects and Future Trends of Low-
Frequency Ultrasound-Mediated Transdermal Delivery
The use of LFS has shown great promise in the transdermal delivery of therapeutics, including
hydrophilic drugs and macromolecules. Since the initial investigations of transdermal delivery
utilizing ultrasound frequencies between 20 and 100 kHz two decades ago, this technology has
already spawned a number of startups, received FDA approval for the topical delivery of local
anesthetics, and is currently being investigated for other clinical applications, such as skin
permeabilization for non-invasive blood glucose monitoring. With this strong beginning, LFS-
mediated transdermal delivery has the potential to gain an even stronger clinical foothold by
exploiting the unique strengths of this technology. For example, LFS can be utilized for
systemic, regional, and local delivery, with the ability to control the transdermal delivery profile
of the active therapeutic compound by varying the ultrasound treatment parameters. Therefore,
in addition to the systemic delivery of proteins, such as insulin, local delivery of drugs to treat
skin disorders may be an area where LFS can exploit its ability to permeabilize skin in a
controlled manner. This may be particularly relevant to skin disorders where the delivery of
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active therapeutics through the skin represents a limiting transport step, and the number of side
effects can be limited by localized therapy, such as in the case of psoriasis plaques.[1, 2]
Another application where LFS may be able to distinguish itself from other physical skin
permeability enhancers is in the development of a closed-loop system for the monitoring of
blood analytes and the subsequent delivery of appropriate therapeutics. The advancement of the
cymbal array device by Smith et al. [3] has now opened the door to a wearable LFS device.
Additionally, the feasibility of LFS for non-invasive blood-glucose monitoring has already been
established. [4-6] Therefore, the technology necessary to create such a device already exists.
Nevertheless, many obstacles still need to be overcome before a device is ready for use in the
clinic. For example, potential challenges include the development of efficient algorithms
involved in sensing and delivery (because there is a lag-time associated with both transdermal
blood-glucose monitoring and the transdermal delivery of insulin, accurate predictions will be
crucial), and in the design of a battery system that would be powerful enough to drive the LFS
cymbal array, while still being small enough to allow for a wearable device.
A final exciting area where LFS could have a significant impact is in the field of transdermal
vaccination. The feasibility of transdermally delivering high-molecular weight vaccines, such as
tetanus toxoid, by LFS has already been established in in vitro and in vivo animal models. [7, 8] It
is also known that targeting of the Langerhans cells in the skin can result in an enhanced immune
response with respect to vaccine injection.[9, 10] However, in addition to allowing increased
amounts of antigens to reach the Langerhans cells by increasing skin permeability, the LFS
treatment itself has been shown to activate the Langerhans cells and elicit an immune
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response. [7, 11] In fact, Tezel et al. have shown that the immune response induced by the
delivery of 1.3 pg of tetanus toxoid (TT) to the Langerhans cells by LFS is equal to that of 10 tg
of TT injected subcutaneously in mouse models.[7] Clearly, more research is needed to fully
understand, characterize, and control this effect. This would involve not only studying delivery
of antigens and the resulting immune response, but also the formulation of vaccines for delivery
via the transdermal route. An additional variable that could also be studied is the addition of a
co-enhancer during the LFS treatment, because it has been shown that the immune response
elicited by tetanus toxoid can increase with the inclusion of SLS in the LFS coupling medium,
although the response is not directly proportional to the SLS concentration. [8]
In addition to the specific areas discussed above, additional research is needed on the general
safety of the technology. If a closed-loop device for glucose monitoring and insulin delivery is
developed, long-term safety studies are necessary to determine whether repeated treatments with
LFS are safe. Current safety studies have only been conducted for relatively short times (a
maximum of 24 - 48 hours), and usually following only a single LFS treatment. Moreover, if
drugs are to be systemically and repeatedly delivered by LFS, more research is needed into the
reproducibility of skin permeability induced by the LFS treatments, both between different
patients and after repeated treatments in a single patient. Additionally, further research on the
generation of more uniform skin permeability enhancement would greatly benefit LFS
treatments. Under current treatment protocols with SLS, only 5-25% of the skin surface treated
by LFS contains LTRs, which are the skin regions through which the majority of transdermal
transport occurs.[12] If one could increase the size of the LTRs to cover the entire skin surface
treated, the area of skin treatment sites could decrease by up to 20-fold. This would result in
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decreased power needed to operate the LFS device and aid in further miniaturization of a clinical
device. For example, Paliwal et al. have recently shown that an aqueous mixture of 0.5% 3-
(decyl dimethyl ammonio) propane sulfonate and polyethylene glycol dodecyl ether induced
three times more LTR area than 1% SLS.[ 13] Therefore, research on cavitation enhancers for use
with LFS, including more potent synergistic chemical enhancers, deserve further investigation.
In conclusion, LFS-mediated transdermal delivery of hydrophilic drugs and macromolecules
shows great promise to address key needs in the medical field, such as developing a closed-loop
system for tighter glycemic control, treating localized skin disorders, and transdermal
vaccination. However, there are still opportunities to make technological and mechanistic
advances with this technology that can increase its clinical utility. To reach the ultimate goal of
positively affecting patients' lives, LFS researchers must focus on the unique advantages offered
by LFS, including exploiting these advantages when investigating new treatments involving
LFS.
6.4 Proposed Future Directions
6.4.1 Ultrasonic Transcutaneous Immunization (TCI) via a High-
Throughput Approach
LFS has been shown to act as an adjuvant,[7] but still little is known about how immune
response varies with ultrasound parameters and how to optimize the transdermal delivery of
vaccines. The aims of this type of work would be to formulate better transdermal vaccines and to
optimize skin treatments in order to create a platform for transdermal vaccination.
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TCI would allow for the elimination of many safety concerns associated with needle usage, such
as needle misuse and re-use, especially in developing or third-world countries.[14] Additionally,
it has previously been shown that the amount of antigen required to generate a similar immune
response is nearly an order-of-magnitude less with ultrasonic TCI than with injection, which
could provide added safety benefits.[7] Furthermore, immunization via the transdermal route
(targeting of Langerhans cells or dermal dendritic cells) generates both systemic (IgG and IgM)
and mucosal (IgA) humoral immune responses, while injection-based vaccines produce only
systemic immune response. Finally, utilizing physical (LFS) and chemical (CPE) stimuli to
produce a biological signal (immune response) are not straightforward,[7] and better mechanistic
understanding of these processes would undoubtedly result in a more rational design of TCI
platforms.
The approach of this work could be to test different parameters associated with LFS-treatment
prior to the application of different model antigens. First, LFS treatment parameters should be
tested in vitro, to test for lead candidates. This would be followed by investigation of selected
candidates with in vivo mouse models for immune response. The initial ultrasound parameters to
be tested, in a combinatorial approach, include treatment time, intensity, duty cycle, tip
displacement, and frequency. Additionally, the combination of LFS with specific CPEs, or a
mixture of CPEs for synergistic effects, could also be tested. Because this entails a large number
of experiments, it would be necessary to manufacture multi-cell diffusion arrays, to be used with
multi-element ultrasound probes, which can be ordered in arrays as large as 96 elements
commercially. Following treatment, skin samples would be exposed to model antigens (e.g.,
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ovalbumin or tetanus toxoid) in vitro and the quantity of antigen present in the receiver
compartment of the skin or penetrating into the skin quantified through fluorescence- or radio-
labeling. This would allow for a high-throughput screening approach to identify lead treatment
conditions for delivery of antigens. These candidate treatments could then be tested with in vivo
mouse models, with various toxoids (e.g., tetanus, influenza, and hepatitis, among others) for
immunological response by activation of the Langerhans cells and dermal dendritic cells,
through fluorescently-labeled antibody techniques, and for antibody levels by using enzyme-
linked immunosorbent assay (ELISA).[7]
6.4.2 Non-Invasive Local Delivery of Genetic Drugs and Therapeutics
Delivery of active therapeutics to treat skin disorders is often limited by the barrier properties of
the skin, which does not allow for effective delivery of molecules larger than a few hundred
Daltons in molecular weight or those that are hydrophilic in nature. Delivery is often further
limited by the disorder itself, such as in the case of psoriasis, where over proliferation of the skin
causes the formation of white, scaly plaques. In other cases, such as with melanomas, drugs
must be delivered to deeper tissues of the epidermis or dermis, and therefore topical delivery is
not always appropriate. Often, topical chemotherapy is only possible with small molecules, such
as 5-fluorouracil (MW=130 g/mol). Conversely, larger or hydrophilic molecules require injection
or IV administration for the necessary therapeutic effect to be achieved. These modes of
administration can cause increased systemic side-effects, such as cardiotoxicity, and, for the case
of injection, only allows for the administration of a bolus, which may provide sub-optimal
delivery profiles.
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Additionally, recent research has demonstrated that mutations in certain genes (e.g., B-Raf) can
regulate protein synthesis and signaling cascades in melanomas.[15] Some of these complex
signals, although not fully understood, are known to lead to cancer progression. However, by
utilizing RNA interference, the activity of such genes can be decreased in a very specific
manner. In fact, siRNA have been identified that target only mutations in B-Raf, and not the
wild-type, which can lead to far fewer side-effects related to treatment.[15] Delivery of siRNA
can be a significant challenge, however, as they are known to degrade quite rapidly in the body
when not protected[16] and are generally too large to be administered topically through intact
skin.[17] However, encapsulating siRNA and utilizing a controlled method of skin perturbation
may allow for increased penetration of siRNA into the epidermal/dermal junction and dermis
where melanoma and melanoma metastases occur. Furthermore, combination therapies of
siRNA, to minimize cancer progression, with chemotherapeutics may allow for an improvement,
or even synergism, in melanoma therapies.
The aim of this research would be to investigate the delivery of siRNA to melanomas in order to
knockdown genes that encode for proteins (e.g. B-Raf) that promote cancer progression,
including combination therapies of siRNA with chemotherapeutics, by developing and utilizing a
dual-frequency ultrasonic transdermal delivery platform. In addition, a further application could
be to increase the penetration of therapeutics, such as the anti-psoriatic drug methotrexate, into
deeper tissue layers to treat diseases of the skin.
A multi-frequency ultrasound method could be developed to deliver nude active therapeutics or
liposome encapsulated biologics (for the case of siRNA). Synthesis and loading of liposomes
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with siRNA should initially be conducted according to previously published methods.[18]
However, anti-psoriatic and chemotherapeutic agents could be delivered in initial experiments
without encapsulation. Preliminary experiments would be conducted in vitro, with porcine skin.
Skin samples would be initially treated with LFS (20-60 kHz), in order to increase the
permeability of the skin. Parameters tested could include ultrasound frequency and intensity, as
well as the composition of the coupling solution (e.g., inclusion of CPEs). Following skin
perturbation by LFS, a coupling solution containing the active therapeutic would then be applied
to the treated skin area and high-frequency ultrasound would be applied (1-3 MHz). High-
frequency sonophoresis (HFS) can induce convective currents by acoustic streaming, which can
lead to increased penetration of compounds into the skin, without appreciable degradation of
compounds, as is the case with LFS. Therefore, the combination of LFS and HFS in-series
should allow for increased penetration of therapeutics. After identification of the optimal
treatment parameters for delivery of each drug type, the studies involving treatment of melanoma
could be continued with in vitro melanoma-containing skin reconstructs in order to understand
the response of the cancer to the identified treatments. If the skin reconstructs, grown from
human melanoma and keratinocyte cell lines,[18] cannot mechanically withstand treatment by
LFS, experiments could be continued with in vivo nude mouse models. Delivery and response
studies with both chemotherapeutic agents and siRNA may be investigated, as well as
combination therapies including both types of agents. For studies involving anti-psoriatic agents,
preliminary experiments may involve experiments with an in vitro psoriasis model,[19] to test
for efficacy of treatment. Further experimentation could be conducted with in vivo mouse
psoriasis models.[20] For anti-psoriatic agents, a solely HFS treatment approach may also be
tested, in addition to the combined LFS/HFS approach.
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